US9414918B2 - Heart valve sealing devices - Google Patents

Heart valve sealing devices Download PDF

Info

Publication number
US9414918B2
US9414918B2 US14/019,332 US201314019332A US9414918B2 US 9414918 B2 US9414918 B2 US 9414918B2 US 201314019332 A US201314019332 A US 201314019332A US 9414918 B2 US9414918 B2 US 9414918B2
Authority
US
United States
Prior art keywords
leaflet
anchor
native
mitral valve
prosthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/019,332
Other versions
US20140067052A1 (en
Inventor
Mark Chau
Travis Oba
Sergio Delgado
Robert C. Taft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edwards Lifesciences Corp
Original Assignee
Edwards Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edwards Lifesciences Corp filed Critical Edwards Lifesciences Corp
Priority to US14/019,332 priority Critical patent/US9414918B2/en
Assigned to EDWARDS LIFESCIENCES CORPORATION reassignment EDWARDS LIFESCIENCES CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAFT, ROBERT C., DELGADO, Sergio, CHAU, MARK, OBA, TRAVIS
Publication of US20140067052A1 publication Critical patent/US20140067052A1/en
Priority to US15/204,874 priority patent/US9907652B2/en
Application granted granted Critical
Publication of US9414918B2 publication Critical patent/US9414918B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2427Devices for manipulating or deploying heart valves during implantation
    • A61F2/2436Deployment by retracting a sheath
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2427Devices for manipulating or deploying heart valves during implantation
    • A61F2/243Deployment by mechanical expansion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2454Means for preventing inversion of the valve leaflets, e.g. chordae tendineae prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2454Means for preventing inversion of the valve leaflets, e.g. chordae tendineae prostheses
    • A61F2/2457Chordae tendineae prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/246Devices for obstructing a leak through a native valve in a closed condition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2463Implants forming part of the valve leaflets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2466Delivery devices therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2427Devices for manipulating or deploying heart valves during implantation
    • A61F2/243Deployment by mechanical expansion
    • A61F2/2433Deployment by mechanical expansion using balloon catheter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2445Annuloplasty rings in direct contact with the valve annulus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0069Three-dimensional shapes cylindrical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0003Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having an inflatable pocket filled with fluid, e.g. liquid or gas

Definitions

  • This disclosure pertains generally to prosthetic devices and related methods for helping to seal native heart valves and prevent or reduce regurgitation therethrough, as well as devices and related methods for implanting such prosthetic devices.
  • the native heart valves i.e., the aortic, pulmonary, tricuspid and mitral valves
  • These heart valves can be rendered less effective by congenital malformations, inflammatory processes, infectious conditions or disease. Such damage to the valves can result in serious cardiovascular compromise or death.
  • the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery. However, such surgeries are highly invasive and are prone to many complications. Therefore, elderly and frail patients with defective heart valves often went untreated.
  • transvascular techniques have been developed for introducing and implanting prosthetic devices in a manner that is much less invasive than open heart surgery. Such transvascular techniques have increased in popularity due to their high success rates.
  • a healthy heart has a generally conical shape that tapers to a lower apex.
  • the heart is four-chambered and comprises the left atrium, right atrium, left ventricle, and right ventricle.
  • the left and right sides of the heart are separated by a wall generally referred to as the septum.
  • the native mitral valve of the human heart connects the left atrium to the left ventricle.
  • the mitral valve has a very different anatomy than other native heart valves.
  • the mitral valve includes an annulus portion, which is an annular portion of the native valve tissue surrounding the mitral valve orifice, and a pair of cusps, or leaflets extending downward from the annulus into the left ventricle.
  • the mitral valve annulus can form a “D” shaped, oval, or otherwise out-of-round cross-sectional shape having major and minor axes.
  • the anterior leaflet can be larger than the posterior leaflet, forming a generally “C” shaped boundary between the abutting free edges of the leaflets when they are closed together.
  • the anterior leaflet and the posterior leaflet function together as a one-way valve to allow blood to flow only from the left atrium to the left ventricle.
  • the left atrium receives oxygenated blood from the pulmonary veins.
  • the oxygenated blood that is collected in the left atrium flows into the left ventricle.
  • the muscles of the left atrium relax and the muscles of the left ventricle contract, the increased blood pressure in the left ventricle urges the two leaflets together, thereby closing the one-way mitral valve so that blood cannot flow back to the left atrium and is instead expelled out of the left ventricle through the aortic valve.
  • chordae tendineae tether the leaflets to papillary muscles in the left ventricle.
  • Mitral regurgitation occurs when the native mitral valve fails to close properly and blood flows into the left atrium from the left ventricle during the systole phase of heart contraction. Mitral regurgitation is the most common form of valvular heart disease. Mitral regurgitation has different causes, such as leaflet prolapse, dysfunctional papillary muscles and/or stretching of the mitral valve annulus resulting from dilation of the left ventricle. Mitral regurgitation at a central portion of the leaflets can be referred to as central jet mitral regurgitation and mitral regurgitation nearer to one commissure (i.e., location where the leaflets meet) of the leaflets can be referred to as eccentric jet mitral regurgitation.
  • Some prior techniques for treating mitral regurgitation include stitching portions of the native mitral valve leaflets directly to one another. Other prior techniques include the use of a spacer implanted between the native mitral valve leaflets. Despite these prior techniques, there is a continuing need for improved devices and methods for treating mitral valve regurgitation.
  • This disclosure pertains generally to prosthetic devices and related methods for helping to seal native heart valves and prevent or reduce regurgitation therethrough, as well as devices and related methods for implanting such prosthetic devices.
  • a prosthetic device for treating heart valve regurgitation comprises a radially compressible and radially expandable body having a first end, a second end, and an outer surface extending from the first end to the second end and an anchor having a connection portion and a leaflet capture portion, wherein the connection portion is coupled to the body such that the leaflet capture portion is biased against the outer surface of the body when the body is in a radially expanded state, the prosthetic device is configured to capture a leaflet of a native heart valve between the leaflet capture portion of the anchor and the outer surface of the body, and the body is configured to prevent blood from flowing through the body in a direction extending from the first end to the second end and in a direction extending from the second end to the first end.
  • the outer surface of the body comprises a first side against which the anchor is biased and a second side opposite the first side, and the connection portion of the anchor is coupled to the body on the second side of the body.
  • the anchor comprises an elongated member that is coupled to the second side of the body at a connection location and the elongated member comprises a ventricular portion that extends from the connection location across the first end of the body.
  • the ventricular portion comprises first and second ventricular portions and the first ventricular portion is substantially parallel to the second ventricular portion.
  • the body is radially compressible to a compressed state in which a leaflet-receiving gap exists between the body and the leaflet capture portion of the anchor, and the body is resiliently radially self-expandable to the radially expanded state.
  • the anchor comprises a first clip portion and a second clip portion, and the device is configured to capture the leaflet between the first and second clip portions.
  • the body is formed from Nitinol and is radially self-expandable to the expanded state.
  • the body comprises a metallic frame and a blood-impermeable fabric mounted on the frame.
  • the body is configured to allow blood to flow around the body between the body and a non-captured leaflet during diastole, and configured to allow the non-captured leaflet to close around the body to prevent mitral regurgitation during systole.
  • the anchor is coupled to the first end of the body and the device further comprises an atrial stabilizing member extending from the second end of the body.
  • the body is configured to move within the native heart valve along with motion of the captured leaflet.
  • an atrial end portion of the body comprises a tapered shoulder that reduces in diameter moving toward the atrial end portion of the body.
  • the body comprises a crescent cross-sectional shape.
  • the anchor comprises first and second anchors and the device is configured to be secured to both native mitral valve leaflets.
  • a prosthetic device for treating heart valve regurgitation comprises a main body portion having a connection portion and a free end portion, wherein the connection portion is configured to be coupled to a first one of the two native mitral valve leaflets such that the device is implanted within a native mitral valve orifice, and when the device is implanted within the native mitral valve orifice, the free end portion moves laterally toward a second one of the two native mitral valve leaflets during systole, thereby helping to seal the orifice and reduce mitral regurgitation during systole, and the free end portion moves laterally away from the second native mitral valve leaflet during diastole to allow blood to flow from the left atrium to the left ventricle during diastole.
  • connection portion of the main body is thicker than the free end portion.
  • the main body portion further comprises an atrial portion that contacts the native mitral valve annulus within the left atrium adjacent to the first native mitral valve leaflet.
  • the device further comprises a ventricular anchor that clips around a lower end of the first native mitral valve leaflet, thereby securing the device to the first native mitral valve leaflet.
  • the anchor comprises a paddle shape with a broad upper end portion and a relatively narrow neck portion, wherein the neck portion couples the upper end portion to the main body.
  • a prosthetic device comprises a sheet of flexible, blood-impermeable material configured to be implanted within a native mitral valve orifice and coupled to a first one of the two native mitral leaflets or to the native mitral annulus adjacent the first native mitral leaflet, wherein when implanted the sheet is configured to inflate with blood during systole such that a free portion of the sheet not coupled to the first native mitral leaflet or the mitral annulus adjacent the first native mitral leaflet moves laterally toward and seals against the second of the two native mitral leaflets to reduce mitral regurgitation, and when implanted the sheet is configured to deflate during diastole such that the portion of the sheet not coupled to the first native mitral leaflet or the native mitral annulus adjacent the first native mitral leaflet moves laterally away from the second native mitral leaflet to allow blood to flow from the left atrium to the left ventricle.
  • the sheet is supported by a rigid frame that is secured to the first native mitral leaflet.
  • the frame comprises a ventricular anchor that clips around a lower end of the first native mitral leaflet.
  • the frame comprises an atrial portion that contacts the native mitral annulus within the left atrium adjacent to the first native mitral leaflet.
  • an upper end of the sheet is secured directly to the native mitral annulus adjacent the first native mitral leaflet or to the first native mitral leaflet adjacent the native mitral annulus.
  • the upper end of the sheet is secured to native tissue via rigid anchors that puncture the native tissue.
  • the sheet comprises an annular cross-sectional profile perpendicular to an axis extending through the mitral orifice from the left atrium to the left ventricle.
  • the sheet comprises a closed atrial end and an open ventricular end.
  • the open lower end is biased toward an open position and is configured to collapse to a closed position during diastole.
  • the sheet is supported by a rigid frame that is secured to the first native mitral leaflet, and the frame comprises a plurality of longitudinal splines extending from the upper end of the sheet to the lower end of the sheet. In some embodiments, the splines are biased to cause the lower end of the sheet to open away from the first native leaflet.
  • a lower end of the sheet is tethered to a location in the left ventricle below the native mitral leaflets.
  • the lower end of the sheet is tethered to the papillary muscle heads in the left ventricle.
  • the lower end of the sheet is tethered to a lower end of the rigid frame.
  • opposing lateral ends of the lower end of the sheet are tethered to the lower end of the frame such that an intermediate portion of the lower end of the sheet can billow out away from the frame and toward the second leaflet during systole.
  • the sheet has a generally trapezoidal shape, with a broader portion adjacent to the mitral annulus and a narrower portion positioned between the native mitral leaflets.
  • a prosthetic device for treating heart valve regurgitation comprises a radially compressible and radially expandable body having a first end, a second end, and an outer surface extending from the first end to the second end, a first anchor coupled to the body and configured to capture the anterior native mitral valve leaflet between the first anchor and the body to secure the device to the anterior leaflet, and a second anchor coupled to the body and configured to capture the posterior native mitral valve leaflet between the second anchor and the body to secure the device to the posterior leaflet, wherein when the first and second anchors capture the anterior and posterior leaflets, the body is situated within a mitral valve orifice between the anterior and posterior leaflets, thereby decreasing a size of the orifice.
  • the body is radially compressible to a collapsed delivery configuration suitable for delivering the device to the native mitral valve, and radially expandable from the collapsed delivery configuration to an expanded, operational configuration suitable for operation in the native mitral valve.
  • the body is formed from Nitinol and is radially self-expandable from the collapsed configuration to the expanded configuration.
  • the device further comprises a sheet of blood impermeable fabric covering the body.
  • the body has an elliptical cross-sectional shape.
  • the body has a crescent cross-sectional shape.
  • the body comprises a prosthetic valve.
  • the body is configured to prevent blood from flowing through the body in a direction extending from the first end to the second end and in a direction from the second end to the first end.
  • a method of implanting a prosthetic sealing device at a native mitral valve of a heart comprises advancing a delivery catheter to a native mitral valve region of a heart from a left atrium of the heart, the delivery catheter housing the prosthetic sealing device in a radially compressed configuration, advancing the prosthetic sealing device distally relative to the delivery catheter such that an anchor of the prosthetic sealing device moves out of the catheter and forms a leaflet-receiving gap between an end portion of the anchor and the delivery catheter, positioning either a posterior or an anterior mitral valve leaflet in the gap, and advancing a radially compressed body of the prosthetic sealing device out of the delivery catheter such that the body self-expands radially toward the end portion of the anchor, reducing the gap, and capturing the leaflet between the body and the end portion of the anchor, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole.
  • a non-captured one of the anterior and posterior leaflets is not secured to the prosthetic sealing device when the prosthetic sealing device is implanted at the native mitral valve.
  • advancing a delivery catheter through the native mitral valve from a left atrium comprises advancing the delivery catheter through an incision in a portion of a septum between the left atrium and a right atrium.
  • the anchor is held in a substantially straightened position within the delivery catheter extending distally from body of the prosthetic sealing device.
  • a method of implanting a prosthetic sealing device at a native mitral valve comprises advancing a delivery device to a native mitral valve region via a left ventricle, the delivery catheter housing the prosthetic sealing device in a compressed configuration, allowing an anchor of the prosthetic sealing device to move radially out of the delivery device while a body of the delivery device is in a compressed configuration, such that a leaflet-receiving gap forms between an end portion of the anchor and the delivery device, positioning either a posterior or an anterior mitral valve leaflet in the gap, and allowing the body of the prosthetic sealing device to radially self-expand such that the leaflet is captured between the body and the anchor, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole.
  • a non-captured one of the anterior and posterior mitral valve leaflets is not secured to the prosthetic sealing device when the prosthetic sealing device is implanted at the native mitral valve.
  • advancing a delivery device to a native mitral valve region via a left ventricle comprises inserting the delivery device into the left ventricle through an incision in an apex of the left ventricle.
  • a method of implanting a prosthetic sealing device at a native mitral valve of a heart comprises advancing a delivery system to a native mitral valve region of a heart from a left ventricle of the heart, the delivery system housing the prosthetic sealing device in a radially compressed configuration, proximally retracting an outer sheath of the delivery system such that anchors of the prosthetic sealing device are not confined within the delivery system, advancing the delivery system toward the left atrium of the heart such that native mitral valve leaflets are positioned between the anchors of the prosthetic sealing device and the delivery system, proximally retracting an inner sheath of the delivery system such that a body of the prosthetic sealing device is not confined within the delivery system, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole, and removing the delivery system from the native mitral valve region of the heart.
  • advancing the delivery system to the native mitral valve region from the left ventricle comprises inserting the delivery device into the left ventricle through an incision in an apex of the left ventricle.
  • the anchor is held in a substantially straightened position within the delivery catheter extending distally along a side of the body of the prosthetic sealing device.
  • a method of implanting a prosthetic sealing device at a native mitral valve of a heart comprises advancing a delivery system to a native mitral valve region of a heart from a left atrium of the heart, the delivery system housing the prosthetic sealing device in a radially compressed configuration, proximally retracting an outer sheath of the delivery system such that anchors of the prosthetic sealing device are not confined within the delivery system, retracting the delivery system toward the left atrium of the heart such that native mitral valve leaflets are positioned between the anchors of the prosthetic sealing device and the delivery system, proximally retracting an inner sheath of the delivery system such that a body of the prosthetic sealing device is not confined within the delivery system, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole, and removing the delivery system from the native mitral valve region of the heart.
  • advancing the delivery system to the native mitral valve region from the left atrium comprises advancing the delivery system through an incision in a portion of a septum between the left atrium and a right atrium.
  • the anchor when the delivery system is advanced to the native mitral valve region of the heart, the anchor is held in a substantially straightened position within the delivery catheter extending proximally from body of the prosthetic sealing device.
  • FIG. 1 shows a portion of a human heart with an exemplary embodiment of a sealing device attached to the native posterior mitral leaflet.
  • FIG. 2 shows a portion of a human heart with an exemplary embodiment of a sealing device attached to the native anterior mitral leaflet.
  • FIG. 3 shows a portion of a human heart with an exemplary embodiment of a sealing device attached to the native posterior mitral leaflet and having an atrial anchor.
  • FIG. 4 is an atrial end view of one embodiment of the sealing device of FIG. 3 having a lattice-type atrial anchor.
  • FIG. 5 is an atrial end view of another embodiment of the sealing device of FIG. 3 having a loop-type atrial anchor.
  • FIG. 6 is a side view of an exemplary sealing device.
  • FIG. 7 is another side view of the sealing device of FIG. 6 .
  • FIG. 8 is an atrial end view of the sealing device of FIG. 6 .
  • FIG. 9 is an atrial end view of the sealing device of FIG. 6 implanted at a native mitral valve.
  • FIG. 10 shows a crescent-shaped embodiment of a sealing device.
  • FIG. 11 shows a sealing device having an anchor that extends from one side of a body, around a ventricular end of the body, and along a second side of the body.
  • FIGS. 12-15 show a method of deploying the sealing device of FIG. 11 from a delivery sheath.
  • FIG. 16 is a side view of another embodiment of a sealing device having an anchor that extends from one side of a body, around a ventricular end of the body, and along a second side of the body.
  • FIG. 17 is another side view of the embodiment of FIG. 16 .
  • FIG. 18 is an atrial end view of the embodiment of FIG. 16 .
  • FIG. 19 is a side view of an embodiment similar to that shown in FIG. 16 .
  • FIG. 20 shows the embodiment of FIG. 19 covered with a fabric layer.
  • FIG. 21 is a ventricular end view of the embodiment of FIG. 20 implanted at a native mitral valve.
  • FIG. 22 shows a portion of a human heart with an exemplary sealing device being implanted at the mitral region in a transeptal approach.
  • FIG. 23 shows a portion of a human heart with an exemplary sealing device being implanted at the mitral region in a transapical approach.
  • FIG. 24 shows a human heart with an exemplary prosthetic device attached to a native mitral leaflet.
  • FIG. 25 shows an exemplary prosthetic device being coupled to a native mitral leaflet in a transeptal approach.
  • FIG. 26 shows an exemplary prosthetic device being coupled to a native mitral leaflet in a transapical approach.
  • FIGS. 27 and 28 show another exemplary prosthetic device being coupled to a native mitral leaflet.
  • FIGS. 29-31 show an exemplary prosthetic device attached to the mitral valve region of a human heart.
  • FIGS. 32-34 show another exemplary prosthetic device attached to the mitral valve region of a human heart.
  • FIG. 35 shows two exemplary prosthetic devices, each being coupled to a respective one of the native mitral valve leaflets.
  • FIG. 36 shows two exemplary prosthetic devices, each being coupled to a respective one of the native mitral valve leaflets.
  • FIG. 37 shows two exemplary prosthetic devices, each being coupled to a respective one of the native mitral valve leaflets.
  • FIGS. 38-41 show an exemplary prosthetic device having two anchors.
  • FIG. 42 shows an exemplary prosthetic device having two anchors, coupled to both of the native mitral valve leaflets.
  • FIG. 43 shows an exemplary prosthetic device having two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
  • FIG. 44 shows an exemplary prosthetic device having an elongated body and two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
  • FIG. 45 shows an exemplary prosthetic device having a valve and two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
  • FIG. 46 shows an exemplary prosthetic device having a crescent-shaped body and two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
  • FIGS. 47-51 show exemplary prosthetic devices having three anchors.
  • FIGS. 52-54 show the prosthetic device of FIGS. 38-41 implanted at a native mitral valve.
  • FIGS. 55 and 56 show another exemplary prosthetic device comprising a radially compressible and expandable body.
  • FIGS. 57 and 58 show the prosthetic device of FIGS. 55 and 56 with a fabric layer.
  • FIGS. 59-63 show an exemplary prosthetic device with an exemplary delivery system, in various configurations.
  • FIGS. 64-67 show various exemplary delivery approaches for delivering a prosthetic device to a native mitral valve.
  • FIG. 68 shows an exemplary prosthetic device including a nosecone.
  • prosthetic devices that are primarily intended to be implanted at one of the mitral, aortic, tricuspid, or pulmonary valve regions of a human heart, as well as apparatuses and methods for implanting the same.
  • the prosthetic devices can be used to help restore and/or replace the functionality of a defective native mitral valve.
  • the disclosed embodiments should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another.
  • a prosthetic device comprises a body and an anchor.
  • the body is configured to be positioned within the native mitral valve orifice to help create a more effective seal between the native leaflets to prevent or minimize mitral regurgitation.
  • the body can comprise a structure that is impervious to blood and that allows the native leaflets to close around the sides of the body during ventricular systole to block blood from flowing from the left ventricle back into the left atrium.
  • the body is sometimes referred to herein as a spacer because the body can fill a space between improperly functioning native mitral leaflets that do not naturally close completely.
  • the body can comprise a prosthetic valve structure positioned within an annular body.
  • the body can have various shapes.
  • the body can have an elongated cylindrical shape having a round cross-sectional shape.
  • the body can have an ovular cross-sectional shape, a crescent cross-sectional shape, or various other non-cylindrical shapes.
  • the body can have an atrial or upper end positioned in or adjacent to the left atrium, a ventricular or lower end positioned in or adjacent to the left ventricle, and an annular side surface that extends between the native mitral leaflets.
  • the anchor can be configured to secure the device to one or both of the native mitral leaflets such that the body is positioned between the two native leaflets.
  • the anchor can attach to the body at a location adjacent the ventricular end of the body.
  • the anchor can be configured to be positioned behind a native leaflet when implanted such that the leaflet is captured between the anchor and the body.
  • the prosthetic device can be configured to be implanted via a delivery sheath.
  • the body and the anchor can be compressible to a radially compressed state and can be self-expandable to a radially expanded state when compressive pressure is released.
  • the device can be configured to allow the anchor to self-expand radially away from the still-compressed body initially in order to create a gap between the body and the anchor.
  • the leaflet can then be positioned in the gap.
  • the body can then be allowed to self-expand radially, closing the gap between the body and the anchor and capturing the leaflet between the body and the anchor.
  • Some embodiments disclosed herein are generally configured to be secured to only one of the native mitral leaflets. However, other embodiments comprise more than one anchor and can be configured to be secured to both mitral leaflets. Unless otherwise stated, any of the embodiments disclosed herein that comprise a single anchor can optionally be secured to the anterior mitral leaflet or secured to the posterior mitral leaflet, regardless of whether the particular embodiments are shown as being secured to a particular one of the leaflets.
  • some embodiments can optionally also include one or more atrial anchors, such as to provide additional stabilization.
  • atrial anchors such as to provide additional stabilization.
  • any of the embodiments disclosed herein can optionally include an atrial anchor or not include an atrial anchor, regardless of whether the particular embodiments are shown with an atrial anchor or not.
  • Some of the disclosed prosthetic devices are prevented from atrial embolization by having the anchor hooked around a leaflet, utilizing the tension from native chordae tendinae to resist high systolic pressure urging the device toward the left atrium.
  • the devices can rely on the compressive forces exerted on the leaflet that is captured between the body and the anchor to resist embolization into the left ventricle.
  • FIG. 1 shows an exemplary embodiment of a prosthetic device 10 that comprises a body 12 and an anchor 14 .
  • the device 10 is secured to the posterior mitral leaflet 8 with the free end of the leaflet 8 captured between the anchor 14 and the body 12 .
  • the anterior mitral leaflet 6 is shown separated from the body 12 during diastole as blood flows from the left atrium 2 into the left ventricle 4 .
  • the device 10 can move with the posterior leaflet 8 , allowing the anterior leaflet 6 to open away from the body 12 .
  • the back pressure on the leaflets closes them together around the body 12 to prevent mitral regurgitation.
  • FIG. 2 shows the device 10 alternatively secured to the anterior mitral leaflet 6 with the posterior mitral leaflet 8 free to articulate toward and away from the device 10 .
  • FIG. 3 shows a prosthetic device 20 having a body 22 , a ventricular anchor 24 , and an atrial anchor 26 .
  • the device 20 is shown secured to the posterior leaflet 8 via the ventricular anchor 24 .
  • the atrial anchor 26 can extend laterally from adjacent the atrial end of the body 22 toward the mitral annulus or other lateral portions of the left atrium 2 adjacent to the posterior leaflet 8 .
  • the atrial anchor 26 can help stabilize the device.
  • the atrial anchor 26 can prevent the body 22 from tilting and keep it oriented longitudinally along the blood flow direction through the mitral orifice.
  • the atrial anchor 26 can also help prevent the device 20 from embolizing into the left ventricle 4 .
  • FIGS. 4 and 5 are atrial end views showing two alternative embodiments of atrial anchors for the device 20 .
  • FIG. 4 shows an atrial anchor 26 A that comprises a lattice-type framework supported by two connections to the body 22
  • FIG. 5 shows an atrial anchor 26 B that comprises a single elongated member extending in a loop between two connections to the body 22 .
  • the atrial anchor comprises a relatively broader or wider end portion configured to engage with the atrial tissue so as to spread out the engagement forces to avoid tissue damage and promote increased tissue ingrowth.
  • FIGS. 6-8 show three views of an exemplary embodiment of the prosthetic device 20 having a cylindrical body 22 , a ventricular anchor 24 , and an atrial anchor 26 C.
  • the ventricular anchor 24 as shown in FIGS. 6 and 7 , comprises an elongated member that extends from two connection points adjacent the ventricular end of the body 22 and along one side of the body toward the atrial end of the body.
  • the ventricular anchor is contoured around the generally cylindrical side surface of the body 22 .
  • the atrial anchor 26 C comprises a lattice-type framework made up of several diamond-shaped segments 29 coupled side-by-side in an arc.
  • the atrial anchor 26 C further comprises three connecting members 27 coupling it to the body 22 adjacent the atrial end of the body. As shown in FIG.
  • the atrial member 26 C extends generally laterally to the same side of the body 22 as the ventricular anchor 24 .
  • the radially outward end portion of the atrial anchor can have an upward curvature to conform to the curved geometry of the left atrium.
  • Each of the diamond-shaped segments 29 comprises radially outwardly pointing tip 30 that can press into and/or penetrate adjacent tissue in some cases.
  • the device 20 is shown in an expanded configuration in FIGS. 3-9 .
  • the atrial anchor 26 can be folded down against the side of the body 22 or extended upwardly away from the body 22 .
  • the atrial anchor 26 can be circumferentially compressed, especially embodiments having a lattice-type structure.
  • the body 22 can comprise an annular metal frame 32 covered with a blood-impervious fabric 28 , as shown in FIGS. 6-9 . One or both ends of the body can also be covered with the blood-impervious fabric 28 , as shown in FIG. 8 .
  • the frame 32 can comprise a mesh-like structure comprising a plurality of interconnected metal struts, like a conventional radially compressible and expandable stent.
  • the body can comprise a solid block of material, such as flexible sponge-like block.
  • the body 22 can be hollow or filled with material.
  • the frame 32 can be formed from a self-expandable material, such as Nitinol. When formed from a self-expandable material, the frame 32 can be radially compressed to a delivery configuration and can be retained in the delivery configuration by placing the device in the sheath of a delivery apparatus. When deployed from the sheath, the frame 32 can self-expand to its functional size.
  • the frame can be formed from a plastically expandable material, such as stainless steel or a cobalt chromium alloy. When formed from a plastically expandable material, the prosthetic device can be crimped onto a delivery apparatus and radially expanded to its functional size by an inflatable balloon or an equivalent expansion mechanism. It should be noted that any of the embodiments disclosed herein can comprise a self-expandable main body or a plastically expandable main body.
  • FIG. 9 is a view from the left atrium 2 of the device 20 of FIGS. 6-8 implanted at a mitral valve.
  • the body 22 is positioned between the native leaflets 6 , 8 in a sealed position with the atrial anchor 26 C engaged with the atrial tissue adjacent the posterior mitral leaflet 8 .
  • the atrial end of the body 22 is open while the ventricular end of the body is covered with the impervious fabric 28 .
  • FIG. 10 shows an exemplary prosthetic device 34 having a crescent shaped body 36 .
  • the body 36 is configured to be positioned with the convex side facing the posterior mitral leaflet 8 and the concave side facing the anterior mitral leaflet 6 .
  • the body 36 can comprise a flexible, sponge-like material. Consequently, the device 34 can comprise two ventricular anchors to capture the anterior leaflet 6 .
  • a first ventricular anchor 44 is configured to be positioned behind the anterior leaflet while a second ventricular anchor 42 is configured to be positioned between the body 36 and the anterior leaflet. The anterior leaflet 6 is therefore captured and pinched between the two anchors 42 , 44 to secure the body 36 within the mitral orifice.
  • the device 34 relies on the two anchors 42 , 44 to capture the leaflet because the body 36 in this embodiment may lack sufficient rigidity to grip the leaflet.
  • Both of the ventricular anchors 42 , 44 can extend from adjacent a ventricular end 40 of the body 36 and extend up toward an atrial end 38 of the body along the same side of the body.
  • the anchors 42 , 44 can be positioned on the convex side of the body 36 in order to secure the body to the posterior leaflet.
  • the anchor 42 can be nested within the anchor 44 to provide a smaller crimped profile.
  • the anchors 42 , 44 can have various other shapes.
  • the body 36 can be cylindrical or can have any of various other shapes described herein.
  • FIG. 11 shows an exemplary embodiment of a prosthetic device 50 having a body 52 and an anchor 54 that attaches to a first side of the body, extends around the ventricular end of the body, and extends along a second side of the body opposite the first side of the body.
  • the device 50 is configured to capture a mitral leaflet between the anchor 54 and the second side of the body 52 to secure the body within the mitral orifice.
  • the body 52 can comprise, for example, a radially compressible and expandable metal stent covered by a blood impermeable fabric, as described above.
  • FIGS. 12-15 illustrate an exemplary method of deployment of the device 50 from a delivery catheter 56 .
  • the body 52 is shown in a radially compressed state within the catheter 56 with the anchor 54 extending distally from the ventricular end of the body in a straightened, or unfurled, state.
  • the device 50 can be resiliently deformed in this configuration such that the device 50 resiliently returns to the configuration shown in FIG. 11 when released from constraint.
  • a pusher member 59 can be used to push the device 50 distally relative to the catheter 56 or to hold the device 50 steady as the catheter is retracted.
  • FIG. 12 the body 52 is shown in a radially compressed state within the catheter 56 with the anchor 54 extending distally from the ventricular end of the body in a straightened, or unfurled, state.
  • the device 50 can be resiliently deformed in this configuration such that the device 50 resiliently returns to the configuration shown in FIG. 11 when released from constraint.
  • a pusher member 59 can be used to push the device 50 dist
  • the catheter 56 is retracted proximally from the device 50 and/or the device 50 is advanced distally from the catheter 56 such that the elongated anchor 54 begins to extend out of the distal outlet 58 of the catheter.
  • the anchor 54 moves out of the outlet 58 , the anchor begins to naturally return toward the shape of FIG. 11 , curling gradually as it is freed from the confining forces of the catheter.
  • the entire anchor 54 has moved out of the catheter 56 and has returned to its natural shape of FIG. 11 .
  • the body 52 is still held in radial compression by the catheter, creating a gap 60 between the second side of the body 52 and the end of the anchor 54 .
  • a mitral leaflet can be positioned within the gap 60 while the device is in the configuration of FIG. 14 .
  • the ventricular end 62 of the body 52 begins to advance out of the outlet 58 , allowing the ventricular end 62 of the body to radially expand while the atrial end 64 of the body remains held in compression within the catheter. This causes the body 52 to expand gradually toward the anchor 54 , decreasing the width of the gap 60 , thereby capturing the leaflet within the gap.
  • the entire body 52 can expand to its fully expanded state shown in FIG. 11 , pinching or compressing the leaflet between the end of the anchor 54 and the side of the body. In the fully expanded state shown in FIG.
  • a gap remains between the body 52 and the anchor 54 , although the gap is desirably sized such that a leaflet is engaged by the body and the anchor when placed in the gap. In alternative embodiments, however, such a gap may not exist when the device is in its fully expanded state (i.e., the anchor 54 contacts the body 52 when a leaflet is not positioned between these two components).
  • FIGS. 16-18 show orthogonal views of an exemplary embodiment of a device 70 similar to the device 50 .
  • the device 70 can be deployed from a catheter in the manner described above with respect to FIGS. 11-15 .
  • the device 70 comprises a radially self-expandable body 72 and a ventricular anchor 74 .
  • the body 72 can comprise a narrowed atrial end 76 and a tapered shoulder region 77 , such as to provide improved hemodynamics as blood flows around the shoulder region.
  • the body 72 has a ventricular end 78 opposite from the atrial end 76 .
  • the ventricular anchor 74 can comprise an elongated, curved member that connects to the body 72 at two connection points 80 , 82 adjacent to the ventricular end 78 on a first side of the body (i.e., the right side of the body in FIG. 16 ). As shown in FIGS. 16-18 , the anchor 74 comprises first portions 84 , 86 that extend from the connection points 80 , 82 , respectively, around the ventricular end 78 of the body, to a second, opposite side of the body (i.e., the left side of the body in FIG. 16 ). The anchor 74 further comprises second portions 88 , 90 that extend from the first portions 84 , 86 , respectively, along the second side of the body toward the atrial end 76 of the body.
  • the second portions 88 , 90 gradually expand apart from each other moving atrially toward an end portion 92 of the anchor 74 .
  • the second portions 88 , 90 and the end portion 92 of the anchor 74 can form a paddle shape, as shown in FIG. 17 , and can have a circumferential curvature that substantially matches the curvature of the body 72 .
  • FIGS. 16-18 appear to show the end portion 92 of the anchor passing within a portion of the body 72 , the end portion 92 actually extends around the outer surface of the body 72 , as shown in FIGS. 19 and 20 .
  • the position of the end portion 92 in FIGS. 16-18 illustrates the position that the anchor 74 wants to resiliently move toward in the absence of resistance from body 72 .
  • the anchor 74 is provided with a pre-bend that causes the end portion 92 to press against the outer surface of the body 72 , as shown in FIGS. 19 and 20 . This provides the device 70 the ability to apply a strong enough clamping force on a leaflet positioned between the end portion 92 and the body 72 , even when the leaflet is very thin.
  • FIG. 20 also shows a blood-impervious fabric layer 94 covering the body 72 which can prevent blood from flowing through the body 72 .
  • the fabric layer can comprise, for example, polyethylene terephthalate (PET) or polyurethane. Any of the spacers described herein (even if shown just as a frame) can include such a blood-impervious fabric layer covering the spacer, which can prevent blood from flowing through the spacer.
  • the device 70 can be can be deployed from a delivery catheter according to the method illustrated with respect to device 50 in FIGS. 11-15 , by releasing the anchor 74 first to create a leaflet-receiving gap between the end portion 92 and the body 72 . After positioning a leaflet in the gap, the body 72 can subsequently be freed to self-expand radially toward the end portion 92 to clamp the leaflet between the end portion 92 and the second side of the body 72 .
  • the first portions 84 , 86 can be provided with a larger radius of curvature compared to if the anchor 74 was connected to the body 72 on the same side as the end portion 92 .
  • This large radius of curvature of the first portions 84 , 86 can provide greater control over the clamping forces between the end portion 92 and the body 72 , and provide a more robust and durable anchor configuration, reducing stress concentrations in the anchor 74 and connection points 80 , 82 .
  • the anchor 74 can pass around the ventricular end 78 of the body without obstructing the flow of blood any more than necessary.
  • Having the anchor members 84 , 86 positioned below the ventricular end of the body may not be as desirable in embodiments where the body comprises an annular frame with a prosthetic valve within the annular frame, since the members 84 , 86 could restrict the flow of blood through the body to some degree.
  • FIG. 21 shows a ventricular end view of the device 70 implanted in a mitral orifice with the posterior leaflet 8 captured between the anchor 74 and the body 72 .
  • the anterior leaflet 6 is opened away from the body 72 in FIG. 21 , allowing blood to flow around three sides of the body during diastole. As shown in FIG.
  • the first members 84 , 86 of the anchor 74 extend across the body without blocking the flow of blood around the body.
  • the anterior leaflet 6 can close around the body 72 and create a seal with the body and the side portions of the posterior leaflet 8 to prevent regurgitation into the left atrium 2 .
  • the body 72 is shown in FIG. 21 covered with the blood-impervious fabric 94 that extends around the atrial end 76 of the body and is open on the ventricular end 78 of the body, preventing blood from flowing through the body 72 .
  • the ventricular end 72 can also be covered by the fabric to fully enclose the body and provide improved hemodynamics.
  • FIG. 22 shows an exemplary prosthetic device 100 having a single anchor 102 , being delivered with a catheter 104 via an exemplary transeptal atrial approach.
  • the catheter 104 passes through the inferior vena cava 110 , the right atrium 112 , and through an incision made in the septum 114 , to reach the left atrium 2 .
  • the distal end portion 106 of the catheter 104 serves as a sheath for containing the prosthetic device 100 in a compressed state during delivery to the heart.
  • the delivery apparatus can further include a pusher member 116 extending coaxially through the catheter 104 .
  • implantation of the device 100 can be performed similar to the methods described in relation to FIGS. 11-21 herein.
  • the prosthetic devices described herein can be implanted via an atrial approach using any of the methods and/or devices described in U.S. Patent Application Publication No. 2011/0137397 in relation to FIGS. 63-67 thereof, or in U.S. Provisional Patent Application No. 61/760,577.
  • FIG. 23 shows an exemplary prosthetic device 120 having a single anchor 122 , being delivered with a delivery device 124 through the apex 126 of the heart in an exemplary transapical approach.
  • the prosthetic device 120 is held in a compressed configuration in a distal end of the delivery device 124 as the delivery device is inserted through an incision in the heart apex 126 and delivered through the left ventricle 4 to the mitral region.
  • the delivery device 124 can have features that allow the anchor 122 to radially expand out of the delivery device 124 and away from the still-compressed body of the prosthetic device 120 , as shown in FIG. 23 , to capture one of the native mitral leaflets 6 or 8 .
  • the delivery device 124 can have an outer sheath configured to release the anchor 122 while the body of the prosthetic device is held in a compressed state in an inner sheath, such as by providing a slot in the distal end portion of sheath 124 through which the anchor 122 can extend.
  • the delivery device 124 can be similar to the delivery device 2000 described in U.S. Patent Application Publication No. 2011/0137397 (for example, with only one of the slots 2028 instead of two), and can be used to implant the prosthetic device 120 via methods similar to those described therein in relation to FIGS. 49-62 thereof.
  • the delivery device 124 can also be similar to the delivery devices described in U.S. Provisional Patent Application No. 61/760,577, and can be used to implant prosthetic devices via methods similar to those described therein.
  • FIG. 24 shows an exemplary prosthetic device 200 that is configured to inflate with blood and expand radially during systole and to collapse radially during diastole.
  • the device 200 can comprise a structural portion 202 , an anchor 204 , and an inflatable portion, or parachute, 206 having an annular cross-sectional profile.
  • the structural portion 202 can comprise a rigid member or frame that supports one side of the parachute 206 .
  • the anchor 204 can comprise an extension of the structural member 202 or a separate member coupled to the structural member and is configured to attach the device 200 to one of the native mitral leaflets, such as the posterior native leaflet as shown in FIG. 24 , by capturing the leaflet between the anchor 204 and the structural portion 202 .
  • the parachute 206 can comprise a flexible, blood-impermeable material, such as PET fabric or the like.
  • the parachute 206 has an open lower end 208 and a closed upper end 210 .
  • the device 200 can comprise additional structural elements.
  • some embodiments can comprise longitudinal splines that extend from the upper end 210 to the lower end 208 to provide longitudinal rigidity to the parachute without impeding expansion/contraction in the radial direction, much like a common umbrella.
  • the device 200 can comprise a structural member at the lower opening 208 to prevent the lower opening from fully closing during diastole, such that blood can more easily enter the lower opening at the beginning of systole.
  • the device 200 can comprise a biased portion that urges the lower opening 208 toward an opened position.
  • the biased portion can comprise a spring mechanism, resiliently flexible members, or other mechanisms.
  • the device 200 can further comprise an atrial portion that extends from or adjacent to the upper end 210 and contacts the atrial walls and/or the atrial side of the leaflet to which the device is attached.
  • the atrial body can help secure the device within the mitral orifice and can prevent movement toward the left ventricle.
  • the atrial body can comprise a separate component or an extension of the structural member 202 .
  • the atrial body can be configured like the atrial bodies 26 A, 26 B or 26 C described above, or can have other configurations.
  • FIGS. 25-28 show a prosthetic spacer 220 according to another embodiment, wherein the spacer 220 is coupled to one of the native leaflets using, for example, sutures.
  • the spacer 220 can be formed from any of various suitable materials, including bio-compatible materials such as pericardial tissue, polymers, sponge, or a gel or saline filled structure such as a balloon.
  • the material composition of the spacer 220 can be selected to increase desirable characteristics of the spacer 220 , such as performance, durability, promotion of native tissue growth, etc.
  • the spacer 220 can be formed in any of various suitable shapes, such as a rectangle, a semi-elliptical ring or generally u-shape, or a semi-ellipse. As shown in FIG.
  • the spacer 220 can be sutured to the posterior leaflet 8 using sutures 222 via a transeptal approach, and as shown in FIG. 26 , the spacer 220 can be sutured to the posterior leaflet 8 using sutures 222 via a transapical approach.
  • the opposite leaflet (the anterior leaflet in the illustrated embodiment) can coapt against the spacer 220 to prevent or minimize regurgitation.
  • FIG. 27 shows the spacer 220 after it has been sutured to the native posterior leaflet 8 .
  • two sutures 222 can be sufficient to couple the spacer 220 to the leaflet 8 .
  • the sutures 222 can be positioned as shown, with one suture 222 at either end of the spacer 220 , which spans across the leaflet 8 .
  • additional or fewer sutures can be used, and the sutures can be situated in alternative locations on the spacer 220 and/or on the leaflet 8 .
  • FIG. 28 shows the spacer 220 being coupled to the posterior native leaflet 8 using a length of elongated material 224 and a pair of slidable locking devices 226 .
  • the elongated material 224 can comprise, for example, a length of thread or suture material, or a metal or polymeric wire, or other material suitable for suturing, such as biological tissue.
  • a single strand of material 224 is used, although in alternative embodiments, two or more strands 224 can be used to couple the spacer 220 to the native leaflet 8 .
  • one or both of the slidable locking devices 226 can be guided along the strand of material 224 toward the native leaflet 8 , thereby decreasing the length of the strand 224 between the locking devices 226 until the spacer 220 is held firmly against the leaflet 8 in a desired deployed configuration. Because the locking devices 226 are positioned behind the posterior leaflet 8 in this configuration (that is, they are located between the native leaflet 8 and the wall of the left ventricle 4 ), the potential for interference between the locking devices 226 and the coaptation area of the leaflets 6 , 8 is minimized.
  • any excess material 228 can be trimmed to prevent interference of the material 224 with the operation of the heart valve.
  • the locking devices 226 can be configured to be slid or passed over a suture in one direction and resist movement in the opposite direction. Examples of locking devices (also referred to as suture securement devices) that can be implemented in the embodiment of FIG. 28 are disclosed in co-pending application Ser. No. 13/938,071, filed Jul. 9, 2013, which is incorporated herein by reference.
  • FIGS. 25-28 show one spacer 220 coupled or secured to the posterior leaflet 8 .
  • a spacer 220 can be coupled as described above to the anterior leaflet 6 in place of or in addition to the spacer 220 coupled to the posterior leaflet 8 .
  • any of the embodiments described herein can be sutured to native tissue as described above with reference to spacer 220 , rather than or in addition to being clipped to the native leaflets using one or more anchors.
  • the device anchorage is made independent of the motions of the ventricular walls and atrial walls, which move significantly during contractions of the heart. This can provide a more stable anchorage for a prosthetic mitral device, and eliminate the risk of hook-type or cork screw-type anchors tearing or otherwise causing trauma to the walls of the left ventricle or left atrium.
  • the device body can be held in a more consistent position with respect to the mitral leaflets as the leaflets articulate, eliminating undesirable motion imparted on the device from the contraction motions of the left ventricle walls and left atrium walls.
  • Anchoring to a mitral leaflet can also allow for a shorter body length compared to devices having other anchorage means.
  • FIG. 29 shows another exemplary prosthetic device 300 implanted at the mitral valve region for treating regurgitation.
  • the device 300 comprises a strong, flexible sheet of blood-impermeable material.
  • the device 300 has an upper end 302 that is secured to the mitral annulus and/or the region of a mitral valve leaflet adjacent to the mitral annulus.
  • the portion of the device 300 extending away from this upper end portion 302 is a free end portion of the device 300 .
  • the upper end 302 is attached to the mitral annulus above the posterior leaflet 8 .
  • the arrangement can be reversed with the device 300 secured to the anterior leaflet 6 .
  • the device 300 can be secured to the native tissue by various means, such as via suturing or via barbed anchors or microanchors 304 .
  • the upper end 302 of the device 300 can be wider than the free end portion of the device 300 , thus the device 300 can have a generally trapezoidal shape.
  • the lower end of the anterior leaflet 6 is not shown in order to show the lower end of the posterior leaflet 8 and the lower end 306 of the device 300 extending downwardly through the mitral orifice and into the left ventricle 4 .
  • the lower end 306 of the device can be shorter, longer, or about the same length as the leaflet to which it is attached.
  • the lower end 306 of the device in the illustrated embodiment extends below the lower end of the posterior leaflet during diastole ( FIG. 31 ), and extends short of the lower end of the anterior leaflet 6 during systole ( FIG. 30 ).
  • the lower end 306 can be tethered to a location in the left ventricle 4 .
  • the lower end 306 can be tethered to the papillary muscle heads 310 via tethers 308 and anchors 312 , as shown, (in a manner similar to the way in which the native chordae tendineae 314 tether the native leaflet 8 to the papillary muscles 310 ), or can be tethered to the apex of the left ventricle.
  • the device 300 inflates or fills with blood from the left ventricle 4 and expands laterally toward the anterior leaflet 6 .
  • This causes the lower portion of the device 300 to seal against the anterior leaflet 6 , blocking the flow of blood back into the left atrium 2 .
  • the lateral edges of the device 300 can seal between the two native leaflets adjacent to the commissures where the native leaflets still naturally coapt with each other.
  • the tethers 308 prevent the lower end 306 of the device 300 from moving toward and/or into the left atrium 2 and thereby breaking the seal with the anterior leaflet 6 .
  • the device 300 augments the native posterior leaflet and helps seal the mitral orifice in the case where the native leaflets 6 , 8 do not otherwise not fully coapt and allow regurgitation between them.
  • FIG. 32 shows another exemplary prosthetic device 400 implanted at the mitral valve region for treating mitral regurgitation.
  • the device 400 comprises a rigid frame 402 (e.g., a metal frame) that clips around the posterior leaflet 8 with an anchor portion 404 being positioned behind the posterior leaflet 8 and an atrial portion 406 being positioned along the atrial surface of the mitral annulus and/or the portion of the posterior leaflet adjacent to the annulus.
  • the frame 402 can secure the device 400 to the posterior leaflet 8 without sutures or other tissue puncturing elements like the anchors 304 in FIGS. 29-31 .
  • the device 400 also can be implanted on the anterior leaflet 6 .
  • the device 400 further comprises a strong, flexible sheet 408 of blood-impermeable material, like the device 300 .
  • An upper end 410 of the sheet 408 can be secured to the frame 402 at or near the atrial portion 406 .
  • the portion of the sheet 408 extending away from this upper end portion 410 is a free end portion of the sheet 408 .
  • the lower end of the anterior leaflet 6 is not shown in order to show the lower end of the posterior leaflet 8 and the lower portions of the device 400 extending downwardly through the mitral orifice and into the left ventricle 4 .
  • the lower end 412 of the sheet 408 can be shorter, longer, or about the same length as the lower end of the leaflet to which it is attached.
  • the lower end 412 of the sheet 408 in the illustrated embodiment extends below the lower end of the posterior leaflet during diastole ( FIG. 34 ), and extends short of the lower end of the anterior leaflet 6 during systole ( FIG. 33 ).
  • the lower end 412 can be tethered to a location in the left ventricle 4 and/or can be tethered to one or more points 420 near the lower end of the frame 402 (both tethering means are shown in FIGS. 33 and 34 , though one can be used without the other).
  • the lower end 412 of the sheet 408 can be tethered to the papillary muscle heads 416 via tethers 424 and anchors 426 (in a manner similar to the way in which the native chordae tendineae 414 tether the native leaflet 8 to the papillary muscles 416 ), and/or can be tethered to the apex of the left ventricle 4 .
  • the sheet 408 is tethered only to the frame 402 and tethers extending down into the left ventricle 4 are optional.
  • one or more tethers 428 can extend from adjacent the lower end 412 of the sheet, such as from the lower lateral corners 422 , and attach to the lower end of the frame at or near points 420 .
  • the sheet 408 can adopt a three dimensional curvature when inflated, with the lower corners being held closer to the lower end of the frame 402 while an intermediate portion of the lower edge 412 is allowed to billow out (somewhat like a spinnaker sail) further toward the anterior leaflet 6 to create a seal.
  • the sheet 408 inflates or fills with blood from the left ventricle 4 and expands laterally toward the anterior leaflet 6 .
  • the lateral edges of the sheet 408 can seal between the two native leaflets adjacent to the commissures where the native leaflets naturally coapt with each other.
  • the device 400 augments the native posterior leaflet and helps seal the mitral orifice in the case where the native leaflets 6 , 8 do not otherwise not fully coapt and allow regurgitation between them.
  • FIGS. 35 and 36 show embodiments of prosthetic devices 460 , 470 which can be used to extend the effective length of the native leaflets 6 , 8 .
  • a prosthetic device 460 can include a body 462 and a clip 464 for clipping the device 460 to one of the anterior or posterior native leaflets 6 , 8 .
  • a prosthetic device 470 can include a body 472 and one or more sutures 474 for coupling the device 470 to one of the anterior or posterior native leaflets 6 , 8 .
  • the devices 460 , 470 have free end portions extending away from the native leaflets which extend the effective length of the native leaflets, thereby increasing the chance of and extent of coaptation between them, as described more fully below.
  • the bodies 462 , 472 can comprise a material which is stiff enough to reduce the chance of leaflet prolapse, and flexible enough to increase the extent of leaflet coaptation. Suitable materials can include, for example, biological materials such as pericardial tissue, goretex, silicone, polyurethane, or other polymeric materials.
  • FIG. 35 shows that a device 460 can be used on each of the anterior and posterior native leaflets 6 , 8 , and FIG.
  • FIG. 36 shows that a device 470 can be used on each of the anterior and posterior native leaflets 6 , 8 , but in alternative embodiments, only one such device can be used, or one device 460 and one device 470 can be used.
  • FIG. 35 shows that tethers 461 can be used to tether free end portions of the bodies 462 to locations in the left ventricle, thus reducing the chances of prolapse of the prosthetic devices 460 during systole.
  • the tethers 461 are optional, and can be used in a similar fashion in combination with the devices 470 , 500 , 502 , or any other suitable devices described herein.
  • FIG. 37 shows exemplary prosthetic devices 500 , 502 which combine features of the prosthetic spacers and the leaflet extensions described above.
  • Prosthetic device 500 is shown coupled to the posterior native leaflet 8 while the prosthetic device 502 is shown coupled to the anterior native leaflet 6 .
  • the prosthetic devices 500 , 502 include relatively thick upper portions 504 , 506 , which function in a manner similar to the prosthetic spacers described above, and relatively thin, elongate free end portions 508 , 510 , which function in a manner similar to the devices 300 , 400 , described above.
  • the free end portions 508 , 510 can have respective distal end portions 514 , 516 , which represent the effective distal ends of the extended leaflets.
  • the free end portions 508 , 510 extend the effective length of the respective leaflets, and can facilitate initiation of leaflet coaptation during ventricular systole.
  • the leaflets are urged toward one another due to the pressures extant in the left ventricle and left atrium. Due to the extended effective length of the leaflets, the end portions 514 , 516 are more likely to coapt than were the ends of the native leaflets without the extensions.
  • the pressure in the left ventricle can increase, further increasing the pressure differential between the left ventricle and the left atrium and urging the leaflets 6 , 8 , further toward one another.
  • the portions of the leaflets 6 , 8 , and their respective extensions 502 , 500 which coapt increases (both in the direction from the end portions 514 , 516 toward the left atrium 2 , and from the locations of the devices 500 , 502 , toward the commissure points of the mitral valve), leading to a cycle of increasingly impeded blood flow, increased pressure differential, and increased coaptation of the leaflets.
  • the free end portions 508 , 510 can help to reduce regurgitation of blood from the left ventricle to the left atrium during ventricular systole.
  • the upper portions 504 , 506 can further help to prevent regurgitation in the manner described above with respect to prosthetic device 10 .
  • the relatively thick upper portions 504 , 506 can help to increase their coaptation and thereby reduce regurgitation.
  • FIG. 37 shows that the devices 500 , 502 can be sutured to the native leaflets 8 , 6 , with sutures 512 , but in alternative embodiments, the devices 500 , 502 can be clipped to the native leaflets 8 , 6 , as described above. In alternative embodiments, only one of the devices 500 , 502 can be used rather than both.
  • prosthetic devices can include a body and a plurality of anchors such that the body can be clipped to more than one leaflet. Such embodiments can be used to effectively couple two or more leaflets to one another. Thus, such a device can be used to bring native leaflets closer to one another and restrict their mobility in order help increase the chance of or extent of coaptation between the leaflets.
  • FIGS. 38-41 show a prosthetic spacer 600 having a body 602 , a first anchor 604 and a second anchor 606 .
  • the body 602 and anchors 604 , 606 can be fabricated from any of various suitable materials, and the body is desirably made from a relatively compressible material so that its profile can be reduced for delivery into a patient's heart within a delivery catheter.
  • the body 602 can be inflatable (e.g., to be inflated with a fluid such as saline or a curing epoxy or polymer) or otherwise expandable (e.g., it can be fabricated from a frame comprising a self-expanding material such as Nitinol) such that the cross section of the body 602 can be reduced for delivery into a patient's heart and then expanded to a final, deployed configuration therein.
  • a fluid such as saline or a curing epoxy or polymer
  • an inflatable spacer can be particularly advantageous because it can allow enhanced customization of the spacer, and can allow fine control over the final, deployed size and configuration of the spacer.
  • FIGS. 38 and 39 show that the anchors can have similar structures.
  • Each anchor 604 , 606 can be made from a single piece of relatively rigid metallic material (e.g., an elongated wire) which can include first and second inner portions 608 , 610 , first and second bottom portions 612 , 614 , and a main loop portion 616 extending between and connecting the upper ends of the bottom portions 612 , 614 .
  • the inner portions 608 , 610 can be coupled rigidly to the inside of the body 602 .
  • the inner portions 608 , 610 can extend downwardly out of the lower end of body 602 to the respective bottom portions 612 , 614 , which can each curve upwardly around the lower end of the body 602 to meet the main loop portion 616 .
  • FIGS. 39 and 40 show that the structure of the anchors 604 , 606 , and their connections to the body 602 , biases the main loop portions 616 of the anchors 604 , 606 , into contact with the sides of the body 602 .
  • the spacer 600 can be clipped to the anterior and posterior native leaflets 6 , 8 , with one of the leaflets 6 , 8 clipped between the anchor 604 and the body 602 , and the other of the leaflets 6 , 8 , clipped between the anchor 606 and the body 602 .
  • FIG. 41 shows that the anchors 604 , 606 can be splayed apart so that gaps exist between the anchors 604 , 606 , and the body 602 .
  • the spacer 600 can be introduced into the region of a patient's native mitral valve in a closed configuration with the anchors 604 , 606 against the side of the body 602 ( FIGS. 38-40 ).
  • the anchors 604 , 606 can then be splayed apart or expanded into an open configuration ( FIG. 41 ) so the spacer can be positioned with the native leaflets 6 , 8 , in the gaps between the anchors 604 , 606 and the body 602 , after which the anchors 604 , 606 can be allowed to return to the closed configuration under their own resiliency to capture the leaflets 6 , 8 , and clip the spacer 600 thereto.
  • FIG. 42 shows that in use, the prosthetic spacer 600 can be clipped to the posterior native mitral valve leaflet 8 using the first anchor 604 , as described above with regard to prosthetic spacer 10 and shown in FIG. 1 , and can be clipped to the anterior native mitral valve leaflet 6 using the second anchor 606 , as described above with regard to prosthetic spacer 10 and shown in FIG. 2 .
  • FIG. 42 shows that in use, the prosthetic spacer 600 can be clipped to the posterior native mitral valve leaflet 8 using the first anchor 604 , as described above with regard to prosthetic spacer 10 and shown in FIG. 1 , and can be clipped to the anterior native mitral valve leaflet 6 using the second anchor 606 , as described above with regard to prosthetic spacer 10 and shown in FIG. 2 .
  • FIG. 42 shows that in use, the prosthetic spacer 600 can be clipped to the posterior native mitral valve leaflet 8 using the first anchor 604 , as described above with regard to prosthetic spacer 10 and shown in FIG. 1 , and
  • FIG. 43 shows that when the prosthetic spacer 600 is clipped to both of the leaflets 6 , 8 , (e.g., at the A 2 and P 2 regions of the leaflets, as identified by Carpentier nomenclature) it brings them together, decreasing the overall area of the mitral valve orifice, and dividing the mitral valve orifice into two orifices 618 , 620 during diastole.
  • the area through which mitral regurgitation can occur is reduced, leaflet coaptation can be initiated at the location of the spacer 600 , and the leaflets can fully coapt more easily, thereby preventing or minimizing mitral regurgitation.
  • FIGS. 44 and 45 show alternative embodiments of dual anchor spacers clipped to the A 2 and P 2 regions of the anterior and posterior native leaflets 6 , 8 , as viewed from the left atrium.
  • FIG. 44 shows an embodiment 640 in which the shape of the body of the spacer 640 is relatively elongate such that the spacer 640 extends substantially between the commissures 650 , 652 of the mitral valve.
  • the native leaflets 6 , 8 are brought toward one another by the anchors of the spacer 640 , the overall area of the valve orifice is reduced, and the orifice is divided into four orifices 642 , 644 , 646 , 648 during diastole.
  • leaflet coaptation can be initiated at the location of the spacer 640 , and the leaflets can fully coapt more easily, thereby preventing or minimizing mitral regurgitation.
  • shape of the spacer 640 can more effectively treat eccentric jet mitral regurgitation, because the extension of the body of the spacer 640 to the commissures 650 , 652 helps the leaflets 6 , 8 , to coapt across the entirety of the native mitral valve orifice.
  • FIG. 45 shows an embodiment of a dual-anchor spacer 660 in which the body of the spacer 660 comprises a prosthetic valve having one or more flexible leaflets 666 that permit blood to flow into the left ventricle during diastole and block the back flow of blood into the left atrium during systole.
  • the native leaflets 6 , 8 are brought closer to one another and the native mitral valve orifice is divided into two orifices 662 , 664 during diastole.
  • the body of the spacer 660 comprises a prosthetic valve, rather than a solid piece of material, the total effective open area between the leaflets during diastole (e.g., the area through which blood can flow) is greater in this embodiment than in the embodiment illustrated in FIGS. 43 and 44 .
  • the body of a dual anchor spacer can have various alternative shapes.
  • cross-sectional profile of the body can be circular, elliptical, or as shown in FIG. 46 , can have a generally crescent shape.
  • a spacer body having a crescent shape such as spacer body 680 in FIG. 46 (viewed from the left atrium) can be particularly advantageous because it can conform to the overall crescent shape of the anterior and posterior leaflets 6 , 8 of the native mitral valve.
  • the concave side 682 of the crescent shaped body 680 can face the anterior native leaflet 6 while the convex side 684 of the crescent shaped body 680 can face the posterior native leaflet 8 .
  • the native mitral valve orifice can be divided into two orifices 686 , 688 , each on the concave side 682 of the spacer 680 , as the convex side 684 can conform to the posterior native leaflet 8 such that no openings exist between them.
  • FIGS. 47-51 show embodiments of spacers having three anchors, which can be clipped to leaflets in the tricuspid valve of the human heart in a manner similar to that described above with regard to spacers in the mitral valve.
  • FIG. 47 shows a tricuspid spacer 700 having a circular body 712 and three anchors 702 .
  • FIG. 48 shows the spacer 700 implanted in the tricuspid valve (as viewed from the right ventricle, as blood is being pumped out of the right ventricle), with each of the three anchors 702 clipped to a respective leaflet 704 of the tricuspid valve, and thereby coupling them to one another.
  • FIG. 49 shows the spacer 700 clipped to the leaflets 704 of the tricuspid valve as blood is pumped from the right atrium to the right ventricle through orifices 706 , 708 , 710 .
  • FIG. 50 shows an alternative tricuspid spacer 720 having a body 722 and three clips 724 . As shown, the body 722 can have a generally Y shape.
  • FIG. 51 shows an alternative tricuspid spacer 730 having a body 732 and three clips 734 . As shown, the body 732 can have a generally triangular shape.
  • FIGS. 52-54 show an exemplary dual anchor spacer 750 having a body 752 and first and second anchors 754 , 756 , positioned within a native mitral valve.
  • FIG. 52 shows the spacer 750 as seen from the left ventricle 4 .
  • FIG. 53 shows the spacer 750 as viewed from the left atrium 2 during systole
  • FIG. 54 shows the spacer 750 from the left atrium 2 during diastole.
  • no openings appear through which regurgitant flow can occur.
  • two openings 758 , 760 exist through which blood can flow from the left atrium 2 to the left ventricle 4 during diastole, as is desirable.
  • a suitable delivery sequence for delivering a prosthetic spacer such as spacer 750 to the mitral valve region of a patient's heart can comprise compressing a spacer to a compressed, delivery configuration, delivering the spacer to the coaptation line of a patient's native mitral valve, expanding the spacer until regurgitation in the patient's mitral valve is adequately reduced (an inflatable device can allow a physician to make fine adjustments to the final size and configuration of the spacer based on information received during the delivery process), manipulating the anchors of the spacer to an open position, capturing the native leaflets between the anchors and the body of the spacer, and then manipulating the anchors to a closed position, thereby clipping the spacer to the native mitral valve leaflets.
  • FIGS. 55 and 56 show an exemplary dual anchor spacer 800 comprising a main body 802 and first and second anchors 804 , 806 .
  • the main body 802 can comprise a plurality of interconnected struts 808 which together form a plurality of open cells and are arranged to form a generally annular shape having first and second end portions 816 , 818 .
  • the body 802 can be formed to be radially self-expandable.
  • the body 802 can be fabricated from a shape-memory material such as Nitinol, which can allow the spacer 800 to be radially compressed to a compressed delivery configuration, delivered to one of a patient's native heart valves, then self-expanded to an expanded functional configuration for use within the patient's heart.
  • a shape-memory material such as Nitinol
  • the first anchor 804 can comprise first and second end portions 810 , 812 which can be coupled to the first end portion 816 of the main body 802 , and a loop portion 814 which can extend between the first and second end portions 810 , 812 .
  • the first and second end portions 810 , 812 can extend away from the first end portion 816 of the body 802 , then curl back and extend toward the second end portion 818 of the main body 802 .
  • the loop portion 814 can be coupled to the first end portion 810 , extend generally toward the second end portion 818 of the main body 802 , curl back and extend toward the first end portion 816 of the main body 802 , and be coupled to the second end portion 812 .
  • the first anchor 804 can be coupled to the first end portion 816 of the main body 802 and extend along the side of the main body 802 toward its second end portion 818 .
  • the second anchor 806 can have a similar structure, and can be coupled to the main body 802 such that it extends along an opposing side of the main body 802 .
  • the spacer 800 can be clipped to native tissues by pinching the native tissues between the anchors 804 , 806 and the respective sides of the main body 802 .
  • the anchors 804 , 806 can be made from various suitable materials, and in one exemplary embodiment can be fabricated from the shape-memory material Nitinol.
  • the anchors 804 , 806 in the illustrated embodiment are fabricated from separate pieces of material from the main body 802 , and are coupled to the main body 802 using coupling mechanisms 820 .
  • the coupling mechanisms 820 can be, for example, crimping rings that extend around a strut at the first end 816 of the main body 802 and an adjacent portion of an anchor.
  • the anchors 804 , 806 and the main body 802 can be fabricated integrally with one another (i.e., from a single piece of material).
  • the main body 802 can have a generally elliptical or oval shape when viewed on end, but in alternative embodiments, the main body can be formed to have any of various suitable shapes when viewed on end, such as a circle.
  • FIGS. 57 and 58 show the spacer 800 covered in a blood impermeable fabric material 822 , such as made of polyethylene terephthalate (PET) or polyurethane.
  • the fabric material 822 can be relatively thick, strong, and soft, such as a knitted lofty cloth.
  • the fabric material 822 can be selected to provide a softer surface for contact with the native tissue, thus reducing trauma caused to the native tissues by the implantation of the spacer 800 , can be selected to promote native tissue ingrowth into the spacer 800 , and/or can be selected to improve the seal formed between native tissues and the portions of the spacer 800 they come into contact with. Additionally, FIG.
  • a fabric layer 824 can be disposed to cover all or substantially all of the opening at the center of the main body 802 .
  • the layer 824 can be blood impermeable, thereby blocking the flow of blood through the spacer 800 .
  • the layer 824 can be formed from the same material as fabric 822 , and together the fabric 822 and layer 824 can work to prevent the regurgitant flow of blood through a heart valve when the spacer has been implanted therein.
  • FIGS. 59-63 illustrate exemplary systems and methods which can be used to implant the spacer 800 in a native heart valve.
  • FIGS. 59-61 illustrate exemplary systems and steps which can be used to crimp the spacer 800 to a compressed, delivery configuration, suitable for delivery to a patient's native heart valve within a delivery device 850 .
  • FIG. 59 shows the spacer 800 with its main body 802 positioned in a crimper mechanism 900 capable of crimping the main body 802 to a compressed configuration.
  • the anchors 804 , 806 can remain outside the crimper mechanism 900 as it is used to crimp the main body portion 802 .
  • U.S. Pat. No. 7,530,253 which is hereby incorporated herein by reference, describes an exemplary prosthetic valve crimping device that can be used to crimp the spacer 800 .
  • the delivery device 850 can be similar to the delivery device 2000 described in U.S. Patent Application Publication No. 2011/0137397 or the delivery devices described in U.S. Provisional Patent Application No. 61/760,577, and can be used to implant prosthetic devices via methods similar to those described therein.
  • FIG. 59 shows that the delivery device 850 can include an inner sheath 852 provided with a pair of slots 854 disposed on opposing sides of the inner sheath 852 , and an internal locking element 856 , which is axially adjustable relative to the inner sheath 852 along a central longitudinal axis of the inner sheath 852 .
  • the internal locking element 856 can comprise a generally cruciform shape, having four extension portions 858 between which are defined four voids 860 . As best shown in FIG. 59 , two of the voids 860 can be aligned with the two slots 854 , which can also be aligned with the portions of the anchors 804 , 806 which are coupled to the body 802 of the spacer 800 . Thus, in this embodiment, the locking element 856 can be retracted into the inner sheath 852 , thereby pulling the main body portion 802 of the spacer 800 into the inner sheath 852 in the same direction. As best shown in FIG.
  • the first and second end portions 810 , 812 of each of the anchors extend from the first end portion 816 of the spacer 800 , through the respective voids 860 in the locking element, and then curl out of the slots 854 in the sides of the inner sheath 852 , extending along the sides of the body 802 toward the second end portion 818 of the main body 802 .
  • the body 802 of the spacer 800 can be pulled into the inner sheath 852 and thereby compressed to a compressed delivery configuration.
  • an outer sheath 862 can be extended toward the distal end of the device 850 so as to enclose the anchors 804 , 806 , thereby causing them to wrap around the inner sheath 852 and be confined between the inner sheath 852 and outer sheath 862 .
  • FIGS. 62 and 63 show a spacer 800 covered in fabric as described above and situated within a delivery device 870 in two different configurations.
  • FIG. 62 shows the spacer 800 having its main body portion 802 situated within an inner sheath 872 of the delivery device 870 such that the anchors 804 , 806 extend toward a distal end portion of the delivery device 870 .
  • an outer sheath 874 can be extended distally to retain and secure the anchors 804 , 806 against the sides of the inner sheath 872 .
  • Such a configuration can be used to deliver the spacer transapically, as described below.
  • retraction of the outer sheath 874 can allow the anchors 804 , 806 to self-expand to a splayed-apart configuration.
  • FIG. 62 also shows that forcible expanders, or levers, 876 can be used to force the anchors 804 , 806 to splay apart.
  • the forcible expanders 876 can be radially self-expanding levers which radially self-expand when the outer sheath 874 is retracted or are otherwise configured to radially expand away from the inner sheath when they are actuated by a physician (such as by actuating a control knob on a handle that is operatively connected to the expanders 876 ).
  • the expanders 876 can alternatively be sutures or other mechanisms which can be actuated by a physician to force the anchors 804 , 806 to splay apart.
  • retraction of the outer sheath 874 can allow the anchors 804 , 806 to self-expand to a first splayed-apart configuration, and forcible expanders 876 can be actuated to force the anchors 804 , 806 to further radially expand to a second splayed-apart configuration.
  • the expanders 876 can be actuated to cause the anchors 804 , 806 to radially expand to the second splayed apart configuration, and can then be actuated to allow the anchors 804 , 806 to move radially inward and return to the first splayed-apart configuration.
  • FIGS. 62 and 63 illustrate the spacer 800 situated within the delivery system 870 such that the anchors 804 , 806 extend generally along the outside of the body 802 toward the second end portion 818 of the spacer 800 .
  • the configuration of the body 802 and anchors 804 , 806 within the delivery system 870 , and the deployment of the spacer 800 from the delivery system 870 can be similar to that illustrated in FIGS. 12-15 with respect to device 50 and delivery catheter 56 .
  • FIG. 63 shows the spacer 800 having its main body portion 802 situated within the inner sheath 872 of the delivery device 870 such that the anchors 804 , 806 extend toward a proximal end portion of the delivery device 870 .
  • the outer sheath 874 can be extended distally to retain and secure the anchors 804 , 806 against the sides of the inner sheath 872 .
  • Such a configuration can be used to deliver the spacer transatrially, as described below.
  • FIGS. 64-67 show various approaches by which a prosthetic spacer 800 can be delivered to the region of a patient's mitral valve using a delivery system 920 .
  • a prosthetic spacer can be delivered via a transapical approach ( FIG. 64 ), via a transeptal approach ( FIG. 65 ), via a transatrial approach ( FIG. 66 ), or via a transfemoral approach ( FIG. 67 ).
  • FIGS. 64-67 show that the delivery system 920 can comprise an outer sheath 922 , an inner sheath 924 , and a guidewire 930 which can extend through the outer sheath 922 and inner sheath 924 .
  • the delivery system 920 can also include a pusher element (not illustrated in FIGS. 64-67 , but similar to those described above), which can be actuated to move the spacer 800 within the inner sheath 924 .
  • the outer sheath 922 , inner sheath 924 , guidewire 930 , and pusher element can each be retracted proximally or extended distally with respect to one another.
  • the guidewire 930 can be used to guide the delivery of the other components of the system 920 to an appropriate location within a patient's vasculature.
  • the guidewire 930 can extend through a small opening or pore in the spacer 800 , for example in the fabric layer 824 , the small opening or pore being small enough that substantial blood cannot flow therethrough.
  • FIGS. 64 and 67 show that the deployment of the spacer 800 to a native mitral valve via the transapical approach can be similar to the deployment of the valve 800 via the transfemoral approach, at least because in both cases the valve is delivered to the mitral valve from the left ventricle.
  • the spacer 800 can be situated within the system 920 with the second end portion 818 of the spacer 800 disposed at the distal end of the system 920 (such as shown in FIG. 62 ).
  • the delivery system 920 can be used to first deliver the spacer 800 to the region of the native mitral valve from the left ventricle.
  • the delivery device 920 is inserted into the left ventricle via an opening in the chest and the apex of the heart.
  • the delivery device 920 can be inserted into a femoral artery and advanced through the aorta in a retrograde direction until the distal end of the delivery device is in the left ventricle.
  • the outer sheath 922 can then be retracted proximally such that the anchors 804 , 806 are no longer confined within the outer sheath 922 .
  • the anchors 804 , 806 can be configured to self-expand to a splayed apart configuration shown in FIGS. 64 and 67 .
  • the delivery system 920 can include a mechanism for forcing the anchors 804 , 806 to splay apart to the splayed-apart configuration (such as described above with respect to the embodiment of FIG. 62 ).
  • the device 920 can then be distally advanced so that the native mitral valve leaflets are positioned between the splayed apart anchors 804 , 806 , and the body 802 .
  • the inner sheath 924 can then be retracted so that the body 802 is no longer confined within the inner sheath 924 and can radially expand to an expanded configuration between the native mitral valve leaflets.
  • the body 802 can expand such that the native leaflets are pinched between the body 802 and the anchors 804 , 806 .
  • the mechanism for forcing the anchors 804 , 806 to splay apart can be actuated to allow the anchors 804 , 806 to move radially inward toward the main body 802 , thereby pinching the native leaflets between the main body 802 and the anchors 804 , 806 .
  • FIGS. 65 and 66 show that the deployment of the spacer 800 to a native mitral valve via the transseptal approach can be similar to the deployment of the valve 800 via the transatrial approach, at least because in both cases the valve is delivered to the mitral valve from the left atrium.
  • the spacer 800 can be situated within the system 920 with the first end portion 816 of the spacer 800 disposed at the distal end of the system 920 (such as shown in FIG. 63 ).
  • the delivery system 920 can be used to first deliver the spacer 800 to the region of the native mitral valve from the left atrium.
  • the outer sheath 922 can then be retracted proximally such that the anchors 804 , 806 are no longer confined within the outer sheath 922 .
  • the anchors 804 , 806 can be configured to self-expand to a splayed apart configuration shown in FIGS. 65 and 66 .
  • the delivery system 920 can include a mechanism for forcing the anchors 804 , 806 to splay apart to the splayed-apart configuration.
  • the system 920 can then be proximally retracted so that the native mitral valve leaflets are positioned between the splayed apart anchors 804 , 806 , and the body 802 .
  • the inner sheath 924 can then be retracted so that the body 802 is no longer confined within the inner sheath 924 and can radially expand to an expanded configuration between the native mitral valve leaflets.
  • the body 802 can expand such that the native leaflets are pinched between the body 802 and the anchors 804 , 806 .
  • the mechanism for forcing the anchors 804 , 806 to splay apart can be actuated to allow the anchors 804 , 806 to move radially inward toward the main body 802 , thereby pinching the native leaflets between the main body 802 and the anchors 804 , 806 .
  • the delivery system 920 can be retracted and removed from the patient's vasculature.
  • the spacer 800 can remain in the native mitral valve region, with the main body 802 being situated between the two native leaflets, thereby helping to reduce or prevent mitral regurgitation. It will be understood that similar techniques can be used to deliver a spacer to the native aortic, tricuspid, or pulmonary valves, depending on the needs of the patient.
  • a marker catheter or other similar device can be used to help coordinate delivery and ensure that a desirable delivery position is achieved.
  • An exemplary suitable marker catheter can include a standard catheter designed for angiograms, for example, a catheter made of a relatively low-density plastic material having relatively high-density metal marker bands (e.g., radiopaque marker bands) disposed at regular intervals thereon.
  • the device can be introduced into a patient's vasculature and can be viewed under echocardiography or fluoroscopy.
  • a marker wire can be used in place of the marker catheter.
  • Another suitable alternative technique is left atrium angiography, which can help a physician visualize components of a patient's heart.
  • a marker catheter or marker wire can be introduced into a patient's vasculature and advanced to specific areas of the vasculature near a patient's heart.
  • a marker catheter can be advanced from a patient's jugular or femoral vein into the right atrium, then into the patient's coronary sinus.
  • a marker catheter can be advanced from a patient's femoral artery to the patient's circumflex artery.
  • a marker catheter can be advanced into a patient's left atrium.
  • the marker catheter can be used to aid a physician in delivering and ensuring desirable implantation of a prosthetic device.
  • the coronary sinus extends around the heart near the location and elevation of the mitral valve and thus can help a physician to properly size and position a prosthetic device for implantation.
  • the patient's vasculature can be viewed under echocardiography, fluoroscopy, or other visualization technique which allows a physician to view the prosthetic device being delivered and the marker catheter.
  • a physician can first view the devices along an axis extending from the patient's left atrium to the patient's left ventricle (referred to as a “short axis”). By viewing the devices along the short axis, a physician can deploy (such as by inflating a balloon on which an implantable device is mounted) an implantable prosthetic device and expand portions of the device to desired sizes and/or configurations based on the size and location of the marker catheter, which can provide an estimate of the size of features of the native mitral valve.
  • a physician can use the marker catheter to obtain an estimate of the size of a patient's native heart valve, from which estimate a prosthetic device to be implanted in the patient's native heart valve can be selected from a set of devices having differing sizes, e.g., a set of devices having differing diameters.
  • a physician can also view the devices along an axis perpendicular to the short axis (referred to as a “long axis”).
  • the long axis can have several orientations, such as from commissure to commissure, but in one specific embodiment, the long axis is oriented from the A 2 location to the P 2 location of the native mitral valve.
  • a physician can align an implantable prosthetic device relative to the marker catheter at a desirable location along the short axis, such that an atrial anchor of the implantable device is situated in the left atrium (above the marker catheter) and a ventricular anchor of the implantable device is situated in the left ventricle (below the marker catheter).
  • FIG. 68 shows an exemplary dual anchor spacer 950 which can be delivered to the region of the native mitral valve via any suitable delivery method, for example, using the transapical, transeptal, transatrial, or transfemoral techniques described above.
  • the spacer 950 can include a main body 952 , a first anchor 954 , a second anchor 956 , and a nosecone 958 .
  • the spacer 950 can also include a tapered portion 962 , which can couple the main body portion 952 to a neck portion 964 .
  • the taperer portion 962 can have a variable width which can taper from the width of the main body 952 to the width of the neck portion 964 .
  • the neck portion 964 can be configured to receive a portion of the nosecone 958 therein, and can be coupled to the nosecone 958 .
  • the main body 952 and anchors 954 , 956 can be fabricated from various materials, as described above with regard to other embodiments, and the nosecone 958 can be fabricated from various suitable materials such as a long term implantable silicone or other suitable elastomers.
  • the nosecone 958 can have a small pore, or opening, or slit, 966 , which can extend through and along the length of the nosecone 958 .
  • the guidewire can extend through the opening 966 , thus eliminating the need for an opening or pore in a fabric layer.
  • the spacer 950 can facilitate crossing of a native heart valve due to its tapered tip, which can also provide improvements in hydrodynamics during diastolic blood flow.
  • the opening 966 can be sufficiently small to prevent significant amounts of blood from travelling through the nosecone 958 .
  • the multi-anchor spacers described herein offer several advantages over previous techniques for treating regurgitation in heart valves.
  • the multi-anchor spacers described herein can be used to treat patients whose native leaflets fail to coapt at all, whereas many previous techniques required some amount of native coaptation to be efficacious.
  • the spacers described herein e.g., spacer 640
  • the terms “a”, “an” and “at least one” encompass one or more of the specified element. That is, if two of a particular element are present, one of these elements is also present and thus “an” element is present.
  • the terms “a plurality of” and “plural” mean two or more of the specified element.
  • the term “and/or” used between the last two of a list of elements means any one or more of the listed elements.
  • the phrase “A, B, and/or C” means “A,” “B,” “C,” “A and B,” “A and C,” “B and C” or “A, B and C.”
  • Coupled generally means physically coupled or linked and does not exclude the presence of intermediate elements between the coupled items absent specific contrary language.

Abstract

This disclosure pertains generally to prosthetic devices and related methods for helping to seal native heart valves and prevent or reduce regurgitation therethrough, as well as devices and related methods for implanting such prosthetic devices. In some cases, a spacer having a single anchor can be implanted within a native heart valve. In some cases, a spacer having dual anchors can be implanted within a native heart valve. In some cases, devices can be used to extend the effective length of a native heart valve leaflet.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Patent Application No. 61/697,706, filed Sep. 6, 2012, and 61/763,848, filed Feb. 12, 2013, which are each hereby incorporated herein by reference in their entirety.
FIELD
This disclosure pertains generally to prosthetic devices and related methods for helping to seal native heart valves and prevent or reduce regurgitation therethrough, as well as devices and related methods for implanting such prosthetic devices.
BACKGROUND
The native heart valves (i.e., the aortic, pulmonary, tricuspid and mitral valves) serve critical functions in assuring the forward flow of an adequate supply of blood through the cardiovascular system. These heart valves can be rendered less effective by congenital malformations, inflammatory processes, infectious conditions or disease. Such damage to the valves can result in serious cardiovascular compromise or death. For many years the definitive treatment for such disorders was the surgical repair or replacement of the valve during open heart surgery. However, such surgeries are highly invasive and are prone to many complications. Therefore, elderly and frail patients with defective heart valves often went untreated. More recently, transvascular techniques have been developed for introducing and implanting prosthetic devices in a manner that is much less invasive than open heart surgery. Such transvascular techniques have increased in popularity due to their high success rates.
A healthy heart has a generally conical shape that tapers to a lower apex. The heart is four-chambered and comprises the left atrium, right atrium, left ventricle, and right ventricle. The left and right sides of the heart are separated by a wall generally referred to as the septum. The native mitral valve of the human heart connects the left atrium to the left ventricle. The mitral valve has a very different anatomy than other native heart valves. The mitral valve includes an annulus portion, which is an annular portion of the native valve tissue surrounding the mitral valve orifice, and a pair of cusps, or leaflets extending downward from the annulus into the left ventricle. The mitral valve annulus can form a “D” shaped, oval, or otherwise out-of-round cross-sectional shape having major and minor axes. The anterior leaflet can be larger than the posterior leaflet, forming a generally “C” shaped boundary between the abutting free edges of the leaflets when they are closed together.
When operating properly, the anterior leaflet and the posterior leaflet function together as a one-way valve to allow blood to flow only from the left atrium to the left ventricle. The left atrium receives oxygenated blood from the pulmonary veins. When the muscles of the left atrium contract and the left ventricle dilates, the oxygenated blood that is collected in the left atrium flows into the left ventricle. When the muscles of the left atrium relax and the muscles of the left ventricle contract, the increased blood pressure in the left ventricle urges the two leaflets together, thereby closing the one-way mitral valve so that blood cannot flow back to the left atrium and is instead expelled out of the left ventricle through the aortic valve. To prevent the two leaflets from prolapsing under pressure and folding back through the mitral annulus toward the left atrium, a plurality of fibrous cords called chordae tendineae tether the leaflets to papillary muscles in the left ventricle.
Mitral regurgitation occurs when the native mitral valve fails to close properly and blood flows into the left atrium from the left ventricle during the systole phase of heart contraction. Mitral regurgitation is the most common form of valvular heart disease. Mitral regurgitation has different causes, such as leaflet prolapse, dysfunctional papillary muscles and/or stretching of the mitral valve annulus resulting from dilation of the left ventricle. Mitral regurgitation at a central portion of the leaflets can be referred to as central jet mitral regurgitation and mitral regurgitation nearer to one commissure (i.e., location where the leaflets meet) of the leaflets can be referred to as eccentric jet mitral regurgitation.
Some prior techniques for treating mitral regurgitation include stitching portions of the native mitral valve leaflets directly to one another. Other prior techniques include the use of a spacer implanted between the native mitral valve leaflets. Despite these prior techniques, there is a continuing need for improved devices and methods for treating mitral valve regurgitation.
SUMMARY
This disclosure pertains generally to prosthetic devices and related methods for helping to seal native heart valves and prevent or reduce regurgitation therethrough, as well as devices and related methods for implanting such prosthetic devices.
In some embodiments, a prosthetic device for treating heart valve regurgitation comprises a radially compressible and radially expandable body having a first end, a second end, and an outer surface extending from the first end to the second end and an anchor having a connection portion and a leaflet capture portion, wherein the connection portion is coupled to the body such that the leaflet capture portion is biased against the outer surface of the body when the body is in a radially expanded state, the prosthetic device is configured to capture a leaflet of a native heart valve between the leaflet capture portion of the anchor and the outer surface of the body, and the body is configured to prevent blood from flowing through the body in a direction extending from the first end to the second end and in a direction extending from the second end to the first end.
In some embodiments, the outer surface of the body comprises a first side against which the anchor is biased and a second side opposite the first side, and the connection portion of the anchor is coupled to the body on the second side of the body. In some embodiments, the anchor comprises an elongated member that is coupled to the second side of the body at a connection location and the elongated member comprises a ventricular portion that extends from the connection location across the first end of the body. In some embodiments, the ventricular portion comprises first and second ventricular portions and the first ventricular portion is substantially parallel to the second ventricular portion.
In some embodiments, the body is radially compressible to a compressed state in which a leaflet-receiving gap exists between the body and the leaflet capture portion of the anchor, and the body is resiliently radially self-expandable to the radially expanded state. In some embodiments, the anchor comprises a first clip portion and a second clip portion, and the device is configured to capture the leaflet between the first and second clip portions. In some embodiments, the body is formed from Nitinol and is radially self-expandable to the expanded state. In some embodiments, the body comprises a metallic frame and a blood-impermeable fabric mounted on the frame. In some embodiments, the body is configured to allow blood to flow around the body between the body and a non-captured leaflet during diastole, and configured to allow the non-captured leaflet to close around the body to prevent mitral regurgitation during systole.
In some embodiments, the anchor is coupled to the first end of the body and the device further comprises an atrial stabilizing member extending from the second end of the body. In some embodiments, the body is configured to move within the native heart valve along with motion of the captured leaflet. In some embodiments, an atrial end portion of the body comprises a tapered shoulder that reduces in diameter moving toward the atrial end portion of the body. In some embodiments, the body comprises a crescent cross-sectional shape. In some embodiments, the anchor comprises first and second anchors and the device is configured to be secured to both native mitral valve leaflets.
In some embodiments, a prosthetic device for treating heart valve regurgitation comprises a main body portion having a connection portion and a free end portion, wherein the connection portion is configured to be coupled to a first one of the two native mitral valve leaflets such that the device is implanted within a native mitral valve orifice, and when the device is implanted within the native mitral valve orifice, the free end portion moves laterally toward a second one of the two native mitral valve leaflets during systole, thereby helping to seal the orifice and reduce mitral regurgitation during systole, and the free end portion moves laterally away from the second native mitral valve leaflet during diastole to allow blood to flow from the left atrium to the left ventricle during diastole.
In some embodiments, the connection portion of the main body is thicker than the free end portion. In some embodiments, the main body portion further comprises an atrial portion that contacts the native mitral valve annulus within the left atrium adjacent to the first native mitral valve leaflet. In some embodiments, the device further comprises a ventricular anchor that clips around a lower end of the first native mitral valve leaflet, thereby securing the device to the first native mitral valve leaflet. In some embodiments, the anchor comprises a paddle shape with a broad upper end portion and a relatively narrow neck portion, wherein the neck portion couples the upper end portion to the main body.
In some embodiments, a prosthetic device comprises a sheet of flexible, blood-impermeable material configured to be implanted within a native mitral valve orifice and coupled to a first one of the two native mitral leaflets or to the native mitral annulus adjacent the first native mitral leaflet, wherein when implanted the sheet is configured to inflate with blood during systole such that a free portion of the sheet not coupled to the first native mitral leaflet or the mitral annulus adjacent the first native mitral leaflet moves laterally toward and seals against the second of the two native mitral leaflets to reduce mitral regurgitation, and when implanted the sheet is configured to deflate during diastole such that the portion of the sheet not coupled to the first native mitral leaflet or the native mitral annulus adjacent the first native mitral leaflet moves laterally away from the second native mitral leaflet to allow blood to flow from the left atrium to the left ventricle.
In some embodiments, the sheet is supported by a rigid frame that is secured to the first native mitral leaflet. In some embodiments, the frame comprises a ventricular anchor that clips around a lower end of the first native mitral leaflet. In some embodiments, the frame comprises an atrial portion that contacts the native mitral annulus within the left atrium adjacent to the first native mitral leaflet. In some embodiments, an upper end of the sheet is secured directly to the native mitral annulus adjacent the first native mitral leaflet or to the first native mitral leaflet adjacent the native mitral annulus. In some embodiments, the upper end of the sheet is secured to native tissue via rigid anchors that puncture the native tissue.
In some embodiments, the sheet comprises an annular cross-sectional profile perpendicular to an axis extending through the mitral orifice from the left atrium to the left ventricle. In some embodiments, the sheet comprises a closed atrial end and an open ventricular end. In some embodiments, the open lower end is biased toward an open position and is configured to collapse to a closed position during diastole. In some embodiments, the sheet is supported by a rigid frame that is secured to the first native mitral leaflet, and the frame comprises a plurality of longitudinal splines extending from the upper end of the sheet to the lower end of the sheet. In some embodiments, the splines are biased to cause the lower end of the sheet to open away from the first native leaflet.
In some embodiments, a lower end of the sheet is tethered to a location in the left ventricle below the native mitral leaflets. In some embodiments, the lower end of the sheet is tethered to the papillary muscle heads in the left ventricle. In some embodiments, the lower end of the sheet is tethered to a lower end of the rigid frame. In some embodiments, opposing lateral ends of the lower end of the sheet are tethered to the lower end of the frame such that an intermediate portion of the lower end of the sheet can billow out away from the frame and toward the second leaflet during systole. In some embodiments, the sheet has a generally trapezoidal shape, with a broader portion adjacent to the mitral annulus and a narrower portion positioned between the native mitral leaflets.
In some embodiments, a prosthetic device for treating heart valve regurgitation comprises a radially compressible and radially expandable body having a first end, a second end, and an outer surface extending from the first end to the second end, a first anchor coupled to the body and configured to capture the anterior native mitral valve leaflet between the first anchor and the body to secure the device to the anterior leaflet, and a second anchor coupled to the body and configured to capture the posterior native mitral valve leaflet between the second anchor and the body to secure the device to the posterior leaflet, wherein when the first and second anchors capture the anterior and posterior leaflets, the body is situated within a mitral valve orifice between the anterior and posterior leaflets, thereby decreasing a size of the orifice.
In some embodiments, the body is radially compressible to a collapsed delivery configuration suitable for delivering the device to the native mitral valve, and radially expandable from the collapsed delivery configuration to an expanded, operational configuration suitable for operation in the native mitral valve. In some embodiments, the body is formed from Nitinol and is radially self-expandable from the collapsed configuration to the expanded configuration. In some embodiments, the device further comprises a sheet of blood impermeable fabric covering the body. In some embodiments, the body has an elliptical cross-sectional shape. In some embodiments, the body has a crescent cross-sectional shape. In some embodiments, the body comprises a prosthetic valve. In some embodiments, the body is configured to prevent blood from flowing through the body in a direction extending from the first end to the second end and in a direction from the second end to the first end.
In some embodiments, a method of implanting a prosthetic sealing device at a native mitral valve of a heart comprises advancing a delivery catheter to a native mitral valve region of a heart from a left atrium of the heart, the delivery catheter housing the prosthetic sealing device in a radially compressed configuration, advancing the prosthetic sealing device distally relative to the delivery catheter such that an anchor of the prosthetic sealing device moves out of the catheter and forms a leaflet-receiving gap between an end portion of the anchor and the delivery catheter, positioning either a posterior or an anterior mitral valve leaflet in the gap, and advancing a radially compressed body of the prosthetic sealing device out of the delivery catheter such that the body self-expands radially toward the end portion of the anchor, reducing the gap, and capturing the leaflet between the body and the end portion of the anchor, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole.
In some embodiments, a non-captured one of the anterior and posterior leaflets is not secured to the prosthetic sealing device when the prosthetic sealing device is implanted at the native mitral valve. In some embodiments, advancing a delivery catheter through the native mitral valve from a left atrium comprises advancing the delivery catheter through an incision in a portion of a septum between the left atrium and a right atrium. In some embodiments, when the delivery catheter is advanced to the native mitral valve region of the heart, the anchor is held in a substantially straightened position within the delivery catheter extending distally from body of the prosthetic sealing device.
In some embodiments, a method of implanting a prosthetic sealing device at a native mitral valve comprises advancing a delivery device to a native mitral valve region via a left ventricle, the delivery catheter housing the prosthetic sealing device in a compressed configuration, allowing an anchor of the prosthetic sealing device to move radially out of the delivery device while a body of the delivery device is in a compressed configuration, such that a leaflet-receiving gap forms between an end portion of the anchor and the delivery device, positioning either a posterior or an anterior mitral valve leaflet in the gap, and allowing the body of the prosthetic sealing device to radially self-expand such that the leaflet is captured between the body and the anchor, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole.
In some embodiments, a non-captured one of the anterior and posterior mitral valve leaflets is not secured to the prosthetic sealing device when the prosthetic sealing device is implanted at the native mitral valve. In some embodiments, advancing a delivery device to a native mitral valve region via a left ventricle comprises inserting the delivery device into the left ventricle through an incision in an apex of the left ventricle.
In some embodiments, a method of implanting a prosthetic sealing device at a native mitral valve of a heart comprises advancing a delivery system to a native mitral valve region of a heart from a left ventricle of the heart, the delivery system housing the prosthetic sealing device in a radially compressed configuration, proximally retracting an outer sheath of the delivery system such that anchors of the prosthetic sealing device are not confined within the delivery system, advancing the delivery system toward the left atrium of the heart such that native mitral valve leaflets are positioned between the anchors of the prosthetic sealing device and the delivery system, proximally retracting an inner sheath of the delivery system such that a body of the prosthetic sealing device is not confined within the delivery system, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole, and removing the delivery system from the native mitral valve region of the heart.
In some embodiments, advancing the delivery system to the native mitral valve region from the left ventricle comprises inserting the delivery device into the left ventricle through an incision in an apex of the left ventricle. In some embodiments, when the delivery system is advanced to the native mitral valve region of the heart, the anchor is held in a substantially straightened position within the delivery catheter extending distally along a side of the body of the prosthetic sealing device.
In some embodiments, a method of implanting a prosthetic sealing device at a native mitral valve of a heart comprises advancing a delivery system to a native mitral valve region of a heart from a left atrium of the heart, the delivery system housing the prosthetic sealing device in a radially compressed configuration, proximally retracting an outer sheath of the delivery system such that anchors of the prosthetic sealing device are not confined within the delivery system, retracting the delivery system toward the left atrium of the heart such that native mitral valve leaflets are positioned between the anchors of the prosthetic sealing device and the delivery system, proximally retracting an inner sheath of the delivery system such that a body of the prosthetic sealing device is not confined within the delivery system, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole, and removing the delivery system from the native mitral valve region of the heart.
In some embodiments, advancing the delivery system to the native mitral valve region from the left atrium comprises advancing the delivery system through an incision in a portion of a septum between the left atrium and a right atrium. In some embodiments, when the delivery system is advanced to the native mitral valve region of the heart, the anchor is held in a substantially straightened position within the delivery catheter extending proximally from body of the prosthetic sealing device.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a portion of a human heart with an exemplary embodiment of a sealing device attached to the native posterior mitral leaflet.
FIG. 2 shows a portion of a human heart with an exemplary embodiment of a sealing device attached to the native anterior mitral leaflet.
FIG. 3 shows a portion of a human heart with an exemplary embodiment of a sealing device attached to the native posterior mitral leaflet and having an atrial anchor.
FIG. 4 is an atrial end view of one embodiment of the sealing device of FIG. 3 having a lattice-type atrial anchor.
FIG. 5 is an atrial end view of another embodiment of the sealing device of FIG. 3 having a loop-type atrial anchor.
FIG. 6 is a side view of an exemplary sealing device.
FIG. 7 is another side view of the sealing device of FIG. 6.
FIG. 8 is an atrial end view of the sealing device of FIG. 6.
FIG. 9 is an atrial end view of the sealing device of FIG. 6 implanted at a native mitral valve.
FIG. 10 shows a crescent-shaped embodiment of a sealing device.
FIG. 11 shows a sealing device having an anchor that extends from one side of a body, around a ventricular end of the body, and along a second side of the body.
FIGS. 12-15 show a method of deploying the sealing device of FIG. 11 from a delivery sheath.
FIG. 16 is a side view of another embodiment of a sealing device having an anchor that extends from one side of a body, around a ventricular end of the body, and along a second side of the body.
FIG. 17 is another side view of the embodiment of FIG. 16.
FIG. 18 is an atrial end view of the embodiment of FIG. 16.
FIG. 19 is a side view of an embodiment similar to that shown in FIG. 16.
FIG. 20 shows the embodiment of FIG. 19 covered with a fabric layer.
FIG. 21 is a ventricular end view of the embodiment of FIG. 20 implanted at a native mitral valve.
FIG. 22 shows a portion of a human heart with an exemplary sealing device being implanted at the mitral region in a transeptal approach.
FIG. 23 shows a portion of a human heart with an exemplary sealing device being implanted at the mitral region in a transapical approach.
FIG. 24 shows a human heart with an exemplary prosthetic device attached to a native mitral leaflet.
FIG. 25 shows an exemplary prosthetic device being coupled to a native mitral leaflet in a transeptal approach.
FIG. 26 shows an exemplary prosthetic device being coupled to a native mitral leaflet in a transapical approach.
FIGS. 27 and 28 show another exemplary prosthetic device being coupled to a native mitral leaflet.
FIGS. 29-31 show an exemplary prosthetic device attached to the mitral valve region of a human heart.
FIGS. 32-34 show another exemplary prosthetic device attached to the mitral valve region of a human heart.
FIG. 35 shows two exemplary prosthetic devices, each being coupled to a respective one of the native mitral valve leaflets.
FIG. 36 shows two exemplary prosthetic devices, each being coupled to a respective one of the native mitral valve leaflets.
FIG. 37 shows two exemplary prosthetic devices, each being coupled to a respective one of the native mitral valve leaflets.
FIGS. 38-41 show an exemplary prosthetic device having two anchors.
FIG. 42 shows an exemplary prosthetic device having two anchors, coupled to both of the native mitral valve leaflets.
FIG. 43 shows an exemplary prosthetic device having two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
FIG. 44 shows an exemplary prosthetic device having an elongated body and two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
FIG. 45 shows an exemplary prosthetic device having a valve and two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
FIG. 46 shows an exemplary prosthetic device having a crescent-shaped body and two anchors, coupled to both of the native mitral valve leaflets, from an atrial view.
FIGS. 47-51 show exemplary prosthetic devices having three anchors.
FIGS. 52-54 show the prosthetic device of FIGS. 38-41 implanted at a native mitral valve.
FIGS. 55 and 56 show another exemplary prosthetic device comprising a radially compressible and expandable body.
FIGS. 57 and 58 show the prosthetic device of FIGS. 55 and 56 with a fabric layer.
FIGS. 59-63 show an exemplary prosthetic device with an exemplary delivery system, in various configurations.
FIGS. 64-67 show various exemplary delivery approaches for delivering a prosthetic device to a native mitral valve.
FIG. 68 shows an exemplary prosthetic device including a nosecone.
DETAILED DESCRIPTION
Described herein are embodiments of prosthetic devices that are primarily intended to be implanted at one of the mitral, aortic, tricuspid, or pulmonary valve regions of a human heart, as well as apparatuses and methods for implanting the same. The prosthetic devices can be used to help restore and/or replace the functionality of a defective native mitral valve. The disclosed embodiments should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another.
Prosthetic Spacers
In some embodiments, a prosthetic device comprises a body and an anchor. The body is configured to be positioned within the native mitral valve orifice to help create a more effective seal between the native leaflets to prevent or minimize mitral regurgitation. The body can comprise a structure that is impervious to blood and that allows the native leaflets to close around the sides of the body during ventricular systole to block blood from flowing from the left ventricle back into the left atrium. The body is sometimes referred to herein as a spacer because the body can fill a space between improperly functioning native mitral leaflets that do not naturally close completely. In some embodiments, the body can comprise a prosthetic valve structure positioned within an annular body.
The body can have various shapes. In some embodiments, the body can have an elongated cylindrical shape having a round cross-sectional shape. In other embodiments, the body can have an ovular cross-sectional shape, a crescent cross-sectional shape, or various other non-cylindrical shapes. The body can have an atrial or upper end positioned in or adjacent to the left atrium, a ventricular or lower end positioned in or adjacent to the left ventricle, and an annular side surface that extends between the native mitral leaflets.
The anchor can be configured to secure the device to one or both of the native mitral leaflets such that the body is positioned between the two native leaflets. The anchor can attach to the body at a location adjacent the ventricular end of the body. The anchor can be configured to be positioned behind a native leaflet when implanted such that the leaflet is captured between the anchor and the body.
The prosthetic device can be configured to be implanted via a delivery sheath. The body and the anchor can be compressible to a radially compressed state and can be self-expandable to a radially expanded state when compressive pressure is released. The device can be configured to allow the anchor to self-expand radially away from the still-compressed body initially in order to create a gap between the body and the anchor. The leaflet can then be positioned in the gap. The body can then be allowed to self-expand radially, closing the gap between the body and the anchor and capturing the leaflet between the body and the anchor. The implantation methods for various embodiments can be different, and are more fully discussed below with respect to each embodiment. Additional information regarding these and other delivery methods can be found in U.S. Patent Application Publication No. 2011/0137397 and U.S. Provisional Patent Application No. 61/760,577, which are incorporated by reference herein in their entirety.
Some embodiments disclosed herein are generally configured to be secured to only one of the native mitral leaflets. However, other embodiments comprise more than one anchor and can be configured to be secured to both mitral leaflets. Unless otherwise stated, any of the embodiments disclosed herein that comprise a single anchor can optionally be secured to the anterior mitral leaflet or secured to the posterior mitral leaflet, regardless of whether the particular embodiments are shown as being secured to a particular one of the leaflets.
Furthermore, some embodiments can optionally also include one or more atrial anchors, such as to provide additional stabilization. Unless otherwise stated, any of the embodiments disclosed herein can optionally include an atrial anchor or not include an atrial anchor, regardless of whether the particular embodiments are shown with an atrial anchor or not.
Some of the disclosed prosthetic devices are prevented from atrial embolization by having the anchor hooked around a leaflet, utilizing the tension from native chordae tendinae to resist high systolic pressure urging the device toward the left atrium. During diastole, the devices can rely on the compressive forces exerted on the leaflet that is captured between the body and the anchor to resist embolization into the left ventricle.
FIG. 1 shows an exemplary embodiment of a prosthetic device 10 that comprises a body 12 and an anchor 14. The device 10 is secured to the posterior mitral leaflet 8 with the free end of the leaflet 8 captured between the anchor 14 and the body 12. In FIG. 1, the anterior mitral leaflet 6 is shown separated from the body 12 during diastole as blood flows from the left atrium 2 into the left ventricle 4. As the mitral leaflets open apart from each other, the device 10 can move with the posterior leaflet 8, allowing the anterior leaflet 6 to open away from the body 12. During systole, the back pressure on the leaflets closes them together around the body 12 to prevent mitral regurgitation. FIG. 2 shows the device 10 alternatively secured to the anterior mitral leaflet 6 with the posterior mitral leaflet 8 free to articulate toward and away from the device 10.
FIG. 3 shows a prosthetic device 20 having a body 22, a ventricular anchor 24, and an atrial anchor 26. The device 20 is shown secured to the posterior leaflet 8 via the ventricular anchor 24. The atrial anchor 26 can extend laterally from adjacent the atrial end of the body 22 toward the mitral annulus or other lateral portions of the left atrium 2 adjacent to the posterior leaflet 8. The atrial anchor 26 can help stabilize the device. For example, the atrial anchor 26 can prevent the body 22 from tilting and keep it oriented longitudinally along the blood flow direction through the mitral orifice. The atrial anchor 26 can also help prevent the device 20 from embolizing into the left ventricle 4.
FIGS. 4 and 5 are atrial end views showing two alternative embodiments of atrial anchors for the device 20. FIG. 4 shows an atrial anchor 26A that comprises a lattice-type framework supported by two connections to the body 22, while FIG. 5 shows an atrial anchor 26B that comprises a single elongated member extending in a loop between two connections to the body 22. In both embodiments, the atrial anchor comprises a relatively broader or wider end portion configured to engage with the atrial tissue so as to spread out the engagement forces to avoid tissue damage and promote increased tissue ingrowth.
FIGS. 6-8 show three views of an exemplary embodiment of the prosthetic device 20 having a cylindrical body 22, a ventricular anchor 24, and an atrial anchor 26C. The ventricular anchor 24, as shown in FIGS. 6 and 7, comprises an elongated member that extends from two connection points adjacent the ventricular end of the body 22 and along one side of the body toward the atrial end of the body. The ventricular anchor is contoured around the generally cylindrical side surface of the body 22. The atrial anchor 26C comprises a lattice-type framework made up of several diamond-shaped segments 29 coupled side-by-side in an arc. The atrial anchor 26C further comprises three connecting members 27 coupling it to the body 22 adjacent the atrial end of the body. As shown in FIG. 6, the atrial member 26C extends generally laterally to the same side of the body 22 as the ventricular anchor 24. The radially outward end portion of the atrial anchor can have an upward curvature to conform to the curved geometry of the left atrium. Each of the diamond-shaped segments 29 comprises radially outwardly pointing tip 30 that can press into and/or penetrate adjacent tissue in some cases.
The device 20 is shown in an expanded configuration in FIGS. 3-9. In a compressed delivery configuration, the atrial anchor 26 can be folded down against the side of the body 22 or extended upwardly away from the body 22. Furthermore, the atrial anchor 26 can be circumferentially compressed, especially embodiments having a lattice-type structure.
The body 22 can comprise an annular metal frame 32 covered with a blood-impervious fabric 28, as shown in FIGS. 6-9. One or both ends of the body can also be covered with the blood-impervious fabric 28, as shown in FIG. 8. The frame 32 can comprise a mesh-like structure comprising a plurality of interconnected metal struts, like a conventional radially compressible and expandable stent. In other embodiments, the body can comprise a solid block of material, such as flexible sponge-like block. In some embodiments, the body 22 can be hollow or filled with material.
The frame 32 can be formed from a self-expandable material, such as Nitinol. When formed from a self-expandable material, the frame 32 can be radially compressed to a delivery configuration and can be retained in the delivery configuration by placing the device in the sheath of a delivery apparatus. When deployed from the sheath, the frame 32 can self-expand to its functional size. In other embodiments, the frame can be formed from a plastically expandable material, such as stainless steel or a cobalt chromium alloy. When formed from a plastically expandable material, the prosthetic device can be crimped onto a delivery apparatus and radially expanded to its functional size by an inflatable balloon or an equivalent expansion mechanism. It should be noted that any of the embodiments disclosed herein can comprise a self-expandable main body or a plastically expandable main body.
FIG. 9 is a view from the left atrium 2 of the device 20 of FIGS. 6-8 implanted at a mitral valve. The body 22 is positioned between the native leaflets 6, 8 in a sealed position with the atrial anchor 26C engaged with the atrial tissue adjacent the posterior mitral leaflet 8. The atrial end of the body 22 is open while the ventricular end of the body is covered with the impervious fabric 28.
FIG. 10 shows an exemplary prosthetic device 34 having a crescent shaped body 36. The body 36 is configured to be positioned with the convex side facing the posterior mitral leaflet 8 and the concave side facing the anterior mitral leaflet 6. In this embodiment, the body 36 can comprise a flexible, sponge-like material. Consequently, the device 34 can comprise two ventricular anchors to capture the anterior leaflet 6. A first ventricular anchor 44 is configured to be positioned behind the anterior leaflet while a second ventricular anchor 42 is configured to be positioned between the body 36 and the anterior leaflet. The anterior leaflet 6 is therefore captured and pinched between the two anchors 42, 44 to secure the body 36 within the mitral orifice. The device 34 relies on the two anchors 42, 44 to capture the leaflet because the body 36 in this embodiment may lack sufficient rigidity to grip the leaflet. Both of the ventricular anchors 42, 44 can extend from adjacent a ventricular end 40 of the body 36 and extend up toward an atrial end 38 of the body along the same side of the body. In other embodiments, the anchors 42, 44 can be positioned on the convex side of the body 36 in order to secure the body to the posterior leaflet. In some embodiments, the anchor 42 can be nested within the anchor 44 to provide a smaller crimped profile. In other embodiments, the anchors 42, 44 can have various other shapes. In still other embodiments, the body 36 can be cylindrical or can have any of various other shapes described herein.
FIG. 11 shows an exemplary embodiment of a prosthetic device 50 having a body 52 and an anchor 54 that attaches to a first side of the body, extends around the ventricular end of the body, and extends along a second side of the body opposite the first side of the body. The device 50 is configured to capture a mitral leaflet between the anchor 54 and the second side of the body 52 to secure the body within the mitral orifice. The body 52 can comprise, for example, a radially compressible and expandable metal stent covered by a blood impermeable fabric, as described above.
FIGS. 12-15 illustrate an exemplary method of deployment of the device 50 from a delivery catheter 56. In FIG. 12, the body 52 is shown in a radially compressed state within the catheter 56 with the anchor 54 extending distally from the ventricular end of the body in a straightened, or unfurled, state. The device 50 can be resiliently deformed in this configuration such that the device 50 resiliently returns to the configuration shown in FIG. 11 when released from constraint. A pusher member 59 can be used to push the device 50 distally relative to the catheter 56 or to hold the device 50 steady as the catheter is retracted. In FIG. 13, the catheter 56 is retracted proximally from the device 50 and/or the device 50 is advanced distally from the catheter 56 such that the elongated anchor 54 begins to extend out of the distal outlet 58 of the catheter. As the anchor 54 moves out of the outlet 58, the anchor begins to naturally return toward the shape of FIG. 11, curling gradually as it is freed from the confining forces of the catheter. In FIG. 14, the entire anchor 54 has moved out of the catheter 56 and has returned to its natural shape of FIG. 11. However, the body 52 is still held in radial compression by the catheter, creating a gap 60 between the second side of the body 52 and the end of the anchor 54. A mitral leaflet can be positioned within the gap 60 while the device is in the configuration of FIG. 14. In FIG. 15, the ventricular end 62 of the body 52 begins to advance out of the outlet 58, allowing the ventricular end 62 of the body to radially expand while the atrial end 64 of the body remains held in compression within the catheter. This causes the body 52 to expand gradually toward the anchor 54, decreasing the width of the gap 60, thereby capturing the leaflet within the gap. Once the atrial end 64 of the body 52 is freed from the catheter 56, the entire body 52 can expand to its fully expanded state shown in FIG. 11, pinching or compressing the leaflet between the end of the anchor 54 and the side of the body. In the fully expanded state shown in FIG. 11, a gap remains between the body 52 and the anchor 54, although the gap is desirably sized such that a leaflet is engaged by the body and the anchor when placed in the gap. In alternative embodiments, however, such a gap may not exist when the device is in its fully expanded state (i.e., the anchor 54 contacts the body 52 when a leaflet is not positioned between these two components).
FIGS. 16-18 show orthogonal views of an exemplary embodiment of a device 70 similar to the device 50. The device 70 can be deployed from a catheter in the manner described above with respect to FIGS. 11-15. The device 70 comprises a radially self-expandable body 72 and a ventricular anchor 74. The body 72 can comprise a narrowed atrial end 76 and a tapered shoulder region 77, such as to provide improved hemodynamics as blood flows around the shoulder region. The body 72 has a ventricular end 78 opposite from the atrial end 76. The ventricular anchor 74 can comprise an elongated, curved member that connects to the body 72 at two connection points 80, 82 adjacent to the ventricular end 78 on a first side of the body (i.e., the right side of the body in FIG. 16). As shown in FIGS. 16-18, the anchor 74 comprises first portions 84, 86 that extend from the connection points 80, 82, respectively, around the ventricular end 78 of the body, to a second, opposite side of the body (i.e., the left side of the body in FIG. 16). The anchor 74 further comprises second portions 88, 90 that extend from the first portions 84, 86, respectively, along the second side of the body toward the atrial end 76 of the body. The second portions 88, 90 gradually expand apart from each other moving atrially toward an end portion 92 of the anchor 74. The second portions 88, 90 and the end portion 92 of the anchor 74 can form a paddle shape, as shown in FIG. 17, and can have a circumferential curvature that substantially matches the curvature of the body 72.
Note that, while FIGS. 16-18 appear to show the end portion 92 of the anchor passing within a portion of the body 72, the end portion 92 actually extends around the outer surface of the body 72, as shown in FIGS. 19 and 20. The position of the end portion 92 in FIGS. 16-18 illustrates the position that the anchor 74 wants to resiliently move toward in the absence of resistance from body 72. When manufactured, the anchor 74 is provided with a pre-bend that causes the end portion 92 to press against the outer surface of the body 72, as shown in FIGS. 19 and 20. This provides the device 70 the ability to apply a strong enough clamping force on a leaflet positioned between the end portion 92 and the body 72, even when the leaflet is very thin.
FIG. 20 also shows a blood-impervious fabric layer 94 covering the body 72 which can prevent blood from flowing through the body 72. The fabric layer can comprise, for example, polyethylene terephthalate (PET) or polyurethane. Any of the spacers described herein (even if shown just as a frame) can include such a blood-impervious fabric layer covering the spacer, which can prevent blood from flowing through the spacer.
The device 70 can be can be deployed from a delivery catheter according to the method illustrated with respect to device 50 in FIGS. 11-15, by releasing the anchor 74 first to create a leaflet-receiving gap between the end portion 92 and the body 72. After positioning a leaflet in the gap, the body 72 can subsequently be freed to self-expand radially toward the end portion 92 to clamp the leaflet between the end portion 92 and the second side of the body 72.
Because the anchor 74 extends around the ventricular end 78 of the body, the first portions 84, 86 can be provided with a larger radius of curvature compared to if the anchor 74 was connected to the body 72 on the same side as the end portion 92. This large radius of curvature of the first portions 84, 86 can provide greater control over the clamping forces between the end portion 92 and the body 72, and provide a more robust and durable anchor configuration, reducing stress concentrations in the anchor 74 and connection points 80, 82. Because the body is acting as a spacer, causing the blood to flow around it, the anchor 74 can pass around the ventricular end 78 of the body without obstructing the flow of blood any more than necessary. Having the anchor members 84, 86 positioned below the ventricular end of the body may not be as desirable in embodiments where the body comprises an annular frame with a prosthetic valve within the annular frame, since the members 84, 86 could restrict the flow of blood through the body to some degree.
In the case of the device 70, when the device is clipped onto a mitral leaflet between the end portion 92 and the second side of the body 72, a majority of the blood flow passes around the other three sides of the body (i.e., the left, right, and bottom side in FIG. 18). This is illustrated in FIG. 21, which shows a ventricular end view of the device 70 implanted in a mitral orifice with the posterior leaflet 8 captured between the anchor 74 and the body 72. The anterior leaflet 6 is opened away from the body 72 in FIG. 21, allowing blood to flow around three sides of the body during diastole. As shown in FIG. 21, the first members 84, 86 of the anchor 74 extend across the body without blocking the flow of blood around the body. Though not shown, during systole, the anterior leaflet 6 can close around the body 72 and create a seal with the body and the side portions of the posterior leaflet 8 to prevent regurgitation into the left atrium 2. The body 72 is shown in FIG. 21 covered with the blood-impervious fabric 94 that extends around the atrial end 76 of the body and is open on the ventricular end 78 of the body, preventing blood from flowing through the body 72. In some embodiments, the ventricular end 72 can also be covered by the fabric to fully enclose the body and provide improved hemodynamics.
The exemplary prosthetic devices disclosed herein can be delivered to the mitral region via plural different approaches. FIG. 22 shows an exemplary prosthetic device 100 having a single anchor 102, being delivered with a catheter 104 via an exemplary transeptal atrial approach. In the approach shown in FIG. 22, the catheter 104 passes through the inferior vena cava 110, the right atrium 112, and through an incision made in the septum 114, to reach the left atrium 2. The distal end portion 106 of the catheter 104 serves as a sheath for containing the prosthetic device 100 in a compressed state during delivery to the heart. The delivery apparatus can further include a pusher member 116 extending coaxially through the catheter 104. Once the catheter enters the left atrium 2, implantation of the device 100 can be performed similar to the methods described in relation to FIGS. 11-21 herein. Alternatively, the prosthetic devices described herein can be implanted via an atrial approach using any of the methods and/or devices described in U.S. Patent Application Publication No. 2011/0137397 in relation to FIGS. 63-67 thereof, or in U.S. Provisional Patent Application No. 61/760,577.
FIG. 23 shows an exemplary prosthetic device 120 having a single anchor 122, being delivered with a delivery device 124 through the apex 126 of the heart in an exemplary transapical approach. In the transapical approach shown in FIG. 23, the prosthetic device 120 is held in a compressed configuration in a distal end of the delivery device 124 as the delivery device is inserted through an incision in the heart apex 126 and delivered through the left ventricle 4 to the mitral region. The delivery device 124 can have features that allow the anchor 122 to radially expand out of the delivery device 124 and away from the still-compressed body of the prosthetic device 120, as shown in FIG. 23, to capture one of the native mitral leaflets 6 or 8. For example, the delivery device 124 can have an outer sheath configured to release the anchor 122 while the body of the prosthetic device is held in a compressed state in an inner sheath, such as by providing a slot in the distal end portion of sheath 124 through which the anchor 122 can extend. In some embodiments, the delivery device 124 can be similar to the delivery device 2000 described in U.S. Patent Application Publication No. 2011/0137397 (for example, with only one of the slots 2028 instead of two), and can be used to implant the prosthetic device 120 via methods similar to those described therein in relation to FIGS. 49-62 thereof. The delivery device 124 can also be similar to the delivery devices described in U.S. Provisional Patent Application No. 61/760,577, and can be used to implant prosthetic devices via methods similar to those described therein.
FIG. 24 shows an exemplary prosthetic device 200 that is configured to inflate with blood and expand radially during systole and to collapse radially during diastole. The device 200 can comprise a structural portion 202, an anchor 204, and an inflatable portion, or parachute, 206 having an annular cross-sectional profile. The structural portion 202 can comprise a rigid member or frame that supports one side of the parachute 206. The anchor 204 can comprise an extension of the structural member 202 or a separate member coupled to the structural member and is configured to attach the device 200 to one of the native mitral leaflets, such as the posterior native leaflet as shown in FIG. 24, by capturing the leaflet between the anchor 204 and the structural portion 202. The parachute 206 can comprise a flexible, blood-impermeable material, such as PET fabric or the like. The parachute 206 has an open lower end 208 and a closed upper end 210.
During systole, as illustrated in FIG. 24, higher pressure in the left ventricle relative to the left atrium forces blood from the left ventricle into the open lower end 208 of the parachute. The increased pressure in the parachute (labeled P2 in FIG. 24) exceeds the pressure in the left atrium (labeled P1 in FIG. 24), causing the parachute to inflate with blood and to expand radially and upwardly. At the same time, the native leaflets 6, 8 are caused to collapse toward each other. The device 200 moves along with the leaflet to which it is attached and the other leaflet moves toward the expanding parachute 206. When fully inflated, the parachute 206 can seal the gap between the two native mitral leaflets 6, 8 and prevent or reduce mitral regurgitation.
During diastole (not shown), P1 exceeds P2 causing the parachute 206 to deflate and collapse toward the structural portion 202. At the same time, the two native leaflets 6, 8 are pushed apart. This allows blood to flow from the left atrium to the left ventricle with minimal obstruction by the collapsed parachute 206.
In some embodiments, the device 200 can comprise additional structural elements. For example, some embodiments can comprise longitudinal splines that extend from the upper end 210 to the lower end 208 to provide longitudinal rigidity to the parachute without impeding expansion/contraction in the radial direction, much like a common umbrella. In some embodiments, the device 200 can comprise a structural member at the lower opening 208 to prevent the lower opening from fully closing during diastole, such that blood can more easily enter the lower opening at the beginning of systole. In some embodiments, the device 200 can comprise a biased portion that urges the lower opening 208 toward an opened position. The biased portion can comprise a spring mechanism, resiliently flexible members, or other mechanisms. In some embodiments, the device 200 can further comprise an atrial portion that extends from or adjacent to the upper end 210 and contacts the atrial walls and/or the atrial side of the leaflet to which the device is attached. The atrial body can help secure the device within the mitral orifice and can prevent movement toward the left ventricle. The atrial body can comprise a separate component or an extension of the structural member 202. The atrial body can be configured like the atrial bodies 26A, 26B or 26C described above, or can have other configurations.
FIGS. 25-28 show a prosthetic spacer 220 according to another embodiment, wherein the spacer 220 is coupled to one of the native leaflets using, for example, sutures. The spacer 220 can be formed from any of various suitable materials, including bio-compatible materials such as pericardial tissue, polymers, sponge, or a gel or saline filled structure such as a balloon. The material composition of the spacer 220 can be selected to increase desirable characteristics of the spacer 220, such as performance, durability, promotion of native tissue growth, etc. The spacer 220 can be formed in any of various suitable shapes, such as a rectangle, a semi-elliptical ring or generally u-shape, or a semi-ellipse. As shown in FIG. 25, the spacer 220 can be sutured to the posterior leaflet 8 using sutures 222 via a transeptal approach, and as shown in FIG. 26, the spacer 220 can be sutured to the posterior leaflet 8 using sutures 222 via a transapical approach. In use, the opposite leaflet (the anterior leaflet in the illustrated embodiment) can coapt against the spacer 220 to prevent or minimize regurgitation.
FIG. 27 shows the spacer 220 after it has been sutured to the native posterior leaflet 8. As shown, two sutures 222 can be sufficient to couple the spacer 220 to the leaflet 8. The sutures 222 can be positioned as shown, with one suture 222 at either end of the spacer 220, which spans across the leaflet 8. In alternative embodiments, additional or fewer sutures can be used, and the sutures can be situated in alternative locations on the spacer 220 and/or on the leaflet 8.
FIG. 28 shows the spacer 220 being coupled to the posterior native leaflet 8 using a length of elongated material 224 and a pair of slidable locking devices 226. The elongated material 224 can comprise, for example, a length of thread or suture material, or a metal or polymeric wire, or other material suitable for suturing, such as biological tissue. In the illustrated embodiment, a single strand of material 224 is used, although in alternative embodiments, two or more strands 224 can be used to couple the spacer 220 to the native leaflet 8. In order to couple the spacer 220 to the native posterior leaflet 8, one or both of the slidable locking devices 226 can be guided along the strand of material 224 toward the native leaflet 8, thereby decreasing the length of the strand 224 between the locking devices 226 until the spacer 220 is held firmly against the leaflet 8 in a desired deployed configuration. Because the locking devices 226 are positioned behind the posterior leaflet 8 in this configuration (that is, they are located between the native leaflet 8 and the wall of the left ventricle 4), the potential for interference between the locking devices 226 and the coaptation area of the leaflets 6, 8 is minimized. Once the spacer 220 is situated in this configuration, any excess material 228 can be trimmed to prevent interference of the material 224 with the operation of the heart valve. The locking devices 226 can be configured to be slid or passed over a suture in one direction and resist movement in the opposite direction. Examples of locking devices (also referred to as suture securement devices) that can be implemented in the embodiment of FIG. 28 are disclosed in co-pending application Ser. No. 13/938,071, filed Jul. 9, 2013, which is incorporated herein by reference.
FIGS. 25-28 show one spacer 220 coupled or secured to the posterior leaflet 8. In alternative embodiments, a spacer 220 can be coupled as described above to the anterior leaflet 6 in place of or in addition to the spacer 220 coupled to the posterior leaflet 8. Except where physically impossible, any of the embodiments described herein can be sutured to native tissue as described above with reference to spacer 220, rather than or in addition to being clipped to the native leaflets using one or more anchors.
By anchoring a prosthetic mitral device to one of the mitral leaflets, as disclosed herein, instead of anchoring the device to the walls of the left ventricle, to the walls of the left atrium, to the native valve annulus, and/or the annulus connection portions of the native leaflets, the device anchorage is made independent of the motions of the ventricular walls and atrial walls, which move significantly during contractions of the heart. This can provide a more stable anchorage for a prosthetic mitral device, and eliminate the risk of hook-type or cork screw-type anchors tearing or otherwise causing trauma to the walls of the left ventricle or left atrium. Furthermore, the device body can be held in a more consistent position with respect to the mitral leaflets as the leaflets articulate, eliminating undesirable motion imparted on the device from the contraction motions of the left ventricle walls and left atrium walls. Anchoring to a mitral leaflet can also allow for a shorter body length compared to devices having other anchorage means.
Leaflet Extension
FIG. 29 shows another exemplary prosthetic device 300 implanted at the mitral valve region for treating regurgitation. The device 300 comprises a strong, flexible sheet of blood-impermeable material. The device 300 has an upper end 302 that is secured to the mitral annulus and/or the region of a mitral valve leaflet adjacent to the mitral annulus. The portion of the device 300 extending away from this upper end portion 302 is a free end portion of the device 300. In the illustrated example, the upper end 302 is attached to the mitral annulus above the posterior leaflet 8. In other examples, the arrangement can be reversed with the device 300 secured to the anterior leaflet 6. The device 300 can be secured to the native tissue by various means, such as via suturing or via barbed anchors or microanchors 304. The upper end 302 of the device 300 can be wider than the free end portion of the device 300, thus the device 300 can have a generally trapezoidal shape.
In FIG. 29, the lower end of the anterior leaflet 6 is not shown in order to show the lower end of the posterior leaflet 8 and the lower end 306 of the device 300 extending downwardly through the mitral orifice and into the left ventricle 4. The lower end 306 of the device can be shorter, longer, or about the same length as the leaflet to which it is attached. As shown in FIGS. 30 and 31, the lower end 306 of the device in the illustrated embodiment extends below the lower end of the posterior leaflet during diastole (FIG. 31), and extends short of the lower end of the anterior leaflet 6 during systole (FIG. 30). The lower end 306 can be tethered to a location in the left ventricle 4. For example, the lower end 306 can be tethered to the papillary muscle heads 310 via tethers 308 and anchors 312, as shown, (in a manner similar to the way in which the native chordae tendineae 314 tether the native leaflet 8 to the papillary muscles 310), or can be tethered to the apex of the left ventricle.
During systole, as shown in FIG. 30, the device 300 inflates or fills with blood from the left ventricle 4 and expands laterally toward the anterior leaflet 6. This causes the lower portion of the device 300 to seal against the anterior leaflet 6, blocking the flow of blood back into the left atrium 2. The lateral edges of the device 300 can seal between the two native leaflets adjacent to the commissures where the native leaflets still naturally coapt with each other. The tethers 308 prevent the lower end 306 of the device 300 from moving toward and/or into the left atrium 2 and thereby breaking the seal with the anterior leaflet 6. Thus, the device 300 augments the native posterior leaflet and helps seal the mitral orifice in the case where the native leaflets 6, 8 do not otherwise not fully coapt and allow regurgitation between them.
During diastole, as shown in FIG. 31, high pressure in the left atrium 2 forces the device 300 to collapse against the posterior leaflet 8, allowing blood to flow into the left ventricle 4 with minimal obstruction from the device 300.
FIG. 32 shows another exemplary prosthetic device 400 implanted at the mitral valve region for treating mitral regurgitation. The device 400 comprises a rigid frame 402 (e.g., a metal frame) that clips around the posterior leaflet 8 with an anchor portion 404 being positioned behind the posterior leaflet 8 and an atrial portion 406 being positioned along the atrial surface of the mitral annulus and/or the portion of the posterior leaflet adjacent to the annulus. The frame 402 can secure the device 400 to the posterior leaflet 8 without sutures or other tissue puncturing elements like the anchors 304 in FIGS. 29-31. The device 400 also can be implanted on the anterior leaflet 6. The device 400 further comprises a strong, flexible sheet 408 of blood-impermeable material, like the device 300. An upper end 410 of the sheet 408 can be secured to the frame 402 at or near the atrial portion 406. The portion of the sheet 408 extending away from this upper end portion 410 is a free end portion of the sheet 408.
In FIG. 32, the lower end of the anterior leaflet 6 is not shown in order to show the lower end of the posterior leaflet 8 and the lower portions of the device 400 extending downwardly through the mitral orifice and into the left ventricle 4. The lower end 412 of the sheet 408 can be shorter, longer, or about the same length as the lower end of the leaflet to which it is attached. As shown in FIGS. 33 and 34, the lower end 412 of the sheet 408 in the illustrated embodiment extends below the lower end of the posterior leaflet during diastole (FIG. 34), and extends short of the lower end of the anterior leaflet 6 during systole (FIG. 33). The lower end 412 can be tethered to a location in the left ventricle 4 and/or can be tethered to one or more points 420 near the lower end of the frame 402 (both tethering means are shown in FIGS. 33 and 34, though one can be used without the other). For example, in some embodiments, the lower end 412 of the sheet 408 can be tethered to the papillary muscle heads 416 via tethers 424 and anchors 426 (in a manner similar to the way in which the native chordae tendineae 414 tether the native leaflet 8 to the papillary muscles 416), and/or can be tethered to the apex of the left ventricle 4. In other embodiments, the sheet 408 is tethered only to the frame 402 and tethers extending down into the left ventricle 4 are optional. In such embodiments, one or more tethers 428 can extend from adjacent the lower end 412 of the sheet, such as from the lower lateral corners 422, and attach to the lower end of the frame at or near points 420. In some embodiments, the sheet 408 can adopt a three dimensional curvature when inflated, with the lower corners being held closer to the lower end of the frame 402 while an intermediate portion of the lower edge 412 is allowed to billow out (somewhat like a spinnaker sail) further toward the anterior leaflet 6 to create a seal.
During systole, as shown in FIG. 33, the sheet 408 inflates or fills with blood from the left ventricle 4 and expands laterally toward the anterior leaflet 6. This causes the lower portion of the sheet 408 to seal against the anterior leaflet 6, blocking the flow of blood back into the left atrium 2. The lateral edges of the sheet 408 can seal between the two native leaflets adjacent to the commissures where the native leaflets naturally coapt with each other. Thus, the device 400 augments the native posterior leaflet and helps seal the mitral orifice in the case where the native leaflets 6, 8 do not otherwise not fully coapt and allow regurgitation between them.
During diastole, as shown in FIG. 34, high pressure in the left atrium 2 forces the sheet 408 to collapse against the posterior leaflet 8, allowing blood to flow into the left ventricle 4 with minimal obstruction from the device 400.
FIGS. 35 and 36 show embodiments of prosthetic devices 460, 470 which can be used to extend the effective length of the native leaflets 6, 8. As shown in FIG. 35, a prosthetic device 460 can include a body 462 and a clip 464 for clipping the device 460 to one of the anterior or posterior native leaflets 6, 8. As shown in FIG. 36, a prosthetic device 470 can include a body 472 and one or more sutures 474 for coupling the device 470 to one of the anterior or posterior native leaflets 6, 8. In use, the devices 460, 470 have free end portions extending away from the native leaflets which extend the effective length of the native leaflets, thereby increasing the chance of and extent of coaptation between them, as described more fully below. The bodies 462, 472 can comprise a material which is stiff enough to reduce the chance of leaflet prolapse, and flexible enough to increase the extent of leaflet coaptation. Suitable materials can include, for example, biological materials such as pericardial tissue, goretex, silicone, polyurethane, or other polymeric materials. FIG. 35 shows that a device 460 can be used on each of the anterior and posterior native leaflets 6, 8, and FIG. 36 shows that a device 470 can be used on each of the anterior and posterior native leaflets 6, 8, but in alternative embodiments, only one such device can be used, or one device 460 and one device 470 can be used. FIG. 35 shows that tethers 461 can be used to tether free end portions of the bodies 462 to locations in the left ventricle, thus reducing the chances of prolapse of the prosthetic devices 460 during systole. The tethers 461 are optional, and can be used in a similar fashion in combination with the devices 470, 500, 502, or any other suitable devices described herein.
FIG. 37 shows exemplary prosthetic devices 500, 502 which combine features of the prosthetic spacers and the leaflet extensions described above. Prosthetic device 500 is shown coupled to the posterior native leaflet 8 while the prosthetic device 502 is shown coupled to the anterior native leaflet 6. The prosthetic devices 500, 502 include relatively thick upper portions 504, 506, which function in a manner similar to the prosthetic spacers described above, and relatively thin, elongate free end portions 508, 510, which function in a manner similar to the devices 300, 400, described above. The free end portions 508, 510 can have respective distal end portions 514, 516, which represent the effective distal ends of the extended leaflets.
In use, the free end portions 508, 510 extend the effective length of the respective leaflets, and can facilitate initiation of leaflet coaptation during ventricular systole. During systole, the leaflets are urged toward one another due to the pressures extant in the left ventricle and left atrium. Due to the extended effective length of the leaflets, the end portions 514, 516 are more likely to coapt than were the ends of the native leaflets without the extensions. Once coaptation is initiated, and thus blood flow from the left ventricle to the left atrium at least partially impeded, the pressure in the left ventricle can increase, further increasing the pressure differential between the left ventricle and the left atrium and urging the leaflets 6, 8, further toward one another.
As a result, the portions of the leaflets 6, 8, and their respective extensions 502, 500 which coapt, increases (both in the direction from the end portions 514, 516 toward the left atrium 2, and from the locations of the devices 500, 502, toward the commissure points of the mitral valve), leading to a cycle of increasingly impeded blood flow, increased pressure differential, and increased coaptation of the leaflets. Thus, by facilitating initiation of coaptation, the free end portions 508, 510 can help to reduce regurgitation of blood from the left ventricle to the left atrium during ventricular systole. Further, the upper portions 504, 506 can further help to prevent regurgitation in the manner described above with respect to prosthetic device 10. In cases where the native leaflets 6, 8, do not experience sufficient coaptation to prevent regurgitation, the relatively thick upper portions 504, 506, can help to increase their coaptation and thereby reduce regurgitation.
FIG. 37 shows that the devices 500, 502 can be sutured to the native leaflets 8, 6, with sutures 512, but in alternative embodiments, the devices 500, 502 can be clipped to the native leaflets 8, 6, as described above. In alternative embodiments, only one of the devices 500, 502 can be used rather than both.
Spacers Having Plural Anchors
In some embodiments, prosthetic devices can include a body and a plurality of anchors such that the body can be clipped to more than one leaflet. Such embodiments can be used to effectively couple two or more leaflets to one another. Thus, such a device can be used to bring native leaflets closer to one another and restrict their mobility in order help increase the chance of or extent of coaptation between the leaflets.
FIGS. 38-41 show a prosthetic spacer 600 having a body 602, a first anchor 604 and a second anchor 606. The body 602 and anchors 604, 606 can be fabricated from any of various suitable materials, and the body is desirably made from a relatively compressible material so that its profile can be reduced for delivery into a patient's heart within a delivery catheter. Alternatively, the body 602 can be inflatable (e.g., to be inflated with a fluid such as saline or a curing epoxy or polymer) or otherwise expandable (e.g., it can be fabricated from a frame comprising a self-expanding material such as Nitinol) such that the cross section of the body 602 can be reduced for delivery into a patient's heart and then expanded to a final, deployed configuration therein. An inflatable spacer can be particularly advantageous because it can allow enhanced customization of the spacer, and can allow fine control over the final, deployed size and configuration of the spacer.
FIGS. 38 and 39 show that the anchors can have similar structures. Each anchor 604, 606 can be made from a single piece of relatively rigid metallic material (e.g., an elongated wire) which can include first and second inner portions 608, 610, first and second bottom portions 612, 614, and a main loop portion 616 extending between and connecting the upper ends of the bottom portions 612, 614. The inner portions 608, 610 can be coupled rigidly to the inside of the body 602. The inner portions 608, 610 can extend downwardly out of the lower end of body 602 to the respective bottom portions 612, 614, which can each curve upwardly around the lower end of the body 602 to meet the main loop portion 616.
FIGS. 39 and 40 show that the structure of the anchors 604, 606, and their connections to the body 602, biases the main loop portions 616 of the anchors 604, 606, into contact with the sides of the body 602. Thus, in use, the spacer 600 can be clipped to the anterior and posterior native leaflets 6, 8, with one of the leaflets 6, 8 clipped between the anchor 604 and the body 602, and the other of the leaflets 6, 8, clipped between the anchor 606 and the body 602. FIG. 41 shows that the anchors 604, 606 can be splayed apart so that gaps exist between the anchors 604, 606, and the body 602. Thus, the spacer 600 can be introduced into the region of a patient's native mitral valve in a closed configuration with the anchors 604, 606 against the side of the body 602 (FIGS. 38-40). The anchors 604, 606 can then be splayed apart or expanded into an open configuration (FIG. 41) so the spacer can be positioned with the native leaflets 6, 8, in the gaps between the anchors 604, 606 and the body 602, after which the anchors 604, 606 can be allowed to return to the closed configuration under their own resiliency to capture the leaflets 6, 8, and clip the spacer 600 thereto.
FIG. 42 shows that in use, the prosthetic spacer 600 can be clipped to the posterior native mitral valve leaflet 8 using the first anchor 604, as described above with regard to prosthetic spacer 10 and shown in FIG. 1, and can be clipped to the anterior native mitral valve leaflet 6 using the second anchor 606, as described above with regard to prosthetic spacer 10 and shown in FIG. 2. FIG. 43 shows that when the prosthetic spacer 600 is clipped to both of the leaflets 6, 8, (e.g., at the A2 and P2 regions of the leaflets, as identified by Carpentier nomenclature) it brings them together, decreasing the overall area of the mitral valve orifice, and dividing the mitral valve orifice into two orifices 618, 620 during diastole. Thus, the area through which mitral regurgitation can occur is reduced, leaflet coaptation can be initiated at the location of the spacer 600, and the leaflets can fully coapt more easily, thereby preventing or minimizing mitral regurgitation.
FIGS. 44 and 45 show alternative embodiments of dual anchor spacers clipped to the A2 and P2 regions of the anterior and posterior native leaflets 6, 8, as viewed from the left atrium. FIG. 44 shows an embodiment 640 in which the shape of the body of the spacer 640 is relatively elongate such that the spacer 640 extends substantially between the commissures 650, 652 of the mitral valve. As shown, in this embodiment, the native leaflets 6, 8 are brought toward one another by the anchors of the spacer 640, the overall area of the valve orifice is reduced, and the orifice is divided into four orifices 642, 644, 646, 648 during diastole. Thus, the area through which mitral regurgitation can occur is reduced, leaflet coaptation can be initiated at the location of the spacer 640, and the leaflets can fully coapt more easily, thereby preventing or minimizing mitral regurgitation. In addition, the shape of the spacer 640 can more effectively treat eccentric jet mitral regurgitation, because the extension of the body of the spacer 640 to the commissures 650, 652 helps the leaflets 6, 8, to coapt across the entirety of the native mitral valve orifice.
FIG. 45 shows an embodiment of a dual-anchor spacer 660 in which the body of the spacer 660 comprises a prosthetic valve having one or more flexible leaflets 666 that permit blood to flow into the left ventricle during diastole and block the back flow of blood into the left atrium during systole. In this embodiment, the native leaflets 6, 8 are brought closer to one another and the native mitral valve orifice is divided into two orifices 662, 664 during diastole. Because the body of the spacer 660 comprises a prosthetic valve, rather than a solid piece of material, the total effective open area between the leaflets during diastole (e.g., the area through which blood can flow) is greater in this embodiment than in the embodiment illustrated in FIGS. 43 and 44.
In alternative embodiments, the body of a dual anchor spacer can have various alternative shapes. For example, cross-sectional profile of the body can be circular, elliptical, or as shown in FIG. 46, can have a generally crescent shape. A spacer body having a crescent shape such as spacer body 680 in FIG. 46 (viewed from the left atrium) can be particularly advantageous because it can conform to the overall crescent shape of the anterior and posterior leaflets 6, 8 of the native mitral valve. In such an embodiment, the concave side 682 of the crescent shaped body 680 can face the anterior native leaflet 6 while the convex side 684 of the crescent shaped body 680 can face the posterior native leaflet 8. FIG. 46 shows that in such an embodiment, the native mitral valve orifice can be divided into two orifices 686, 688, each on the concave side 682 of the spacer 680, as the convex side 684 can conform to the posterior native leaflet 8 such that no openings exist between them.
FIGS. 47-51 show embodiments of spacers having three anchors, which can be clipped to leaflets in the tricuspid valve of the human heart in a manner similar to that described above with regard to spacers in the mitral valve. FIG. 47 shows a tricuspid spacer 700 having a circular body 712 and three anchors 702. FIG. 48 shows the spacer 700 implanted in the tricuspid valve (as viewed from the right ventricle, as blood is being pumped out of the right ventricle), with each of the three anchors 702 clipped to a respective leaflet 704 of the tricuspid valve, and thereby coupling them to one another. FIG. 49 shows the spacer 700 clipped to the leaflets 704 of the tricuspid valve as blood is pumped from the right atrium to the right ventricle through orifices 706, 708, 710. FIG. 50 shows an alternative tricuspid spacer 720 having a body 722 and three clips 724. As shown, the body 722 can have a generally Y shape. FIG. 51 shows an alternative tricuspid spacer 730 having a body 732 and three clips 734. As shown, the body 732 can have a generally triangular shape.
FIGS. 52-54 show an exemplary dual anchor spacer 750 having a body 752 and first and second anchors 754, 756, positioned within a native mitral valve. FIG. 52 shows the spacer 750 as seen from the left ventricle 4. FIG. 53 shows the spacer 750 as viewed from the left atrium 2 during systole, and FIG. 54 shows the spacer 750 from the left atrium 2 during diastole. As can be seen in FIG. 53, no openings appear through which regurgitant flow can occur. As can be seen in FIG. 54, two openings 758, 760 exist through which blood can flow from the left atrium 2 to the left ventricle 4 during diastole, as is desirable.
A suitable delivery sequence for delivering a prosthetic spacer such as spacer 750 to the mitral valve region of a patient's heart can comprise compressing a spacer to a compressed, delivery configuration, delivering the spacer to the coaptation line of a patient's native mitral valve, expanding the spacer until regurgitation in the patient's mitral valve is adequately reduced (an inflatable device can allow a physician to make fine adjustments to the final size and configuration of the spacer based on information received during the delivery process), manipulating the anchors of the spacer to an open position, capturing the native leaflets between the anchors and the body of the spacer, and then manipulating the anchors to a closed position, thereby clipping the spacer to the native mitral valve leaflets.
FIGS. 55 and 56 show an exemplary dual anchor spacer 800 comprising a main body 802 and first and second anchors 804, 806. The main body 802 can comprise a plurality of interconnected struts 808 which together form a plurality of open cells and are arranged to form a generally annular shape having first and second end portions 816, 818. The body 802 can be formed to be radially self-expandable. For example, the body 802 can be fabricated from a shape-memory material such as Nitinol, which can allow the spacer 800 to be radially compressed to a compressed delivery configuration, delivered to one of a patient's native heart valves, then self-expanded to an expanded functional configuration for use within the patient's heart.
The first anchor 804 can comprise first and second end portions 810, 812 which can be coupled to the first end portion 816 of the main body 802, and a loop portion 814 which can extend between the first and second end portions 810, 812. The first and second end portions 810, 812 can extend away from the first end portion 816 of the body 802, then curl back and extend toward the second end portion 818 of the main body 802. The loop portion 814 can be coupled to the first end portion 810, extend generally toward the second end portion 818 of the main body 802, curl back and extend toward the first end portion 816 of the main body 802, and be coupled to the second end portion 812.
Thus, the first anchor 804 can be coupled to the first end portion 816 of the main body 802 and extend along the side of the main body 802 toward its second end portion 818. The second anchor 806 can have a similar structure, and can be coupled to the main body 802 such that it extends along an opposing side of the main body 802. In this embodiment, the spacer 800 can be clipped to native tissues by pinching the native tissues between the anchors 804, 806 and the respective sides of the main body 802. The anchors 804, 806 can be made from various suitable materials, and in one exemplary embodiment can be fabricated from the shape-memory material Nitinol. The anchors 804, 806 in the illustrated embodiment are fabricated from separate pieces of material from the main body 802, and are coupled to the main body 802 using coupling mechanisms 820. The coupling mechanisms 820 can be, for example, crimping rings that extend around a strut at the first end 816 of the main body 802 and an adjacent portion of an anchor. In alternative embodiments, however, the anchors 804, 806 and the main body 802 can be fabricated integrally with one another (i.e., from a single piece of material). As best shown in FIG. 56, the main body 802 can have a generally elliptical or oval shape when viewed on end, but in alternative embodiments, the main body can be formed to have any of various suitable shapes when viewed on end, such as a circle.
FIGS. 57 and 58 show the spacer 800 covered in a blood impermeable fabric material 822, such as made of polyethylene terephthalate (PET) or polyurethane. The fabric material 822 can be relatively thick, strong, and soft, such as a knitted lofty cloth. The fabric material 822 can be selected to provide a softer surface for contact with the native tissue, thus reducing trauma caused to the native tissues by the implantation of the spacer 800, can be selected to promote native tissue ingrowth into the spacer 800, and/or can be selected to improve the seal formed between native tissues and the portions of the spacer 800 they come into contact with. Additionally, FIG. 58 shows that a fabric layer 824 can be disposed to cover all or substantially all of the opening at the center of the main body 802. The layer 824 can be blood impermeable, thereby blocking the flow of blood through the spacer 800. The layer 824 can be formed from the same material as fabric 822, and together the fabric 822 and layer 824 can work to prevent the regurgitant flow of blood through a heart valve when the spacer has been implanted therein.
FIGS. 59-63 illustrate exemplary systems and methods which can be used to implant the spacer 800 in a native heart valve. FIGS. 59-61 illustrate exemplary systems and steps which can be used to crimp the spacer 800 to a compressed, delivery configuration, suitable for delivery to a patient's native heart valve within a delivery device 850. FIG. 59 shows the spacer 800 with its main body 802 positioned in a crimper mechanism 900 capable of crimping the main body 802 to a compressed configuration. As shown, the anchors 804, 806 can remain outside the crimper mechanism 900 as it is used to crimp the main body portion 802. For example, U.S. Pat. No. 7,530,253, which is hereby incorporated herein by reference, describes an exemplary prosthetic valve crimping device that can be used to crimp the spacer 800.
In some embodiments, the delivery device 850 can be similar to the delivery device 2000 described in U.S. Patent Application Publication No. 2011/0137397 or the delivery devices described in U.S. Provisional Patent Application No. 61/760,577, and can be used to implant prosthetic devices via methods similar to those described therein. FIG. 59 shows that the delivery device 850 can include an inner sheath 852 provided with a pair of slots 854 disposed on opposing sides of the inner sheath 852, and an internal locking element 856, which is axially adjustable relative to the inner sheath 852 along a central longitudinal axis of the inner sheath 852. The internal locking element 856 can comprise a generally cruciform shape, having four extension portions 858 between which are defined four voids 860. As best shown in FIG. 59, two of the voids 860 can be aligned with the two slots 854, which can also be aligned with the portions of the anchors 804, 806 which are coupled to the body 802 of the spacer 800. Thus, in this embodiment, the locking element 856 can be retracted into the inner sheath 852, thereby pulling the main body portion 802 of the spacer 800 into the inner sheath 852 in the same direction. As best shown in FIG. 60, as the spacer 800 is pulled into the inner sheath 852, the first and second end portions 810, 812 of each of the anchors extend from the first end portion 816 of the spacer 800, through the respective voids 860 in the locking element, and then curl out of the slots 854 in the sides of the inner sheath 852, extending along the sides of the body 802 toward the second end portion 818 of the main body 802. In this way, the body 802 of the spacer 800 can be pulled into the inner sheath 852 and thereby compressed to a compressed delivery configuration.
As shown in FIG. 61, after the main body portion 802 has been situated within the inner sheath 852, an outer sheath 862 can be extended toward the distal end of the device 850 so as to enclose the anchors 804, 806, thereby causing them to wrap around the inner sheath 852 and be confined between the inner sheath 852 and outer sheath 862.
FIGS. 62 and 63 show a spacer 800 covered in fabric as described above and situated within a delivery device 870 in two different configurations. FIG. 62 shows the spacer 800 having its main body portion 802 situated within an inner sheath 872 of the delivery device 870 such that the anchors 804, 806 extend toward a distal end portion of the delivery device 870. In this embodiment, an outer sheath 874 can be extended distally to retain and secure the anchors 804, 806 against the sides of the inner sheath 872. Such a configuration can be used to deliver the spacer transapically, as described below. In some embodiments, retraction of the outer sheath 874 can allow the anchors 804, 806 to self-expand to a splayed-apart configuration.
FIG. 62 also shows that forcible expanders, or levers, 876 can be used to force the anchors 804, 806 to splay apart. The forcible expanders 876 can be radially self-expanding levers which radially self-expand when the outer sheath 874 is retracted or are otherwise configured to radially expand away from the inner sheath when they are actuated by a physician (such as by actuating a control knob on a handle that is operatively connected to the expanders 876). The expanders 876 can alternatively be sutures or other mechanisms which can be actuated by a physician to force the anchors 804, 806 to splay apart. In some embodiments, retraction of the outer sheath 874 can allow the anchors 804, 806 to self-expand to a first splayed-apart configuration, and forcible expanders 876 can be actuated to force the anchors 804, 806 to further radially expand to a second splayed-apart configuration. In such an embodiment, the expanders 876 can be actuated to cause the anchors 804, 806 to radially expand to the second splayed apart configuration, and can then be actuated to allow the anchors 804, 806 to move radially inward and return to the first splayed-apart configuration.
FIGS. 62 and 63 illustrate the spacer 800 situated within the delivery system 870 such that the anchors 804, 806 extend generally along the outside of the body 802 toward the second end portion 818 of the spacer 800. In alternative embodiments, however, the configuration of the body 802 and anchors 804, 806 within the delivery system 870, and the deployment of the spacer 800 from the delivery system 870, can be similar to that illustrated in FIGS. 12-15 with respect to device 50 and delivery catheter 56.
FIG. 63 shows the spacer 800 having its main body portion 802 situated within the inner sheath 872 of the delivery device 870 such that the anchors 804, 806 extend toward a proximal end portion of the delivery device 870. In this embodiment, the outer sheath 874 can be extended distally to retain and secure the anchors 804, 806 against the sides of the inner sheath 872. Such a configuration can be used to deliver the spacer transatrially, as described below.
Prosthetic spacers described herein can be delivered using minimally invasive approaches. FIGS. 64-67 show various approaches by which a prosthetic spacer 800 can be delivered to the region of a patient's mitral valve using a delivery system 920. For example, a prosthetic spacer can be delivered via a transapical approach (FIG. 64), via a transeptal approach (FIG. 65), via a transatrial approach (FIG. 66), or via a transfemoral approach (FIG. 67). FIGS. 64-67 show that the delivery system 920 can comprise an outer sheath 922, an inner sheath 924, and a guidewire 930 which can extend through the outer sheath 922 and inner sheath 924. The delivery system 920 can also include a pusher element (not illustrated in FIGS. 64-67, but similar to those described above), which can be actuated to move the spacer 800 within the inner sheath 924. The outer sheath 922, inner sheath 924, guidewire 930, and pusher element can each be retracted proximally or extended distally with respect to one another. The guidewire 930 can be used to guide the delivery of the other components of the system 920 to an appropriate location within a patient's vasculature. The guidewire 930 can extend through a small opening or pore in the spacer 800, for example in the fabric layer 824, the small opening or pore being small enough that substantial blood cannot flow therethrough.
FIGS. 64 and 67 show that the deployment of the spacer 800 to a native mitral valve via the transapical approach can be similar to the deployment of the valve 800 via the transfemoral approach, at least because in both cases the valve is delivered to the mitral valve from the left ventricle. In preparing the delivery system 920 for delivery of the spacer 800 via the transapical or the transfemoral approach, the spacer 800 can be situated within the system 920 with the second end portion 818 of the spacer 800 disposed at the distal end of the system 920 (such as shown in FIG. 62). In the transapical and the transfemoral approaches, the delivery system 920 can be used to first deliver the spacer 800 to the region of the native mitral valve from the left ventricle. In the transapical approach, the delivery device 920 is inserted into the left ventricle via an opening in the chest and the apex of the heart. In the transfemoral approach, the delivery device 920 can be inserted into a femoral artery and advanced through the aorta in a retrograde direction until the distal end of the delivery device is in the left ventricle. The outer sheath 922 can then be retracted proximally such that the anchors 804, 806 are no longer confined within the outer sheath 922. In some embodiments, the anchors 804, 806 can be configured to self-expand to a splayed apart configuration shown in FIGS. 64 and 67. In other embodiments, as described above, the delivery system 920 can include a mechanism for forcing the anchors 804, 806 to splay apart to the splayed-apart configuration (such as described above with respect to the embodiment of FIG. 62).
The device 920 can then be distally advanced so that the native mitral valve leaflets are positioned between the splayed apart anchors 804, 806, and the body 802. The inner sheath 924 can then be retracted so that the body 802 is no longer confined within the inner sheath 924 and can radially expand to an expanded configuration between the native mitral valve leaflets. In some embodiments, the body 802 can expand such that the native leaflets are pinched between the body 802 and the anchors 804, 806. In alternative embodiments, as described above, the mechanism for forcing the anchors 804, 806 to splay apart can be actuated to allow the anchors 804, 806 to move radially inward toward the main body 802, thereby pinching the native leaflets between the main body 802 and the anchors 804, 806.
FIGS. 65 and 66 show that the deployment of the spacer 800 to a native mitral valve via the transseptal approach can be similar to the deployment of the valve 800 via the transatrial approach, at least because in both cases the valve is delivered to the mitral valve from the left atrium. In preparing the delivery system 920 for delivery of the spacer 800 via the transseptal or the transatrial approach, the spacer 800 can be situated within the system 920 with the first end portion 816 of the spacer 800 disposed at the distal end of the system 920 (such as shown in FIG. 63). In these approaches, the delivery system 920 can be used to first deliver the spacer 800 to the region of the native mitral valve from the left atrium. The outer sheath 922 can then be retracted proximally such that the anchors 804, 806 are no longer confined within the outer sheath 922. In some embodiments, the anchors 804, 806 can be configured to self-expand to a splayed apart configuration shown in FIGS. 65 and 66. In other embodiments, as described above, the delivery system 920 can include a mechanism for forcing the anchors 804, 806 to splay apart to the splayed-apart configuration.
The system 920 can then be proximally retracted so that the native mitral valve leaflets are positioned between the splayed apart anchors 804, 806, and the body 802. The inner sheath 924 can then be retracted so that the body 802 is no longer confined within the inner sheath 924 and can radially expand to an expanded configuration between the native mitral valve leaflets. In some embodiments, the body 802 can expand such that the native leaflets are pinched between the body 802 and the anchors 804, 806. In alternative embodiments, as described above, the mechanism for forcing the anchors 804, 806 to splay apart can be actuated to allow the anchors 804, 806 to move radially inward toward the main body 802, thereby pinching the native leaflets between the main body 802 and the anchors 804, 806.
In any of the four approaches described above, once the native leaflets have been captured by the spacer 800, the delivery system 920 can be retracted and removed from the patient's vasculature. The spacer 800 can remain in the native mitral valve region, with the main body 802 being situated between the two native leaflets, thereby helping to reduce or prevent mitral regurgitation. It will be understood that similar techniques can be used to deliver a spacer to the native aortic, tricuspid, or pulmonary valves, depending on the needs of the patient.
In any of the four approaches described above, a marker catheter or other similar device can be used to help coordinate delivery and ensure that a desirable delivery position is achieved. An exemplary suitable marker catheter can include a standard catheter designed for angiograms, for example, a catheter made of a relatively low-density plastic material having relatively high-density metal marker bands (e.g., radiopaque marker bands) disposed at regular intervals thereon. Thus, the device can be introduced into a patient's vasculature and can be viewed under echocardiography or fluoroscopy. Alternatively, a marker wire can be used in place of the marker catheter. Another suitable alternative technique is left atrium angiography, which can help a physician visualize components of a patient's heart.
A marker catheter or marker wire can be introduced into a patient's vasculature and advanced to specific areas of the vasculature near a patient's heart. For example, a marker catheter can be advanced from a patient's jugular or femoral vein into the right atrium, then into the patient's coronary sinus. As another example, a marker catheter can be advanced from a patient's femoral artery to the patient's circumflex artery. As another example, a marker catheter can be advanced into a patient's left atrium. Once situated in the coronary sinus, circumflex artery, left atrium, or other suitable area of a patient's vasculature, the marker catheter can be used to aid a physician in delivering and ensuring desirable implantation of a prosthetic device. For example, the coronary sinus extends around the heart near the location and elevation of the mitral valve and thus can help a physician to properly size and position a prosthetic device for implantation.
For example, the patient's vasculature can be viewed under echocardiography, fluoroscopy, or other visualization technique which allows a physician to view the prosthetic device being delivered and the marker catheter. A physician can first view the devices along an axis extending from the patient's left atrium to the patient's left ventricle (referred to as a “short axis”). By viewing the devices along the short axis, a physician can deploy (such as by inflating a balloon on which an implantable device is mounted) an implantable prosthetic device and expand portions of the device to desired sizes and/or configurations based on the size and location of the marker catheter, which can provide an estimate of the size of features of the native mitral valve. Alternatively or additionally, a physician can use the marker catheter to obtain an estimate of the size of a patient's native heart valve, from which estimate a prosthetic device to be implanted in the patient's native heart valve can be selected from a set of devices having differing sizes, e.g., a set of devices having differing diameters.
A physician can also view the devices along an axis perpendicular to the short axis (referred to as a “long axis”). The long axis can have several orientations, such as from commissure to commissure, but in one specific embodiment, the long axis is oriented from the A2 location to the P2 location of the native mitral valve. By viewing the devices along the long axis, a physician can align an implantable prosthetic device relative to the marker catheter at a desirable location along the short axis, such that an atrial anchor of the implantable device is situated in the left atrium (above the marker catheter) and a ventricular anchor of the implantable device is situated in the left ventricle (below the marker catheter).
FIG. 68 shows an exemplary dual anchor spacer 950 which can be delivered to the region of the native mitral valve via any suitable delivery method, for example, using the transapical, transeptal, transatrial, or transfemoral techniques described above. The spacer 950 can include a main body 952, a first anchor 954, a second anchor 956, and a nosecone 958. The spacer 950 can also include a tapered portion 962, which can couple the main body portion 952 to a neck portion 964. The taperer portion 962 can have a variable width which can taper from the width of the main body 952 to the width of the neck portion 964. The neck portion 964 can be configured to receive a portion of the nosecone 958 therein, and can be coupled to the nosecone 958. The main body 952 and anchors 954, 956 can be fabricated from various materials, as described above with regard to other embodiments, and the nosecone 958 can be fabricated from various suitable materials such as a long term implantable silicone or other suitable elastomers.
The nosecone 958 can have a small pore, or opening, or slit, 966, which can extend through and along the length of the nosecone 958. In accordance with suitable delivery methods making use of a guidewire such as guidewire 930, the guidewire can extend through the opening 966, thus eliminating the need for an opening or pore in a fabric layer. The spacer 950 can facilitate crossing of a native heart valve due to its tapered tip, which can also provide improvements in hydrodynamics during diastolic blood flow. When a guidewire is removed from the opening 966, the opening can close under its own resiliency and/or blood pressure, thus leaving a sealed spacer implanted at a native heart valve. Alternatively, or in addition, the opening 966 can be sufficiently small to prevent significant amounts of blood from travelling through the nosecone 958.
The multi-anchor spacers described herein offer several advantages over previous techniques for treating regurgitation in heart valves. For example, the multi-anchor spacers described herein can be used to treat patients whose native leaflets fail to coapt at all, whereas many previous techniques required some amount of native coaptation to be efficacious. Additionally, the spacers described herein (e.g., spacer 640) can treat eccentric jet regurgitation more readily than other known techniques. While embodiments have been illustrated with two and three anchors, the techniques described herein are generally application to spacers having any number of anchors.
General Considerations
For purposes of this description, certain aspects, advantages, and novel features of the embodiments of this disclosure are described herein. The disclosed methods, apparatuses, and systems should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed embodiments, alone and in various combinations and sub-combinations with one another. The methods, apparatuses, and systems are not limited to any specific aspect or feature or combination thereof, nor do the disclosed embodiments require that any one or more specific advantages be present or problems be solved.
Although the operations of some of the disclosed methods are described in a particular, sequential order for convenient presentation, it should be understood that this manner of description encompasses rearrangement, unless a particular ordering is required by specific language. For example, operations described sequentially may in some cases be rearranged or performed concurrently. Moreover, for the sake of simplicity, the attached figures may not show the various ways in which the disclosed methods can be used in conjunction with other methods. As used herein, the terms “a”, “an” and “at least one” encompass one or more of the specified element. That is, if two of a particular element are present, one of these elements is also present and thus “an” element is present. The terms “a plurality of” and “plural” mean two or more of the specified element.
As used herein, the term “and/or” used between the last two of a list of elements means any one or more of the listed elements. For example, the phrase “A, B, and/or C” means “A,” “B,” “C,” “A and B,” “A and C,” “B and C” or “A, B and C.”
As used herein, the term “coupled” generally means physically coupled or linked and does not exclude the presence of intermediate elements between the coupled items absent specific contrary language.
In view of the many possible embodiments to which the principles disclosed herein may be applied, it should be recognized that the illustrated embodiments are only preferred examples and should not be taken as limiting the scope of the disclosure. Rather, the scope is defined by the following claims. We therefore claim all that comes within the scope and spirit of these claims.

Claims (5)

We claim:
1. A method of implanting a prosthetic sealing device at a native mitral valve of a heart, the method comprising: advancing a delivery catheter to a native mitral valve region of a heart from a left atrium of the heart, the delivery catheter housing the prosthetic sealing device in a radially compressed configuration; advancing the prosthetic sealing device distally relative to the delivery catheter such that an anchor of the prosthetic sealing device moves out of the catheter and forms a leaflet-receiving gap between an end portion of the anchor and the delivery catheter; positioning either a posterior or an anterior mitral valve leaflet in the gap; and advancing a radially compressed body of the prosthetic sealing device out of the delivery catheter such that the body self-expands radially toward the end portion of the anchor, reducing the gap, and capturing the leaflet between the body and the end portion of the anchor, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole; wherein a non-captured one of the anterior and posterior leaflets is not secured to the prosthetic sealing device when the prosthetic sealing device is implanted for intended use at the native mitral valve.
2. The method of claim 1, wherein advancing a delivery catheter through the native mitral valve from a left atrium comprises advancing the delivery catheter through an incision in a portion of a septum between the left atrium and a right atrium.
3. The method of claim 1, wherein when the delivery catheter is advanced to the native mitral valve region of the heart, the anchor is held in a substantially straightened position within the delivery catheter extending distally from body of the prosthetic sealing device.
4. A method of implanting a prosthetic sealing device at a native mitral valve, the method comprising: advancing a delivery device to a native mitral valve region via a left ventricle, the delivery catheter housing the prosthetic sealing device in a compressed configuration; allowing an anchor of the prosthetic sealing device to move radially out of the delivery device while a body of the prosthetic sealing device is in a compressed configuration, such that a leaflet-receiving gap forms between an end portion of the anchor and the delivery device; positioning either a posterior or an anterior mitral valve leaflet in the gap; and allowing the body of the prosthetic sealing device to radially self-expand such that the leaflet is captured between the body and the anchor, wherein the body is configured to prevent the flow of blood through the body during systole and during diastole; wherein a non-captured one of the anterior and posterior mitral valve leaflets is not secured to the prosthetic sealing device when the prosthetic sealing device is implanted for intended use at the native mitral valve.
5. The method of claim 4, wherein advancing a delivery device to a native mitral valve region via a left ventricle comprises inserting the delivery device into the left ventricle through an incision in an apex of the left ventricle.
US14/019,332 2012-09-06 2013-09-05 Heart valve sealing devices Active 2034-07-13 US9414918B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/019,332 US9414918B2 (en) 2012-09-06 2013-09-05 Heart valve sealing devices
US15/204,874 US9907652B2 (en) 2012-09-06 2016-07-07 Heart valve sealing devices

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261697706P 2012-09-06 2012-09-06
US201361763848P 2013-02-12 2013-02-12
US14/019,332 US9414918B2 (en) 2012-09-06 2013-09-05 Heart valve sealing devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/204,874 Division US9907652B2 (en) 2012-09-06 2016-07-07 Heart valve sealing devices

Publications (2)

Publication Number Publication Date
US20140067052A1 US20140067052A1 (en) 2014-03-06
US9414918B2 true US9414918B2 (en) 2016-08-16

Family

ID=50188535

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/011,590 Abandoned US20140067048A1 (en) 2012-09-06 2013-08-27 Heart Valve Sealing Devices
US14/011,598 Active 2033-12-03 US9510946B2 (en) 2012-09-06 2013-08-27 Heart valve sealing devices
US14/019,332 Active 2034-07-13 US9414918B2 (en) 2012-09-06 2013-09-05 Heart valve sealing devices
US15/204,874 Active US9907652B2 (en) 2012-09-06 2016-07-07 Heart valve sealing devices

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US14/011,590 Abandoned US20140067048A1 (en) 2012-09-06 2013-08-27 Heart Valve Sealing Devices
US14/011,598 Active 2033-12-03 US9510946B2 (en) 2012-09-06 2013-08-27 Heart valve sealing devices

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/204,874 Active US9907652B2 (en) 2012-09-06 2016-07-07 Heart valve sealing devices

Country Status (5)

Country Link
US (4) US20140067048A1 (en)
EP (4) EP3888598A1 (en)
CN (1) CN104768500B (en)
CA (2) CA3145958A1 (en)
WO (1) WO2014039392A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9750605B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US9750607B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US9974647B2 (en) 2014-06-12 2018-05-22 Caisson Interventional, LLC Two stage anchor and mitral valve assembly
US10080656B2 (en) 2012-04-19 2018-09-25 Caisson Interventional Llc Heart valve assembly systems and methods
US10117741B2 (en) 2013-10-23 2018-11-06 Caisson Interventional, LLC Methods and systems for heart valve therapy
WO2019010370A1 (en) 2017-07-06 2019-01-10 Raghuveer Basude Tissue grasping devices and related methods
US10265166B2 (en) 2015-12-30 2019-04-23 Caisson Interventional, LLC Systems and methods for heart valve therapy
US10285810B2 (en) 2012-04-19 2019-05-14 Caisson Interventional, LLC Valve replacement systems and methods
US10383729B2 (en) 2014-09-29 2019-08-20 The Provost, Fellows Foundation Scholars, and The Other Members of the Board, of the College of The Holy and Undivided Trinity of Queen Elizabeth Near Dublin (TCD) Heart valve treatment device and method
WO2019199421A1 (en) 2018-04-12 2019-10-17 Edwards Lifesciences Corporation Mitral valve spacer device
US10507108B2 (en) 2017-04-18 2019-12-17 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10507109B2 (en) 2018-01-09 2019-12-17 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10517726B2 (en) 2015-05-14 2019-12-31 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10524792B2 (en) 2014-12-04 2020-01-07 Edwards Lifesciences Corporation Percutaneous clip for repairing a heart valve
US10667912B2 (en) 2017-04-18 2020-06-02 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10765518B2 (en) 2016-12-21 2020-09-08 TriFlo Cardiovascular Inc. Heart valve support device and methods for making and using the same
US10842628B1 (en) 2019-05-22 2020-11-24 TriFlo Cardiovascular Inc. Heart valve support device
WO2020236417A1 (en) 2019-05-22 2020-11-26 Edwards Lifesciences Corporation Expandable anchor for heart valve repair devices
US10925735B2 (en) 2018-01-09 2021-02-23 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10952854B2 (en) 2018-02-09 2021-03-23 The Provost, Fellows, Foundation Scholars And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin (Tcd) Heart valve therapeutic device
US10959846B2 (en) 2017-05-10 2021-03-30 Edwards Lifesciences Corporation Mitral valve spacer device
US10973639B2 (en) 2018-01-09 2021-04-13 Edwards Lifesciences Corporation Native valve repair devices and procedures
US11026791B2 (en) 2018-03-20 2021-06-08 Medtronic Vascular, Inc. Flexible canopy valve repair systems and methods of use
US11051940B2 (en) 2017-09-07 2021-07-06 Edwards Lifesciences Corporation Prosthetic spacer device for heart valve
US11065117B2 (en) 2017-09-08 2021-07-20 Edwards Lifesciences Corporation Axisymmetric adjustable device for treating mitral regurgitation
US20210282925A1 (en) * 2016-10-24 2021-09-16 Ningbo Jenscare Biotechnology Co., Ltd Heart valve prosthesis anchored to interventricular septum and conveying and releasing method thereof
US11207181B2 (en) 2018-04-18 2021-12-28 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11219525B2 (en) 2019-08-05 2022-01-11 Croivalve Ltd. Apparatus and methods for treating a defective cardiac valve
US11285003B2 (en) 2018-03-20 2022-03-29 Medtronic Vascular, Inc. Prolapse prevention device and methods of use thereof
US11510782B2 (en) 2015-10-27 2022-11-29 Xetis AG Medical device using bioabsorbable material
US11903832B2 (en) * 2018-07-29 2024-02-20 Cuspa Ltd. Transcatheter artificial cusp for valve insufficiency
US11918469B2 (en) 2021-02-05 2024-03-05 Edwards Lifesciences Corporation Native valve repair devices and procedures

Families Citing this family (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8608797B2 (en) 2005-03-17 2013-12-17 Valtech Cardio Ltd. Mitral valve treatment techniques
WO2007058857A2 (en) 2005-11-10 2007-05-24 Arshad Quadri Balloon-expandable, self-expanding, vascular prosthesis connecting stent
US9883943B2 (en) 2006-12-05 2018-02-06 Valtech Cardio, Ltd. Implantation of repair devices in the heart
US11259924B2 (en) 2006-12-05 2022-03-01 Valtech Cardio Ltd. Implantation of repair devices in the heart
US11660190B2 (en) 2007-03-13 2023-05-30 Edwards Lifesciences Corporation Tissue anchors, systems and methods, and devices
DE102007043830A1 (en) 2007-09-13 2009-04-02 Lozonschi, Lucian, Madison Heart valve stent
US8382829B1 (en) 2008-03-10 2013-02-26 Mitralign, Inc. Method to reduce mitral regurgitation by cinching the commissure of the mitral valve
US20090276040A1 (en) * 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
US8652202B2 (en) 2008-08-22 2014-02-18 Edwards Lifesciences Corporation Prosthetic heart valve and delivery apparatus
US10517719B2 (en) 2008-12-22 2019-12-31 Valtech Cardio, Ltd. Implantation of repair devices in the heart
US8715342B2 (en) 2009-05-07 2014-05-06 Valtech Cardio, Ltd. Annuloplasty ring with intra-ring anchoring
US8241351B2 (en) 2008-12-22 2012-08-14 Valtech Cardio, Ltd. Adjustable partial annuloplasty ring and mechanism therefor
WO2010073246A2 (en) 2008-12-22 2010-07-01 Valtech Cardio, Ltd. Adjustable annuloplasty devices and adjustment mechanisms therefor
US8911494B2 (en) 2009-05-04 2014-12-16 Valtech Cardio, Ltd. Deployment techniques for annuloplasty ring
US8353956B2 (en) 2009-02-17 2013-01-15 Valtech Cardio, Ltd. Actively-engageable movement-restriction mechanism for use with an annuloplasty structure
US8366767B2 (en) 2009-03-30 2013-02-05 Causper Medical Inc. Methods and devices for transapical delivery of a sutureless valve prosthesis
US9968452B2 (en) 2009-05-04 2018-05-15 Valtech Cardio, Ltd. Annuloplasty ring delivery cathethers
US9730790B2 (en) 2009-09-29 2017-08-15 Edwards Lifesciences Cardiaq Llc Replacement valve and method
US9180007B2 (en) 2009-10-29 2015-11-10 Valtech Cardio, Ltd. Apparatus and method for guide-wire based advancement of an adjustable implant
US10098737B2 (en) 2009-10-29 2018-10-16 Valtech Cardio, Ltd. Tissue anchor for annuloplasty device
WO2011067770A1 (en) 2009-12-02 2011-06-09 Valtech Cardio, Ltd. Delivery tool for implantation of spool assembly coupled to a helical anchor
US8449599B2 (en) 2009-12-04 2013-05-28 Edwards Lifesciences Corporation Prosthetic valve for replacing mitral valve
AU2010328106A1 (en) 2009-12-08 2012-07-05 Avalon Medical Ltd. Device and system for transcatheter mitral valve replacement
US8870950B2 (en) 2009-12-08 2014-10-28 Mitral Tech Ltd. Rotation-based anchoring of an implant
US8475525B2 (en) 2010-01-22 2013-07-02 4Tech Inc. Tricuspid valve repair using tension
US9307980B2 (en) 2010-01-22 2016-04-12 4Tech Inc. Tricuspid valve repair using tension
US10058323B2 (en) 2010-01-22 2018-08-28 4 Tech Inc. Tricuspid valve repair using tension
US10433956B2 (en) * 2010-02-24 2019-10-08 Medtronic Ventor Technologies Ltd. Mitral prosthesis and methods for implantation
US20110224785A1 (en) 2010-03-10 2011-09-15 Hacohen Gil Prosthetic mitral valve with tissue anchors
US11653910B2 (en) 2010-07-21 2023-05-23 Cardiovalve Ltd. Helical anchor implantation
US9763657B2 (en) 2010-07-21 2017-09-19 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
AU2011349578B2 (en) 2010-12-23 2016-06-30 Twelve, Inc. System for mitral valve repair and replacement
US8888843B2 (en) 2011-01-28 2014-11-18 Middle Peak Medical, Inc. Device, system, and method for transcatheter treatment of valve regurgitation
US8845717B2 (en) 2011-01-28 2014-09-30 Middle Park Medical, Inc. Coaptation enhancement implant, system, and method
EP2723273B1 (en) 2011-06-21 2021-10-27 Twelve, Inc. Prosthetic heart valve devices
US10792152B2 (en) 2011-06-23 2020-10-06 Valtech Cardio, Ltd. Closed band for percutaneous annuloplasty
EP2723277B1 (en) 2011-06-27 2018-05-30 University of Maryland, Baltimore Transapical mitral valve repair device
US20140324164A1 (en) 2011-08-05 2014-10-30 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
EP3417813B1 (en) 2011-08-05 2020-05-13 Cardiovalve Ltd Percutaneous mitral valve replacement
US8852272B2 (en) 2011-08-05 2014-10-07 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
WO2013021374A2 (en) 2011-08-05 2013-02-14 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US9480559B2 (en) 2011-08-11 2016-11-01 Tendyne Holdings, Inc. Prosthetic valves and related inventions
US9549817B2 (en) * 2011-09-22 2017-01-24 Transmural Systems Llc Devices, systems and methods for repairing lumenal systems
CN103974674B (en) 2011-10-19 2016-11-09 托尔福公司 Artificial heart valve film device, artificial mitral valve and related system and method
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9655722B2 (en) 2011-10-19 2017-05-23 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9763780B2 (en) 2011-10-19 2017-09-19 Twelve, Inc. Devices, systems and methods for heart valve replacement
EP4252714A3 (en) 2011-10-19 2023-12-20 Twelve, Inc. Device for heart valve replacement
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US8858623B2 (en) 2011-11-04 2014-10-14 Valtech Cardio, Ltd. Implant having multiple rotational assemblies
EP3970627B1 (en) 2011-11-08 2023-12-20 Edwards Lifesciences Innovation (Israel) Ltd. Controlled steering functionality for implant-delivery tool
US9827092B2 (en) 2011-12-16 2017-11-28 Tendyne Holdings, Inc. Tethers for prosthetic mitral valve
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
WO2014022124A1 (en) 2012-07-28 2014-02-06 Tendyne Holdings, Inc. Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly
WO2014021905A1 (en) 2012-07-30 2014-02-06 Tendyne Holdings, Inc. Improved delivery systems and methods for transcatheter prosthetic valves
US9232995B2 (en) * 2013-01-08 2016-01-12 Medtronic, Inc. Valve prosthesis and method for delivery
US10206775B2 (en) 2012-08-13 2019-02-19 Medtronic, Inc. Heart valve prosthesis
US20140067048A1 (en) 2012-09-06 2014-03-06 Edwards Lifesciences Corporation Heart Valve Sealing Devices
EP2900150B1 (en) 2012-09-29 2018-04-18 Mitralign, Inc. Plication lock delivery system
US9949828B2 (en) 2012-10-23 2018-04-24 Valtech Cardio, Ltd. Controlled steering functionality for implant-delivery tool
WO2014064695A2 (en) 2012-10-23 2014-05-01 Valtech Cardio, Ltd. Percutaneous tissue anchor techniques
US9730793B2 (en) 2012-12-06 2017-08-15 Valtech Cardio, Ltd. Techniques for guide-wire based advancement of a tool
WO2014108903A1 (en) 2013-01-09 2014-07-17 4Tech Inc. Soft tissue anchors
WO2014115149A2 (en) 2013-01-24 2014-07-31 Mitraltech Ltd. Ventricularly-anchored prosthetic valves
US9724084B2 (en) 2013-02-26 2017-08-08 Mitralign, Inc. Devices and methods for percutaneous tricuspid valve repair
US11259923B2 (en) 2013-03-14 2022-03-01 Jc Medical, Inc. Methods and devices for delivery of a prosthetic valve
CN105163687B (en) 2013-03-14 2019-08-13 心肺医疗股份有限公司 Embolus protection device and application method
JP6329570B2 (en) 2013-03-14 2018-05-23 4テック インコーポレイテッド Stent with tether interface
US10449333B2 (en) 2013-03-14 2019-10-22 Valtech Cardio, Ltd. Guidewire feeder
US9730791B2 (en) 2013-03-14 2017-08-15 Edwards Lifesciences Cardiaq Llc Prosthesis for atraumatically grasping intralumenal tissue and methods of delivery
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US11406497B2 (en) 2013-03-14 2022-08-09 Jc Medical, Inc. Heart valve prosthesis
CN105283214B (en) 2013-03-15 2018-10-16 北京泰德制药股份有限公司 Translate conduit, system and its application method
US11224510B2 (en) 2013-04-02 2022-01-18 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US10463489B2 (en) 2013-04-02 2019-11-05 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US10478293B2 (en) 2013-04-04 2019-11-19 Tendyne Holdings, Inc. Retrieval and repositioning system for prosthetic heart valve
CN105246431B (en) 2013-05-20 2018-04-06 托尔福公司 Implantable cardiac valve device, mitral valve repair device and related system and method
US9610159B2 (en) 2013-05-30 2017-04-04 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
CN105451688A (en) * 2013-06-14 2016-03-30 哈祖有限公司 Method and device for treatment of valve regurgitation
JP6461122B2 (en) 2013-06-25 2019-01-30 テンダイン ホールディングス,インコーポレイテッド Thrombus management and structural compliance features of prosthetic heart valves
US8870948B1 (en) 2013-07-17 2014-10-28 Cephea Valve Technologies, Inc. System and method for cardiac valve repair and replacement
JP6465883B2 (en) 2013-08-01 2019-02-06 テンダイン ホールディングス,インコーポレイテッド Epicardial anchor device and method
PL3545906T3 (en) 2013-08-14 2021-07-12 Mitral Valve Technologies Sàrl Replacement heart valve apparatus
US10070857B2 (en) 2013-08-31 2018-09-11 Mitralign, Inc. Devices and methods for locating and implanting tissue anchors at mitral valve commissure
WO2015058039A1 (en) 2013-10-17 2015-04-23 Robert Vidlund Apparatus and methods for alignment and deployment of intracardiac devices
WO2015059699A2 (en) 2013-10-23 2015-04-30 Valtech Cardio, Ltd. Anchor magazine
US9662202B2 (en) 2013-10-24 2017-05-30 Medtronic, Inc. Heart valve prosthesis
US10166098B2 (en) 2013-10-25 2019-01-01 Middle Peak Medical, Inc. Systems and methods for transcatheter treatment of valve regurgitation
CN105682611B (en) 2013-10-28 2018-06-01 坦迪尼控股股份有限公司 Prosthetic heart valve and the system and method for conveying prosthetic heart valve
US9526611B2 (en) 2013-10-29 2016-12-27 Tendyne Holdings, Inc. Apparatus and methods for delivery of transcatheter prosthetic valves
US10022114B2 (en) 2013-10-30 2018-07-17 4Tech Inc. Percutaneous tether locking
US10052095B2 (en) 2013-10-30 2018-08-21 4Tech Inc. Multiple anchoring-point tension system
US9610162B2 (en) 2013-12-26 2017-04-04 Valtech Cardio, Ltd. Implantation of flexible implant
US9681864B1 (en) 2014-01-03 2017-06-20 Harpoon Medical, Inc. Method and apparatus for transapical procedures on a mitral valve
WO2015120122A2 (en) 2014-02-05 2015-08-13 Robert Vidlund Apparatus and methods for transfemoral delivery of prosthetic mitral valve
US9986993B2 (en) 2014-02-11 2018-06-05 Tendyne Holdings, Inc. Adjustable tether and epicardial pad system for prosthetic heart valve
CA3205860A1 (en) 2014-02-20 2015-08-27 Mitral Valve Technologies Sarl Coiled anchor for supporting prosthetic heart valve, prosthetic heart valve, and deployment device
USD755384S1 (en) 2014-03-05 2016-05-03 Edwards Lifesciences Cardiaq Llc Stent
AU2015229708B2 (en) 2014-03-10 2019-08-15 Tendyne Holdings, Inc. Devices and methods for positioning and monitoring tether load for prosthetic mitral valve
US10857263B2 (en) * 2014-03-29 2020-12-08 Cormatrix Cardiovascular, Inc. Prosthetic tissue valves and methods for replacing native atrioventricular valves with same
JP6559161B2 (en) 2014-06-19 2019-08-14 4テック インコーポレイテッド Tightening heart tissue
CA2958065C (en) 2014-06-24 2023-10-31 Middle Peak Medical, Inc. Systems and methods for anchoring an implant
CN104055605B (en) 2014-07-07 2016-06-01 宁波健世生物科技有限公司 A kind of for stoping the prosthese of valve reflux
US10524910B2 (en) 2014-07-30 2020-01-07 Mitraltech Ltd. 3 Ariel Sharon Avenue Articulatable prosthetic valve
PL3000437T3 (en) * 2014-09-26 2018-10-31 Nvt Ag Implantable device for treating mitral valve regurgitation
EP3206629B1 (en) 2014-10-14 2021-07-14 Valtech Cardio, Ltd. Apparatus for heart valve leaflet restraining
EP3284412A1 (en) 2014-12-02 2018-02-21 4Tech Inc. Off-center tissue anchors
WO2016093877A1 (en) 2014-12-09 2016-06-16 Cephea Valve Technologies, Inc. Replacement cardiac valves and methods of use and manufacture
US9517131B2 (en) * 2014-12-12 2016-12-13 Than Nguyen Cardiac valve repair device
CN107405195B (en) 2015-01-07 2020-09-08 坦迪尼控股股份有限公司 Artificial mitral valve and apparatus and method for delivering artificial mitral valve
US9974651B2 (en) 2015-02-05 2018-05-22 Mitral Tech Ltd. Prosthetic valve with axially-sliding frames
CA3162308A1 (en) 2015-02-05 2016-08-11 Cardiovalve Ltd. Prosthetic valve with axially-sliding frames
CA2975294A1 (en) 2015-02-05 2016-08-11 Tendyne Holdings, Inc. Expandable epicardial pads and devices and methods for delivery of same
US20160256269A1 (en) 2015-03-05 2016-09-08 Mitralign, Inc. Devices for treating paravalvular leakage and methods use thereof
US10231827B2 (en) 2015-03-18 2019-03-19 Medtronic Vascular, Inc. Valve prostheses having an integral centering mechanism and methods of use thereof
US10524912B2 (en) 2015-04-02 2020-01-07 Abbott Cardiovascular Systems, Inc. Tissue fixation devices and methods
EP3283010B1 (en) 2015-04-16 2020-06-17 Tendyne Holdings, Inc. Apparatus for delivery and repositioning of transcatheter prosthetic valves
CA2982063A1 (en) 2015-04-30 2016-11-03 Valtech Cardio, Ltd. Annuloplasty technologies
US10849746B2 (en) 2015-05-14 2020-12-01 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
EP3294221B1 (en) 2015-05-14 2024-03-06 Cephea Valve Technologies, Inc. Replacement mitral valves
US10667815B2 (en) 2015-07-21 2020-06-02 Evalve, Inc. Tissue grasping devices and related methods
CN107920895B (en) 2015-08-21 2020-06-26 托尔福公司 Implantable heart valve devices, mitral valve repair devices, and associated systems and methods
US10531956B2 (en) 2015-09-03 2020-01-14 Vesalous Cardiovascular Inc. Apparatus for repairing heart valves and method of use thereof
US10327894B2 (en) 2015-09-18 2019-06-25 Tendyne Holdings, Inc. Methods for delivery of prosthetic mitral valves
WO2017059406A1 (en) * 2015-10-01 2017-04-06 Neochord, Inc. Ringless web for repair of heart valves
WO2017059426A1 (en) 2015-10-02 2017-04-06 Harpoon Medical, Inc. Distal anchor apparatus and methods for mitral valve repair
US10456243B2 (en) * 2015-10-09 2019-10-29 Medtronic Vascular, Inc. Heart valves prostheses and methods for percutaneous heart valve replacement
CN109172046B (en) 2015-11-06 2022-02-11 麦克尔有限公司 Mitral valve prosthesis
EP3383322B1 (en) 2015-12-03 2020-02-12 Tendyne Holdings, Inc. Frame features for prosthetic mitral valves
CA3006010C (en) 2015-12-28 2023-09-26 Tendyne Holdings, Inc. Atrial pocket closures for prosthetic heart valves
WO2017117370A2 (en) 2015-12-30 2017-07-06 Mitralign, Inc. System and method for reducing tricuspid regurgitation
US10426619B2 (en) * 2015-12-30 2019-10-01 Avvie Gmbh Implant and method for improving coaptation of an atrioventricular valve
EP3426195A4 (en) * 2016-03-08 2019-11-20 Dura LLC Heart valve leaflet replacement system and method for same
US10835714B2 (en) 2016-03-21 2020-11-17 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
US11219746B2 (en) 2016-03-21 2022-01-11 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
US10799675B2 (en) 2016-03-21 2020-10-13 Edwards Lifesciences Corporation Cam controlled multi-direction steerable handles
US10799677B2 (en) 2016-03-21 2020-10-13 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
US10799676B2 (en) 2016-03-21 2020-10-13 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
CN105852916B (en) * 2016-04-14 2018-02-06 上海甲悦医疗器械有限公司 A kind of bicuspid valve flexibility closure plate occluder and method for implantation being implanted into through the apex of the heart
US10624743B2 (en) 2016-04-22 2020-04-21 Edwards Lifesciences Corporation Beating-heart mitral valve chordae replacement
CN109069272A (en) 2016-04-29 2018-12-21 美敦力瓦斯科尔勒公司 Prosthetic heart valve equipment and associated system and method with the anchor log with tether
US10470877B2 (en) 2016-05-03 2019-11-12 Tendyne Holdings, Inc. Apparatus and methods for anterior valve leaflet management
US10702274B2 (en) 2016-05-26 2020-07-07 Edwards Lifesciences Corporation Method and system for closing left atrial appendage
WO2017218375A1 (en) 2016-06-13 2017-12-21 Tendyne Holdings, Inc. Sequential delivery of two-part prosthetic mitral valve
US20170360558A1 (en) * 2016-06-16 2017-12-21 Jianlu Ma Method and design for a mitral regurgitation treatment device
US11331187B2 (en) 2016-06-17 2022-05-17 Cephea Valve Technologies, Inc. Cardiac valve delivery devices and systems
US11090157B2 (en) 2016-06-30 2021-08-17 Tendyne Holdings, Inc. Prosthetic heart valves and apparatus and methods for delivery of same
US10973638B2 (en) 2016-07-07 2021-04-13 Edwards Lifesciences Corporation Device and method for treating vascular insufficiency
GB201611910D0 (en) 2016-07-08 2016-08-24 Valtech Cardio Ltd Adjustable annuloplasty device with alternating peaks and troughs
EP3484411A1 (en) 2016-07-12 2019-05-22 Tendyne Holdings, Inc. Apparatus and methods for trans-septal retrieval of prosthetic heart valves
US10350062B2 (en) 2016-07-21 2019-07-16 Edwards Lifesciences Corporation Replacement heart valve prosthesis
US10856975B2 (en) 2016-08-10 2020-12-08 Cardiovalve Ltd. Prosthetic valve with concentric frames
USD800908S1 (en) 2016-08-10 2017-10-24 Mitraltech Ltd. Prosthetic valve element
US10653862B2 (en) 2016-11-07 2020-05-19 Edwards Lifesciences Corporation Apparatus for the introduction and manipulation of multiple telescoping catheters
US10779837B2 (en) 2016-12-08 2020-09-22 Evalve, Inc. Adjustable arm device for grasping tissues
US10905554B2 (en) * 2017-01-05 2021-02-02 Edwards Lifesciences Corporation Heart valve coaptation device
AU2018205222A1 (en) 2017-01-05 2019-07-11 Harmony Development Group, Inc. Expandable device for capturing regurgitant jet, volume, and force to effect ventricular function and remodeling
EP4209196A1 (en) 2017-01-23 2023-07-12 Cephea Valve Technologies, Inc. Replacement mitral valves
CA3051272C (en) 2017-01-23 2023-08-22 Cephea Valve Technologies, Inc. Replacement mitral valves
US11419719B2 (en) 2017-02-06 2022-08-23 Mtex Cardio Ag Methods and systems for assisting or repairing prosthetic cardiac valves
US10675017B2 (en) 2017-02-07 2020-06-09 Edwards Lifesciences Corporation Transcatheter heart valve leaflet plication
US10478303B2 (en) 2017-03-13 2019-11-19 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
US10653524B2 (en) 2017-03-13 2020-05-19 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
DE102017002974A1 (en) 2017-03-28 2018-10-04 Immanuel Diakonie Gmbh Heart valve implant, suitable for use in minimally invasive surgery for the repair of a heart valve and / or a heart valve beating on the beating heart
US10765515B2 (en) 2017-04-06 2020-09-08 University Of Maryland, Baltimore Distal anchor apparatus and methods for mitral valve repair
US11045627B2 (en) 2017-04-18 2021-06-29 Edwards Lifesciences Corporation Catheter system with linear actuation control mechanism
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10702378B2 (en) 2017-04-18 2020-07-07 Twelve, Inc. Prosthetic heart valve device and associated systems and methods
US10433961B2 (en) 2017-04-18 2019-10-08 Twelve, Inc. Delivery systems with tethers for prosthetic heart valve devices and associated methods
US10799312B2 (en) 2017-04-28 2020-10-13 Edwards Lifesciences Corporation Medical device stabilizing apparatus and method of use
US10792151B2 (en) 2017-05-11 2020-10-06 Twelve, Inc. Delivery systems for delivering prosthetic heart valve devices and associated methods
US10842619B2 (en) 2017-05-12 2020-11-24 Edwards Lifesciences Corporation Prosthetic heart valve docking assembly
US10813761B2 (en) * 2017-05-23 2020-10-27 Harmony Development Group, Inc. Tethered implantable device having a vortical intracardiac velocity adjusting balloon
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
US10709591B2 (en) 2017-06-06 2020-07-14 Twelve, Inc. Crimping device and method for loading stents and prosthetic heart valves
EP3634528B1 (en) 2017-06-07 2023-06-07 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
SG11201912367UA (en) 2017-06-19 2020-01-30 Harpoon Medical Inc Method and apparatus for cardiac procedures
US10940002B2 (en) 2017-06-28 2021-03-09 Harmony Development Group, Inc. Force transducting inflatable implant system including a dual force annular transduction implant
US10729541B2 (en) 2017-07-06 2020-08-04 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US10786352B2 (en) 2017-07-06 2020-09-29 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
CN110944599A (en) * 2017-07-10 2020-03-31 克拉玛泽技术有限公司 Heart implant
EP3651695B1 (en) 2017-07-13 2023-04-19 Tendyne Holdings, Inc. Prosthetic heart valves and apparatus for delivery of same
EP3658075A4 (en) * 2017-07-24 2021-04-28 Emory University Cardiac valve leaflet enhancer devices and systems
US10537426B2 (en) 2017-08-03 2020-01-21 Cardiovalve Ltd. Prosthetic heart valve
US10888421B2 (en) 2017-09-19 2021-01-12 Cardiovalve Ltd. Prosthetic heart valve with pouch
US11793633B2 (en) 2017-08-03 2023-10-24 Cardiovalve Ltd. Prosthetic heart valve
US11246704B2 (en) 2017-08-03 2022-02-15 Cardiovalve Ltd. Prosthetic heart valve
US10575948B2 (en) 2017-08-03 2020-03-03 Cardiovalve Ltd. Prosthetic heart valve
AU2018323900A1 (en) 2017-08-28 2020-02-27 Tendyne Holdings, Inc. Prosthetic heart valves with tether coupling features
US11173032B2 (en) * 2017-08-28 2021-11-16 Edwards Lifesciences Corporation Transcatheter device for treating mitral regurgitation
CN116473727A (en) 2017-08-31 2023-07-25 半月医疗有限公司 Artificial valve device
US11040174B2 (en) 2017-09-19 2021-06-22 Edwards Lifesciences Corporation Multi-direction steerable handles for steering catheters
WO2019079252A1 (en) * 2017-10-20 2019-04-25 Edwards Lifesciences Corporation Localized fusion of native leaflets using activated adhesive
US11065120B2 (en) 2017-10-24 2021-07-20 University Of Maryland, Baltimore Method and apparatus for cardiac procedures
US10835221B2 (en) 2017-11-02 2020-11-17 Valtech Cardio, Ltd. Implant-cinching devices and systems
WO2019094963A1 (en) 2017-11-13 2019-05-16 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
US11135062B2 (en) 2017-11-20 2021-10-05 Valtech Cardio Ltd. Cinching of dilated heart muscle
US11083581B2 (en) 2017-12-04 2021-08-10 Edwards Lifesciences Corporation Expandable heart valve coaptation device
GB201720803D0 (en) 2017-12-13 2018-01-24 Mitraltech Ltd Prosthetic Valve and delivery tool therefor
CN210301306U (en) 2018-01-07 2020-04-14 苏州杰成医疗科技有限公司 Heart valve prosthesis delivery system
CN210582753U (en) 2018-01-07 2020-05-22 苏州杰成医疗科技有限公司 Delivery system for delivering a valve prosthesis
US10231837B1 (en) 2018-01-09 2019-03-19 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10123873B1 (en) 2018-01-09 2018-11-13 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10136993B1 (en) 2018-01-09 2018-11-27 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10076415B1 (en) 2018-01-09 2018-09-18 Edwards Lifesciences Corporation Native valve repair devices and procedures
WO2019139904A1 (en) 2018-01-09 2019-07-18 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10238493B1 (en) 2018-01-09 2019-03-26 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10245144B1 (en) 2018-01-09 2019-04-02 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10105222B1 (en) 2018-01-09 2018-10-23 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10111751B1 (en) 2018-01-09 2018-10-30 Edwards Lifesciences Corporation Native valve repair devices and procedures
GB201800399D0 (en) 2018-01-10 2018-02-21 Mitraltech Ltd Temperature-control during crimping of an implant
CA3086884A1 (en) 2018-01-24 2019-08-01 Valtech Cardio, Ltd. Contraction of an annuloplasty structure
CN111818877B (en) 2018-01-25 2023-12-22 爱德华兹生命科学公司 Delivery system for assisting in recapture and repositioning of replacement valves after deployment
EP4248904A3 (en) 2018-01-26 2023-11-29 Edwards Lifesciences Innovation (Israel) Ltd. Techniques for facilitating heart valve tethering and chord replacement
US10722631B2 (en) 2018-02-01 2020-07-28 Shifamed Holdings, Llc Intravascular blood pumps and methods of use and manufacture
CN111902103A (en) 2018-02-08 2020-11-06 因威尔乌治疗公司 Method, apparatus and device for treating heart valves
WO2019173385A1 (en) 2018-03-05 2019-09-12 Harmony Development Group, Inc. A force transducting implant system for the mitigation of atrioventricular pressure gradient loss and the restoration of healthy ventricular geometry
EP3784173A4 (en) * 2018-04-24 2021-12-15 Raghuveer Basude Retrievable tissue grasping devices, spacers, artificial valves and related methods
US11517435B2 (en) 2018-05-04 2022-12-06 Edwards Lifesciences Corporation Ring-based prosthetic cardiac valve
WO2019218930A1 (en) * 2018-05-17 2019-11-21 杭州德晋医疗科技有限公司 Valve clamp and valve clamping system
CA3106104A1 (en) 2018-07-12 2020-01-16 Valtech Cardio, Ltd. Annuloplasty systems and locking tools therefor
EP3620133A1 (en) * 2018-09-07 2020-03-11 AVVie GmbH Implant for improving coaptation of an artrioventricular valve
US10945844B2 (en) 2018-10-10 2021-03-16 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
WO2020101676A1 (en) * 2018-11-14 2020-05-22 Half Moon Medical, Inc. Leaflet extension for cardiac valve leaflet
JP2022509627A (en) 2018-11-21 2022-01-21 エドワーズ ライフサイエンシーズ コーポレイション Heart valve sealing device, delivery device for it, and recovery device
CN114173680A (en) * 2019-01-08 2022-03-11 纽约哥伦比亚大学董事会 Systems and methods for heart valve repair
US11633281B2 (en) 2019-01-16 2023-04-25 Half Moon Medical, Inc. Implantable coaptation assist devices with sensors and associated systems and methods
SG11202108229UA (en) 2019-02-11 2021-08-30 Edwards Lifesciences Corp Heart valve sealing devices and delivery devices therefor
EP3923867B1 (en) 2019-02-14 2023-08-30 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
WO2020172224A1 (en) 2019-02-20 2020-08-27 Edwards Lifesciences Corporation Counterflexing steerable catheter for transcatheter heart valve therapy
CA3131522A1 (en) 2019-02-25 2020-09-03 Edwards Lifesciences Corporation Heart valve sealing devices
WO2020176310A1 (en) * 2019-02-25 2020-09-03 Edwards Lifesciences Corporation Devices and methods for repair of valvular insufficiency
CN113825473A (en) 2019-03-12 2021-12-21 半月医疗有限公司 Heart valve repair devices with annuloplasty features and associated systems and methods
EP3958791A1 (en) * 2019-04-22 2022-03-02 Edwards Lifesciences Corporation Heart valve repair
SG11202112341TA (en) 2019-05-20 2021-12-30 Edwards Lifesciences Corp Heart valve sealing devices, delivery devices therefor, and retrieval devices
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4007546A1 (en) * 2019-09-19 2022-06-08 Half Moon Medical, Inc. Valve repair devices with coaptation structures and multiple leaflet capture clips
MX2021014899A (en) 2019-09-30 2022-01-18 Edwards Lifesciences Corp Heart valve sealing devices and delivery devices therefor.
CR20210633A (en) 2019-10-09 2022-05-30 Edwards Lifesciences Corp Heart valve sealing devices and delivery devices therefor
CN114007554A (en) 2019-10-15 2022-02-01 爱德华兹生命科学公司 Heart valve sealing device and delivery device thereof
AU2020375903A1 (en) 2019-10-29 2021-12-23 Edwards Lifesciences Innovation (Israel) Ltd. Annuloplasty and tissue anchor technologies
EP3831343B1 (en) 2019-12-05 2024-01-31 Tendyne Holdings, Inc. Braided anchor for mitral valve
US11648114B2 (en) 2019-12-20 2023-05-16 Tendyne Holdings, Inc. Distally loaded sheath and loading funnel
AU2020412672A1 (en) 2019-12-23 2022-01-06 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US20210196462A1 (en) * 2019-12-31 2021-07-01 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
WO2021202130A1 (en) 2020-03-31 2021-10-07 Edwards Lifesciences Corporation High flexibility implant catheter with low compression
EP3912595B1 (en) * 2020-05-19 2023-01-04 AVVie GmbH Implant for improving coaptation of an atrioventricular valve
US20220304801A1 (en) * 2020-07-15 2022-09-29 Shanghai Trulive Medtech Co., Ltd. Prosthetic heart valve
CN216417417U (en) 2020-08-14 2022-05-03 爱德华兹生命科学公司 Valve repair device
US11678980B2 (en) 2020-08-19 2023-06-20 Tendyne Holdings, Inc. Fully-transseptal apical pad with pulley for tensioning
WO2022109620A1 (en) * 2020-11-20 2022-05-27 Half Moon Medical, Inc. Cardiac valve repair devices and associated systems and methods
CN116710029A (en) * 2020-11-20 2023-09-05 半月医疗有限公司 Tricuspid valve repair devices and related systems and methods
US11464634B2 (en) 2020-12-16 2022-10-11 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation with secondary anchors
CA3175545A1 (en) 2020-12-23 2022-06-30 Edwards Lifesciences Corporation Heart valve repair devices and delivery devices therefor
KR20230132497A (en) 2021-01-15 2023-09-15 에드워즈 라이프사이언시스 코포레이션 Heart valve sealing device and delivery device therefor
WO2022177562A1 (en) * 2021-02-18 2022-08-25 Cormatrix Cardiovascular, Inc. Reinforced prosthetic valves
WO2022231889A2 (en) 2021-04-28 2022-11-03 Edwards Lifesciences Corporation Delivery devices for heart valve treatment devices
US11759321B2 (en) 2021-06-25 2023-09-19 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
CN115553974A (en) 2021-07-01 2023-01-03 爱德华兹生命科学公司 Heart valve repair device and delivery device thereof
CA3224720A1 (en) 2021-07-20 2023-01-26 Edwards Lifesciences Corporation Sensing heart valve repair devices
TW202315590A (en) 2021-07-23 2023-04-16 美商愛德華生命科學公司 Heart valve repair devices and delivery devices therefor
WO2023086340A1 (en) 2021-11-12 2023-05-19 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
WO2023091520A1 (en) 2021-11-19 2023-05-25 Edwards Lifesciences Corporation Heart valve repair devices
WO2023100176A1 (en) * 2021-12-02 2023-06-08 Cuspa Ltd. Transcatheter artificial cusp for valve insufficiency
WO2023107296A1 (en) 2021-12-09 2023-06-15 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
WO2023119065A1 (en) * 2021-12-21 2023-06-29 Edwards Lifesciences Innovation (Israel) Ltd. Leaflet augmentor
WO2023122695A1 (en) * 2021-12-22 2023-06-29 Invalve Therapeutics, Inc. Heart valve prosteheses and related methods
WO2023146859A1 (en) 2022-01-26 2023-08-03 Edwards Lifesciences Corporation Delivery devices for heart valve repair and replacement devices
WO2023158593A1 (en) 2022-02-15 2023-08-24 Edwards Lifesciences Corporation Heart valve repair devices and delivery devices therefor
WO2023158592A1 (en) 2022-02-15 2023-08-24 Edwards Lifesciences Corporation Heart valve repair devices
WO2023167825A1 (en) 2022-03-02 2023-09-07 Edwards Lifesciences Corporation Heart valve repair devices and delivery devices therefor
CN116763502A (en) * 2022-03-11 2023-09-19 上海臻亿医疗科技有限公司 Artificial heart valve
WO2023183216A1 (en) 2022-03-21 2023-09-28 Edwards Lifesciences Corporation Heart valve repair devices and delivery devices therefor
WO2023196183A1 (en) 2022-04-04 2023-10-12 Edwards Lifesciences Corporation Heart valve repair devices and delivery devices therefor
CN116942367A (en) * 2022-04-14 2023-10-27 上海臻亿医疗科技有限公司 Artificial heart valve
WO2023200706A1 (en) 2022-04-15 2023-10-19 Edwards Lifesciences Corporation Methods and apparatus for removal of valve repair devices
WO2023249858A1 (en) 2022-06-22 2023-12-28 Edwards Lifesciences Corporation Heart valve repair devices and delivery devices therefor
WO2024020182A1 (en) 2022-07-22 2024-01-25 Edwards Lifesciences Corporation Bioimpedance-based feedback for medical procedures

Citations (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409013A (en) 1965-08-23 1968-11-05 Berry Henry Instrument for inserting artificial heart valves
US3472230A (en) 1966-12-19 1969-10-14 Fogarty T J Umbrella catheter
US3548417A (en) 1967-09-05 1970-12-22 Ronnie G Kischer Heart valve having a flexible wall which rotates between open and closed positions
US3587115A (en) 1966-05-04 1971-06-28 Donald P Shiley Prosthetic sutureless heart valves and implant tools therefor
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US3671979A (en) 1969-09-23 1972-06-27 Univ Utah Catheter mounted artificial heart valve for implanting in close proximity to a defective natural heart valve
US3714671A (en) 1970-11-30 1973-02-06 Cutter Lab Tissue-type heart valve with a graft support ring or stent
US3755823A (en) 1971-04-23 1973-09-04 Hancock Laboratories Inc Flexible stent for heart valve
US4035849A (en) 1975-11-17 1977-07-19 William W. Angell Heart valve stent and process for preparing a stented heart valve prosthesis
US4056854A (en) 1976-09-28 1977-11-08 The United States Of America As Represented By The Department Of Health, Education And Welfare Aortic heart valve catheter
US4106129A (en) 1976-01-09 1978-08-15 American Hospital Supply Corporation Supported bioprosthetic heart valve with compliant orifice ring
US4222126A (en) 1978-12-14 1980-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health, Education & Welfare Unitized three leaflet heart valve
US4265694A (en) 1978-12-14 1981-05-05 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making unitized three leaflet heart valve
DE2246526C3 (en) 1971-09-24 1981-07-30 Smiths Industries Ltd., London Catheter with an inflatable cuff
US4297749A (en) 1977-04-25 1981-11-03 Albany International Corp. Heart valve prosthesis
US4339831A (en) 1981-03-27 1982-07-20 Medtronic, Inc. Dynamic annulus heart valve and reconstruction ring
US4343048A (en) 1979-08-06 1982-08-10 Ross Donald N Stent for a cardiac valve
US4345340A (en) 1981-05-07 1982-08-24 Vascor, Inc. Stent for mitral/tricuspid heart valve
US4373216A (en) 1980-10-27 1983-02-15 Hemex, Inc. Heart valves having edge-guided occluders
US4406022A (en) 1981-11-16 1983-09-27 Kathryn Roy Prosthetic valve means for cardiovascular surgery
US4470157A (en) 1981-04-27 1984-09-11 Love Jack W Tricuspid prosthetic tissue heart valve
US4535483A (en) 1983-01-17 1985-08-20 Hemex, Inc. Suture rings for heart valves
US4574803A (en) 1979-01-19 1986-03-11 Karl Storz Tissue cutter
US4592340A (en) 1984-05-02 1986-06-03 Boyles Paul W Artificial catheter means
US4605407A (en) 1983-01-11 1986-08-12 The University Of Sheffield Heart valve replacements
US4612011A (en) 1983-07-22 1986-09-16 Hans Kautzky Central occluder semi-biological heart valve
SU1271508A1 (en) 1984-11-29 1986-11-23 Горьковский государственный медицинский институт им.С.М.Кирова Artificial heart valve
US4643732A (en) 1984-11-17 1987-02-17 Beiersdorf Aktiengesellschaft Heart valve prosthesis
US4655771A (en) 1982-04-30 1987-04-07 Shepherd Patents S.A. Prosthesis comprising an expansible or contractile tubular body
US4692164A (en) 1986-03-06 1987-09-08 Moskovskoe Vysshee Tekhnicheskoe Uchilische, Imeni N.E. Baumana Bioprosthetic heart valve, methods and device for preparation thereof
US4733665A (en) 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
EP0103546B1 (en) 1982-08-09 1988-05-04 Domenico Iorio Surgical instrument for implanting prosthetic heart valves or the like
US4759758A (en) 1984-12-07 1988-07-26 Shlomo Gabbay Prosthetic heart valve
US4762128A (en) 1986-12-09 1988-08-09 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US4777951A (en) 1986-09-19 1988-10-18 Mansfield Scientific, Inc. Procedure and catheter instrument for treating patients for aortic stenosis
US4787901A (en) 1984-07-17 1988-11-29 Doguhan Baykut Two-way acting valve and cardiac valve prosthesis
US4787899A (en) 1983-12-09 1988-11-29 Lazarus Harrison M Intraluminal graft device, system and method
US4796629A (en) 1987-06-03 1989-01-10 Joseph Grayzel Stiffened dilation balloon catheter device
US4829990A (en) 1987-06-25 1989-05-16 Thueroff Joachim Implantable hydraulic penile erector
US4851001A (en) 1987-09-17 1989-07-25 Taheri Syde A Prosthetic valve for a blood vein and an associated method of implantation of the valve
US4856516A (en) 1989-01-09 1989-08-15 Cordis Corporation Endovascular stent apparatus and method
US4878906A (en) 1986-03-25 1989-11-07 Servetus Partnership Endoprosthesis for repairing a damaged vessel
US4878495A (en) 1987-05-15 1989-11-07 Joseph Grayzel Valvuloplasty device with satellite expansion means
EP0144167B1 (en) 1983-11-09 1989-11-08 Dow Corning Corporation Hard organopolysiloxane release coating
US4883458A (en) 1987-02-24 1989-11-28 Surgical Systems & Instruments, Inc. Atherectomy system and method of using the same
US4922905A (en) 1985-11-30 1990-05-08 Strecker Ernst P Dilatation catheter
US4966604A (en) 1989-01-23 1990-10-30 Interventional Technologies Inc. Expandable atherectomy cutter with flexibly bowed blades
US4979939A (en) 1984-05-14 1990-12-25 Surgical Systems & Instruments, Inc. Atherectomy system with a guide wire
US4986830A (en) 1989-09-22 1991-01-22 Schneider (U.S.A.) Inc. Valvuloplasty catheter with balloon which remains stable during inflation
US4994077A (en) 1989-04-21 1991-02-19 Dobben Richard L Artificial heart valve for implantation in a blood vessel
US5007896A (en) 1988-12-19 1991-04-16 Surgical Systems & Instruments, Inc. Rotary-catheter for atherectomy
US5026366A (en) 1984-03-01 1991-06-25 Cardiovascular Laser Systems, Inc. Angioplasty catheter and method of use thereof
US5032128A (en) 1988-07-07 1991-07-16 Medtronic, Inc. Heart valve prosthesis
US5037434A (en) 1990-04-11 1991-08-06 Carbomedics, Inc. Bioprosthetic heart valve with elastic commissures
US5047041A (en) 1989-08-22 1991-09-10 Samuels Peter B Surgical apparatus for the excision of vein valves in situ
US5059177A (en) 1990-04-19 1991-10-22 Cordis Corporation Triple lumen balloon catheter
WO1991017720A1 (en) 1990-05-18 1991-11-28 Henning Rud Andersen A valve prosthesis for implantation in the body and a catheter for implantating such valve prosthesis
US5080668A (en) 1988-11-29 1992-01-14 Biotronik Mess- und Therapiegerate GmbH & Co. KG Ingenieurburo Berlin Cardiac valve prosthesis
US5085635A (en) 1990-05-18 1992-02-04 Cragg Andrew H Valved-tip angiographic catheter
US5089015A (en) 1989-11-28 1992-02-18 Promedica International Method for implanting unstented xenografts and allografts
US5108370A (en) 1989-10-03 1992-04-28 Paul Walinsky Perfusion balloon catheter
US5152771A (en) 1990-12-31 1992-10-06 The Board Of Supervisors Of Louisiana State University Valve cutter for arterial by-pass surgery
WO1992017118A1 (en) 1991-04-04 1992-10-15 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification
US5163953A (en) 1992-02-10 1992-11-17 Vince Dennis J Toroidal artificial heart valve stent
US5167628A (en) 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
WO1993001768A1 (en) 1991-07-16 1993-02-04 Stevens John H Endovascular aortic valve replacement
US5192297A (en) 1991-12-31 1993-03-09 Medtronic, Inc. Apparatus and method for placement and implantation of a stent
US5232446A (en) 1991-10-30 1993-08-03 Scimed Life Systems, Inc. Multi-sinus perfusion balloon dilatation catheter
US5266073A (en) 1987-12-08 1993-11-30 Wall W Henry Angioplasty stent
US5282847A (en) 1991-02-28 1994-02-01 Medtronic, Inc. Prosthetic vascular grafts with a pleated structure
US5332402A (en) 1992-05-12 1994-07-26 Teitelbaum George P Percutaneously-inserted cardiac valve
US5360444A (en) 1991-03-19 1994-11-01 Kenji Kusuhara Occluder supporter and a method of attachment thereof
US5397351A (en) 1991-05-13 1995-03-14 Pavcnik; Dusan Prosthetic valve for percutaneous insertion
US5411055A (en) 1992-11-24 1995-05-02 Mannesmann Aktiengesellschaft Flow limiting throttle element
US5411552A (en) 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5411522A (en) 1993-08-25 1995-05-02 Linvatec Corporation Unitary anchor for soft tissue fixation
US5480424A (en) 1993-11-01 1996-01-02 Cox; James L. Heart valve replacement using flexible tubes
US5500014A (en) 1989-05-31 1996-03-19 Baxter International Inc. Biological valvular prothesis
US5545209A (en) 1993-09-30 1996-08-13 Texas Petrodet, Inc. Controlled deployment of a medical device
US5549665A (en) 1993-06-18 1996-08-27 London Health Association Bioprostethic valve
US5554185A (en) 1994-07-18 1996-09-10 Block; Peter C. Inflatable prosthetic cardiovascular valve for percutaneous transluminal implantation of same
US5571175A (en) 1995-06-07 1996-11-05 St. Jude Medical, Inc. Suture guard for prosthetic heart valve
US5591185A (en) 1989-12-14 1997-01-07 Corneal Contouring Development L.L.C. Method and apparatus for reprofiling or smoothing the anterior or stromal cornea by scraping
US5599305A (en) 1994-10-24 1997-02-04 Cardiovascular Concepts, Inc. Large-diameter introducer sheath having hemostasis valve and removable steering mechanism
US5609626A (en) 1989-05-31 1997-03-11 Baxter International Inc. Stent devices and support/restrictor assemblies for use in conjunction with prosthetic vascular grafts
DE19532846A1 (en) 1995-09-06 1997-03-13 Georg Dr Berg Valve for use in heart
US5639274A (en) 1995-06-02 1997-06-17 Fischell; Robert E. Integrated catheter system for balloon angioplasty and stent delivery
WO1997024080A1 (en) 1995-12-28 1997-07-10 Cogent Kit for surgical treatment of intracorporal lumens
US5665115A (en) 1992-02-21 1997-09-09 Boston Scientific Technology, Inc. Intraluminal stent
US5716417A (en) 1995-06-07 1998-02-10 St. Jude Medical, Inc. Integral supporting structure for bioprosthetic heart valve
US5728068A (en) 1994-06-14 1998-03-17 Cordis Corporation Multi-purpose balloon catheter
US5749890A (en) 1996-12-03 1998-05-12 Shaknovich; Alexander Method and system for stent placement in ostial lesions
US5756476A (en) 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5769812A (en) 1991-07-16 1998-06-23 Heartport, Inc. System for cardiac procedures
EP0850607A1 (en) 1996-12-31 1998-07-01 Cordis Corporation Valve prosthesis for implantation in body channels
US5800508A (en) 1994-02-09 1998-09-01 Boston Scientific Technology, Inc. Bifurcated endoluminal prosthesis
US5855601A (en) 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
US5855597A (en) 1997-05-07 1999-01-05 Iowa-India Investments Co. Limited Stent valve and stent graft for percutaneous surgery
US5855602A (en) 1996-09-09 1999-01-05 Shelhigh, Inc. Heart valve prosthesis
US5906619A (en) 1997-07-24 1999-05-25 Medtronic, Inc. Disposable delivery device for endoluminal prostheses
WO1999033414A1 (en) 1997-12-29 1999-07-08 Ivan Vesely System for minimally invasive insertion of a bioprosthetic heart valve
US5925063A (en) 1997-09-26 1999-07-20 Khosravi; Farhad Coiled sheet valve, filter or occlusive device and methods of use
WO1999040964A1 (en) 1998-02-16 1999-08-19 Medicorp S.A. Angioplasty and stent delivery catheter
WO1999047075A1 (en) 1998-03-17 1999-09-23 Medicorp S.A. Reversible-action endoprosthesis delivery device
US5957949A (en) 1997-05-01 1999-09-28 World Medical Manufacturing Corp. Percutaneous placement valve stent
US5968068A (en) 1996-09-12 1999-10-19 Baxter International Inc. Endovascular delivery system
US6027525A (en) 1996-05-23 2000-02-22 Samsung Electronics., Ltd. Flexible self-expandable stent and method for making the same
US6042607A (en) 1996-02-23 2000-03-28 Cardiovascular Technologies Llc Means and method of replacing a heart valve in a minimally invasive manner
WO2000018333A1 (en) 1998-09-28 2000-04-06 Autogenics Heart valve having tissue retention with anchors and an outer sheath
FR2788217A1 (en) 1999-01-12 2000-07-13 Brice Letac PROSTHETIC VALVE IMPLANTABLE BY CATHETERISM, OR SURGICAL
DE19907646A1 (en) 1999-02-23 2000-08-24 Georg Berg Valve for blood vessels uses flap holders and counterpart holders on stent to latch together in place and all channeled for guide wire.
US6132473A (en) 1997-05-02 2000-10-17 St. Jude Medical, Inc. Differential treatment of prosthetic devices
EP1057460A1 (en) 1999-06-01 2000-12-06 Numed, Inc. Replacement valve assembly and method of implanting same
US6171335B1 (en) 1997-01-24 2001-01-09 Aortech Europe Limited Heart valve prosthesis
US6174327B1 (en) 1998-02-27 2001-01-16 Scimed Life Systems, Inc. Stent deployment apparatus and method
US6210408B1 (en) 1999-02-24 2001-04-03 Scimed Life Systems, Inc. Guide wire system for RF recanalization of vascular blockages
US6217585B1 (en) 1996-08-16 2001-04-17 Converge Medical, Inc. Mechanical stent and graft delivery system
WO2001028459A1 (en) 1999-10-21 2001-04-26 Scimed Life Systems, Inc. Implantable prosthetic valve
US6231602B1 (en) 1999-04-16 2001-05-15 Edwards Lifesciences Corporation Aortic annuloplasty ring
US6245040B1 (en) 1994-01-14 2001-06-12 Cordis Corporation Perfusion balloon brace and method of use
US6245102B1 (en) 1997-05-07 2001-06-12 Iowa-India Investments Company Ltd. Stent, stent graft and stent valve
WO2001054625A1 (en) 2000-01-31 2001-08-02 Cook Biotech Incorporated Stent valves and uses of same
WO2001054624A1 (en) 2000-01-27 2001-08-02 3F Therapeutics, Inc. Prosthetic heart valve
WO2001062189A1 (en) 2000-02-28 2001-08-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Device for fastening and anchoring cardiac valve prostheses
WO2001064137A1 (en) 2000-02-28 2001-09-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anchoring system for implantable heart valve prostheses
US6287339B1 (en) 1999-05-27 2001-09-11 Sulzer Carbomedics Inc. Sutureless heart valve prosthesis
US20010021872A1 (en) 1999-12-31 2001-09-13 Bailey Steven R. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
WO2000047139A9 (en) 1999-02-10 2001-09-13 Heartport Inc Methods and devices for implanting cardiac valves
US6299637B1 (en) 1999-08-20 2001-10-09 Samuel M. Shaolian Transluminally implantable venous valve
US6306141B1 (en) 1983-10-14 2001-10-23 Medtronic, Inc. Medical devices incorporating SIM alloy elements
US6312465B1 (en) 1999-07-23 2001-11-06 Sulzer Carbomedics Inc. Heart valve prosthesis with a resiliently deformable retaining member
WO2001076510A8 (en) 2000-04-06 2002-01-03 Edwards Lifesciences Corp Minimally-invasive heart valves and methods of use
US6350277B1 (en) 1999-01-15 2002-02-26 Scimed Life Systems, Inc. Stents with temporary retaining bands
US20020032481A1 (en) 2000-09-12 2002-03-14 Shlomo Gabbay Heart valve prosthesis and sutureless implantation of a heart valve prosthesis
WO2002022054A1 (en) 2000-09-12 2002-03-21 Gabbay S Valvular prosthesis and method of using same
WO2001035878A3 (en) 1999-11-18 2002-03-28 Thermamed Gmbh Medical warming device
DE10049813C1 (en) 2000-10-09 2002-04-18 Universitaetsklinikum Freiburg Instrument for the local removal of built-up matter at an aortic valve, in a human or animal heart, is a hollow catheter with a cutting unit at the far end within a closure cap for minimum invasion
WO2002036048A1 (en) 2000-10-31 2002-05-10 Jacques Seguin Tubular support for setting, by percutaneous route, a substitution cusp
WO2002041789A3 (en) 2000-11-21 2002-08-22 Rex Medical Lp Percutaneous aortic valve
US6461382B1 (en) 2000-09-22 2002-10-08 Edwards Lifesciences Corporation Flexible heart valve having moveable commissures
US6468660B2 (en) 2000-12-29 2002-10-22 St. Jude Medical, Inc. Biocompatible adhesives
DE19546692C2 (en) 1995-12-14 2002-11-07 Hans-Reiner Figulla Self-expanding heart valve prosthesis for implantation in the human body via a catheter system
US6482228B1 (en) 2000-11-14 2002-11-19 Troy R. Norred Percutaneous aortic valve replacement
US20020173842A1 (en) 2001-05-17 2002-11-21 Buchanan Eric S. Prosthetic heart valve with slit stent
US6488704B1 (en) 2001-05-07 2002-12-03 Biomed Solutions, Llc Implantable particle measuring apparatus
WO2002047575A3 (en) 2000-12-15 2002-12-12 Angiomed Ag Stent with valve
WO2002049540A3 (en) 2000-12-21 2003-02-06 Cleveland Clinic Foundation Bioprosthetic cardiovascular valve system
US6527979B2 (en) 1999-08-27 2003-03-04 Corazon Technologies, Inc. Catheter systems and methods for their use in the treatment of calcified vascular occlusions
US20030050694A1 (en) 2001-09-13 2003-03-13 Jibin Yang Methods and apparatuses for deploying minimally-invasive heart valves
WO2002043620A9 (en) 2000-12-01 2003-04-17 Prodesco Endovascular valve
US20030100939A1 (en) 2001-11-23 2003-05-29 Mindguard Ltd. Expandable delivery appliance particularly for delivering intravascular devices
WO2003047468A1 (en) 2001-10-11 2003-06-12 Percutaneous Valve Technologies Implantable prosthetic valve
US20030130731A1 (en) 2002-01-09 2003-07-10 Myocor, Inc. Devices and methods for heart valve treatment
US6605112B1 (en) 1996-12-18 2003-08-12 Venpro Corporation Device for regulating the flow of blood through the blood system
US20030158597A1 (en) 1993-08-05 2003-08-21 Quiachon Dinah B. Multicapsule intraluminal grafting system and method
US20030212454A1 (en) 2002-05-08 2003-11-13 Scott Michael J. Compressed tissue for heart valve leaflets
US6733525B2 (en) 2001-03-23 2004-05-11 Edwards Lifesciences Corporation Rolled minimally-invasive heart valves and methods of use
US20040092858A1 (en) 2002-08-28 2004-05-13 Heart Leaflet Technologies, Inc. Leaflet valve
DE10049812B4 (en) 2000-10-09 2004-06-03 Universitätsklinikum Freiburg Device for filtering out macroscopic particles from the bloodstream during local removal of an aortic valve on the human or animal heart
US20040133263A1 (en) 1996-08-23 2004-07-08 Scimed Life Systems, Inc. Stent delivery system having stent securement apparatus
US6790229B1 (en) 1999-05-25 2004-09-14 Eric Berreklouw Fixing device, in particular for fixing to vascular wall tissue
US20040186563A1 (en) 2003-03-18 2004-09-23 Lobbi Mario M. Minimally-invasive heart valve with cusp positioners
US6830584B1 (en) 1999-11-17 2004-12-14 Jacques Seguin Device for replacing a cardiac valve by percutaneous route
US20040260389A1 (en) 2003-04-24 2004-12-23 Cook Incorporated Artificial valve prosthesis with improved flow dynamics
WO2005034812A1 (en) 2003-10-02 2005-04-21 Edwards Lifesciences Corporation Implantable prosthetic valve with non-laminar flow
DE19857887B4 (en) 1998-12-15 2005-05-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anchoring support for a heart valve prosthesis
EP1088529B1 (en) 1999-09-30 2005-06-01 Sorin Biomedica Cardio S.R.L. A device for cardiac valve replacement or repair operations
US20050137698A1 (en) 2003-12-23 2005-06-23 Amr Salahieh Leaflet engagement elements and methods for use thereof
US20050137688A1 (en) 2003-12-23 2005-06-23 Sadra Medical, A Delaware Corporation Repositionable heart valve and method
US20050203617A1 (en) 2004-02-27 2005-09-15 Cardiacmd, Inc. Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same
DE10049815B4 (en) 2000-10-09 2005-10-13 Universitätsklinikum Freiburg Device for local ablation of an aortic valve on the human or animal heart
US20050234546A1 (en) 2004-02-05 2005-10-20 Alan Nugent Transcatheter delivery of a replacement heart valve
EP1469797B1 (en) 2002-08-13 2005-11-02 Hans-Reiner Figulla Device for the implantation and fixing of heart valve prostheses
WO2005087140A8 (en) 2004-03-11 2005-11-24 Percutaneous Cardiovascular So Percutaneous heart valve prosthesis
US6974476B2 (en) 2003-05-05 2005-12-13 Rex Medical, L.P. Percutaneous aortic valve
US20050288766A1 (en) 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US20060025857A1 (en) 2004-04-23 2006-02-02 Bjarne Bergheim Implantable prosthetic valve
US20060058872A1 (en) 2003-12-23 2006-03-16 Amr Salahieh Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
WO2006034008A2 (en) 2004-09-17 2006-03-30 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US20060142837A1 (en) 2002-02-22 2006-06-29 Haverkost Patrick A Method and apparatus for deployment of an endoluminal device
US20060149350A1 (en) 2003-06-05 2006-07-06 Flowmedica, Inc. Systems and methods for performing bi-lateral interventions or diagnosis in branched body lumens
US20060161249A1 (en) 2004-11-22 2006-07-20 Fidel Realyvasquez Ring-shaped valve prosthesis attachment device
US20060195134A1 (en) 2005-02-28 2006-08-31 Medtronic Vascular, Inc. Device, system, and method for aiding valve annuloplasty
WO2006014233A3 (en) 2004-07-02 2006-09-14 Xtent Inc Apparatus and methods for positioning prostheses for deployment from a catheter
US20060229719A1 (en) 2005-04-06 2006-10-12 Salvador Marquez Highly flexible heart valve connecting band
DE10049814B4 (en) 2000-10-09 2006-10-19 Universitätsklinikum Freiburg Device for supporting surgical procedures within a vessel, in particular for minimally invasive explantation and implantation of heart valves
US20060241745A1 (en) 2005-04-21 2006-10-26 Solem Jan O Blood flow controlling apparatus
US20060259135A1 (en) 2005-04-20 2006-11-16 The Cleveland Clinic Foundation Apparatus and method for replacing a cardiac valve
US20060259137A1 (en) 2003-10-06 2006-11-16 Jason Artof Minimally invasive valve replacement system
US20060276874A1 (en) 2005-05-27 2006-12-07 Heart Leaflet Technologies, Inc. Intravascular cuff
US20070005231A1 (en) 2005-06-29 2007-01-04 Nissan Motor Co., Ltd. Traffic jam detection system and method
US20070005131A1 (en) 2005-06-13 2007-01-04 Taylor David M Heart valve delivery system
US20070010877A1 (en) 2003-12-23 2007-01-11 Amr Salahieh Methods and Apparatus for Endovascularly Replacing a Heart Valve
US20070027534A1 (en) 2005-07-27 2007-02-01 Bjarne Bergheim Methods and systems for cardiac valve delivery
US7201772B2 (en) 2003-07-08 2007-04-10 Ventor Technologies, Ltd. Fluid flow prosthetic device
US20070088431A1 (en) 2005-10-18 2007-04-19 Henry Bourang Heart valve delivery system with valve catheter
US20070100439A1 (en) 2005-10-31 2007-05-03 Medtronic Vascular, Inc. Chordae tendinae restraining ring
US20070112422A1 (en) 2005-11-16 2007-05-17 Mark Dehdashtian Transapical heart valve delivery system and method
US20070142906A1 (en) 2005-11-04 2007-06-21 Jen. Cardiotec Gmbh Self-expandable medical instrument for treating defects in a patient's heart
US20070203575A1 (en) 2006-02-27 2007-08-30 Cardiacmd, Inc., A California Corporation Methods and devices for delivery of prosthetic heart valves and other prosthetics
US20070203503A1 (en) 2003-12-23 2007-08-30 Amr Salahieh Systems and methods for delivering a medical implant
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US7276078B2 (en) 2004-06-30 2007-10-02 Edwards Lifesciences Pvt Paravalvular leak detection, sealing, and prevention
US20070270943A1 (en) 2006-05-18 2007-11-22 Jan Otto Solem Device and method for improving heart valve function
DE102006052564B3 (en) 2006-11-06 2007-12-13 Georg Lutter Mitral valve stent for surgical implantation and fixation of heart valve prosthesis to heart, has stent clips arranged distally, where one of stent clips forms section that is externally rolled in unfolded condition of stent
WO2008005405A2 (en) 2006-06-28 2008-01-10 Lemaitre Vascular, Inc. Non-occluding dilation device
US7318278B2 (en) 2002-09-20 2008-01-15 Edwards Lifesciences Corporation Method of manufacture of a heart valve support frame
US20080065011A1 (en) 2006-09-08 2008-03-13 Philippe Marchand Integrated heart valve delivery system
US20080071362A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Valve prosthesis implantation techniques
US20080082166A1 (en) 2006-09-28 2008-04-03 Mikolaj Styrc Implant which is intended to be placed in a blood vessel
US20080114442A1 (en) 2006-11-14 2008-05-15 Medtronic Vascular, Inc. Delivery System for Stent-Graft With Anchoring Pins
US7374571B2 (en) 2001-03-23 2008-05-20 Edwards Lifesciences Corporation Rolled minimally-invasive heart valves and methods of manufacture
US7381210B2 (en) 2003-03-14 2008-06-03 Edwards Lifesciences Corporation Mitral valve repair system and method for use
US20080154355A1 (en) 2006-12-22 2008-06-26 Netanel Benichou Implantable prosthetic valve assembly and method of making the same
US20080161911A1 (en) 2004-09-07 2008-07-03 Revuelta Jose M Replacement prosthetic heart valve, system and method of implant
US20080208328A1 (en) 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
US20080221672A1 (en) 2007-02-23 2008-09-11 Endovalve, Inc. Mitral Valve System
US7429269B2 (en) 2003-07-08 2008-09-30 Ventor Technologies Ltd. Aortic prosthetic devices
US20080255660A1 (en) 2007-04-13 2008-10-16 Volker Guyenot Medical device for treating a heart valve insufficiency
US20080255661A1 (en) 2007-04-13 2008-10-16 Helmut Straubinger Medical device for treating a heart valve insufficiency or stenosis
US20080281411A1 (en) 2004-03-26 2008-11-13 Eric Berreklouw Assembly Comprising A Ring For Attachment In A Passage Surrounded By Body Tissue As Well As An Applicator For Fitting The Ring In The Passage
US20080288061A1 (en) * 2007-05-14 2008-11-20 Maurer Christopher W Solid Construct Mitral Spacer
WO2008147964A1 (en) 2007-05-25 2008-12-04 Medical Entrepreneurs Ii, Inc. Prosthetic heart valve
US7462191B2 (en) 2004-06-30 2008-12-09 Edwards Lifesciences Pvt, Inc. Device and method for assisting in the implantation of a prosthetic valve
WO2008150529A1 (en) 2007-06-04 2008-12-11 St. Jude Medical, Inc. Prosthetic heart valves
US20090005863A1 (en) 2006-02-16 2009-01-01 Goetz Wolfgang Minimally invasive heart valve replacement
EP1570809B1 (en) 2004-03-03 2009-01-14 Sorin Biomedica Cardio S.R.L. Cardiac-valve prosthesis
US20090048668A1 (en) * 2008-06-13 2009-02-19 Cardiosolutions, Inc. System and Method for Implanting a Heart Implant
US20090054968A1 (en) 2001-08-03 2009-02-26 Jenavalve Technology Inc. Implant implantation unit and procedure for implanting the unit
WO2009024859A2 (en) 2007-08-21 2009-02-26 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US20090076598A1 (en) 2004-06-16 2009-03-19 Amr Salahieh Everting Heart Valve
US20090112309A1 (en) 2005-07-21 2009-04-30 The Florida International University Board Of Trustees Collapsible Heart Valve with Polymer Leaflets
WO2009053952A2 (en) 2007-10-26 2009-04-30 Mednua Limited A medical device for use in treatment of a valve
US7530253B2 (en) 2005-09-09 2009-05-12 Edwards Lifesciences Corporation Prosthetic valve crimping device
US20090138079A1 (en) 2007-10-10 2009-05-28 Vector Technologies Ltd. Prosthetic heart valve for transfemoral delivery
US20090157175A1 (en) 2007-12-14 2009-06-18 Edwards Lifesciences Corporation Leaflet attachment frame for a prosthetic valve
US20090164005A1 (en) 2007-12-21 2009-06-25 Edwards Lifesciences Corporation Capping Bioprosthetic Tissue to Reduce Calcification
US20090171456A1 (en) 2007-12-28 2009-07-02 Kveen Graig L Percutaneous heart valve, system, and method
US7579381B2 (en) 2005-03-25 2009-08-25 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US20090216310A1 (en) 2008-02-26 2009-08-27 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20090216313A1 (en) 2008-02-26 2009-08-27 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis
US20090216322A1 (en) 2007-08-10 2009-08-27 Le Le Adjustable annuloplasty ring and activation system
EP1653888B1 (en) 2003-07-21 2009-09-09 The Trustees of The University of Pennsylvania Percutaneous heart valve
US20090234443A1 (en) 2005-01-20 2009-09-17 Ottma Ruediger Catheter for the Transvascular Implantation of Prosthetic Heart Valves
WO2009116041A2 (en) 2008-03-18 2009-09-24 Ventor Technologies Ltd. Valve suturing and implantation procedures
US20090276040A1 (en) 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
US20090281619A1 (en) 2008-05-09 2009-11-12 Edwards Lifesciences Corporation Low Profile Delivery System for Transcatheter Heart Valve
US20090287299A1 (en) 2008-01-24 2009-11-19 Charles Tabor Stents for prosthetic heart valves
US20090319037A1 (en) 2008-06-20 2009-12-24 Edwards Lifesciences Corporation Retaining mechanisms for prosthetic valves
US20100016958A1 (en) 1999-04-09 2010-01-21 Evalve, Inc. Methods and apparatus for cardiac valve repair
US20100049313A1 (en) 2008-08-22 2010-02-25 Edwards Lifesciences Corporation Prosthetic heart valve and delivery apparatus
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US20100204781A1 (en) 2007-08-24 2010-08-12 Alkhatib Yousef F Prosthetic aortic heart valves
US20100217382A1 (en) 2009-02-25 2010-08-26 Edwards Lifesciences Mitral valve replacement with atrial anchoring
US20100262231A1 (en) 2006-09-19 2010-10-14 Yossi Tuval Sinus-Engaging Valve Fixation Member
US20110015616A1 (en) 2007-04-13 2011-01-20 Helmut Straubinger Handle for manipulating a catheter tip, catheter system and medical insertion system for inserting a self-expandable heart valve stent
US20110015729A1 (en) 2009-07-14 2011-01-20 Edwards Lifesciences Corporation Transapical delivery system for heart valves
WO2011034628A1 (en) 2005-02-07 2011-03-24 Evalve, Inc. Methods, systems and devices for cardiac valve repair
US20110137397A1 (en) 2009-12-04 2011-06-09 Edwards Lifesciences Corporation Prosthetic valve for replacing mitral valve
US7993394B2 (en) 2008-06-06 2011-08-09 Ilia Hariton Low profile transcatheter heart valve
US20110208298A1 (en) 2010-02-24 2011-08-25 Medtronic Ventor Technologies Ltd Mitral Prosthesis and Methods for Implantation
US20110208290A1 (en) 2008-02-26 2011-08-25 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8007992B2 (en) 2006-10-27 2011-08-30 Edwards Lifesciences Corporation Method of treating glutaraldehyde-fixed pericardial tissue with a non-aqueous mixture of glycerol and a C1-C3 alcohol
US8029556B2 (en) 2006-10-04 2011-10-04 Edwards Lifesciences Corporation Method and apparatus for reshaping a ventricle
US20110319989A1 (en) 2010-05-05 2011-12-29 Neovasc, Inc. Transcatheter mitral valve prosthesis
US8092521B2 (en) 2005-10-28 2012-01-10 Jenavalve Technology, Inc. Device for the implantation and fixation of prosthetic valves
US20120035722A1 (en) 2010-02-24 2012-02-09 Medtronic Ventor Technologies, Ltd Mitral Prosthesis and Methods for Implantation
US20120123529A1 (en) 2010-10-05 2012-05-17 Edwards Lifesciences Corporation Prosthetic heart valve
US8317858B2 (en) 2008-02-26 2012-11-27 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8398704B2 (en) 2008-02-26 2013-03-19 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8407380B2 (en) 2008-04-10 2013-03-26 Fujitsu Component Limited Remote operation system
US8416643B2 (en) 2009-03-24 2013-04-09 Texas Instruments Incorporated Receive beamformer for ultrasound having delay value sorting
WO2013059747A1 (en) 2011-10-19 2013-04-25 Foundry Newco Xii, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US8778017B2 (en) * 2005-10-26 2014-07-15 Cardiosolutions, Inc. Safety for mitral valve implant

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008106A (en) 1934-07-30 1935-07-16 Benjamin E Lawrence Food and beverage mixer
DE3530262A1 (en) 1985-08-22 1987-02-26 Siemens Ag CIRCUIT ARRANGEMENT FOR TESTING A PASSIVE BUS NETWORK SYSTEM (CSMA / CD ACCESS METHOD)
US5295058A (en) 1992-10-13 1994-03-15 Recoton Corporation Universal DC to DC power converter
US5609598A (en) 1994-12-30 1997-03-11 Vnus Medical Technologies, Inc. Method and apparatus for minimally invasive treatment of chronic venous insufficiency
WO1999000059A1 (en) 1997-06-27 1999-01-07 The Trustees Of Columbia University In The City Of New York Method and apparatus for circulatory valve repair
FR2768324B1 (en) 1997-09-12 1999-12-10 Jacques Seguin SURGICAL INSTRUMENT FOR PERCUTANEOUSLY FIXING TWO AREAS OF SOFT TISSUE, NORMALLY MUTUALLY REMOTE, TO ONE ANOTHER
US6165183A (en) 1998-07-15 2000-12-26 St. Jude Medical, Inc. Mitral and tricuspid valve repair
US7569062B1 (en) 1998-07-15 2009-08-04 St. Jude Medical, Inc. Mitral and tricuspid valve repair
US6221001B1 (en) 1999-01-26 2001-04-24 Ada Environmental Solutions Llc Fly-ash slurry with solidification retardant
US10327743B2 (en) 1999-04-09 2019-06-25 Evalve, Inc. Device and methods for endoscopic annuloplasty
US7563267B2 (en) 1999-04-09 2009-07-21 Evalve, Inc. Fixation device and methods for engaging tissue
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US7811296B2 (en) 1999-04-09 2010-10-12 Evalve, Inc. Fixation devices for variation in engagement of tissue
US20040044350A1 (en) 1999-04-09 2004-03-04 Evalve, Inc. Steerable access sheath and methods of use
US8216256B2 (en) 1999-04-09 2012-07-10 Evalve, Inc. Detachment mechanism for implantable fixation devices
CO5170459A1 (en) 1999-06-01 2002-06-27 Pfizer Prod Inc TRANSDERMAL THERAPY WITH LON-OL STROGEN AGONISTS-ANTAGONISTS, ADMINISTERED BY TRANSDERMAL MEDIA
US6312447B1 (en) 1999-10-13 2001-11-06 The General Hospital Corporation Devices and methods for percutaneous mitral valve repair
US6626930B1 (en) 1999-10-21 2003-09-30 Edwards Lifesciences Corporation Minimally invasive mitral valve repair method and apparatus
GB9926538D0 (en) 1999-11-09 2000-01-12 Kci Medical Ltd Multi-lumen connector
SE0002878D0 (en) 2000-08-11 2000-08-11 Kimblad Ola Device and method of treatment of atrioventricular regurgitation
US6454709B1 (en) 2000-08-29 2002-09-24 Peter Kleinschmidt Tele-evaluation system, especially for medicine
US6537290B2 (en) 2001-03-05 2003-03-25 Edwards Lifesciences Corporation Sealing access cannula system
US7125421B2 (en) 2001-08-31 2006-10-24 Mitral Interventions, Inc. Method and apparatus for valve repair
US7048754B2 (en) 2002-03-01 2006-05-23 Evalve, Inc. Suture fasteners and methods of use
US7101395B2 (en) 2002-06-12 2006-09-05 Mitral Interventions, Inc. Method and apparatus for tissue connection
US8348963B2 (en) * 2002-07-03 2013-01-08 Hlt, Inc. Leaflet reinforcement for regurgitant valves
US7404824B1 (en) * 2002-11-15 2008-07-29 Advanced Cardiovascular Systems, Inc. Valve aptation assist device
US7025791B2 (en) * 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
US20050038509A1 (en) * 2003-08-14 2005-02-17 Ashe Kassem Ali Valve prosthesis including a prosthetic leaflet
US7824443B2 (en) * 2003-12-23 2010-11-02 Sadra Medical, Inc. Medical implant delivery and deployment tool
US20050159810A1 (en) * 2004-01-15 2005-07-21 Farzan Filsoufi Devices and methods for repairing cardiac valves
EP3628239B1 (en) 2004-05-14 2022-04-27 Evalve, Inc. Locking mechanisms for fixation devices for engaging tissue
US8052592B2 (en) 2005-09-27 2011-11-08 Evalve, Inc. Methods and devices for tissue grasping and assessment
AU2005289474B2 (en) 2004-09-27 2010-12-09 Evalve, Inc. Methods and devices for tissue grasping and assessment
US20110060407A1 (en) * 2005-02-07 2011-03-10 Ted Ketai Methods, systems and devices for cardiac valve repair
US7854762B2 (en) * 2005-05-20 2010-12-21 Mayo Foundation For Medical Education And Research Devices and methods for reducing cardiac valve regurgitation
US8092525B2 (en) * 2005-10-26 2012-01-10 Cardiosolutions, Inc. Heart valve implant
US20070185571A1 (en) * 2006-02-06 2007-08-09 The Cleveland Clinic Foundation Apparatus and method for treating a regurgitant valve
US8652198B2 (en) * 2006-03-20 2014-02-18 J.W. Medical Systems Ltd. Apparatus and methods for deployment of linked prosthetic segments
JP5200412B2 (en) 2007-04-23 2013-06-05 信越半導体株式会社 Manufacturing method of SOI substrate
CA2749026C (en) * 2008-09-29 2018-01-09 Impala, Inc. Heart valve
US8366767B2 (en) 2009-03-30 2013-02-05 Causper Medical Inc. Methods and devices for transapical delivery of a sutureless valve prosthesis
US9011522B2 (en) * 2009-04-10 2015-04-21 Lon Sutherland ANNEST Device and method for temporary or permanent suspension of an implantable scaffolding containing an orifice for placement of a prosthetic or bio-prosthetic valve
US8961596B2 (en) * 2010-01-22 2015-02-24 4Tech Inc. Method and apparatus for tricuspid valve repair using tension
WO2011109813A2 (en) * 2010-03-05 2011-09-09 Edwards Lifesciences Corporation Retaining mechanisms for prosthetic valves
US9119717B2 (en) * 2010-07-15 2015-09-01 St. Jude Medical, Inc. Retainers for transcatheter heart valve delivery systems
EP2595569A4 (en) * 2010-07-23 2016-02-24 Edwards Lifesciences Corp Retaining mechanisms for prosthetic valves
US8845717B2 (en) * 2011-01-28 2014-09-30 Middle Park Medical, Inc. Coaptation enhancement implant, system, and method
US9055937B2 (en) * 2011-04-01 2015-06-16 Edwards Lifesciences Corporation Apical puncture access and closure system
JP6023799B2 (en) 2011-05-23 2016-11-09 カリフォルニア インスティチュート オブ テクノロジー Adjustable intraocular lens
US8956404B2 (en) * 2011-09-12 2015-02-17 Highlife Sas Transcatheter valve prosthesis
US8926690B2 (en) * 2012-08-13 2015-01-06 Medtronic, Inc. Heart valve prosthesis
US20140067048A1 (en) 2012-09-06 2014-03-06 Edwards Lifesciences Corporation Heart Valve Sealing Devices
US10271949B2 (en) * 2013-03-12 2019-04-30 St. Jude Medical, Cardiology Division, Inc. Paravalvular leak occlusion device for self-expanding heart valves
EP2967855B1 (en) * 2013-03-14 2023-04-26 JC Medical, Inc. Sutureless valve prosthesis delivery device
FR3004336A1 (en) * 2013-04-12 2014-10-17 St George Medical Inc MITRAL HEART VALVE PROSTHESIS AND RELIEF CATHETER
CN105451688A (en) * 2013-06-14 2016-03-30 哈祖有限公司 Method and device for treatment of valve regurgitation

Patent Citations (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3409013A (en) 1965-08-23 1968-11-05 Berry Henry Instrument for inserting artificial heart valves
US3587115A (en) 1966-05-04 1971-06-28 Donald P Shiley Prosthetic sutureless heart valves and implant tools therefor
US3472230A (en) 1966-12-19 1969-10-14 Fogarty T J Umbrella catheter
US3548417A (en) 1967-09-05 1970-12-22 Ronnie G Kischer Heart valve having a flexible wall which rotates between open and closed positions
US3671979A (en) 1969-09-23 1972-06-27 Univ Utah Catheter mounted artificial heart valve for implanting in close proximity to a defective natural heart valve
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US3714671A (en) 1970-11-30 1973-02-06 Cutter Lab Tissue-type heart valve with a graft support ring or stent
US3755823A (en) 1971-04-23 1973-09-04 Hancock Laboratories Inc Flexible stent for heart valve
DE2246526C3 (en) 1971-09-24 1981-07-30 Smiths Industries Ltd., London Catheter with an inflatable cuff
US4035849A (en) 1975-11-17 1977-07-19 William W. Angell Heart valve stent and process for preparing a stented heart valve prosthesis
US4106129A (en) 1976-01-09 1978-08-15 American Hospital Supply Corporation Supported bioprosthetic heart valve with compliant orifice ring
US4056854A (en) 1976-09-28 1977-11-08 The United States Of America As Represented By The Department Of Health, Education And Welfare Aortic heart valve catheter
US4297749A (en) 1977-04-25 1981-11-03 Albany International Corp. Heart valve prosthesis
US4222126A (en) 1978-12-14 1980-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health, Education & Welfare Unitized three leaflet heart valve
US4265694A (en) 1978-12-14 1981-05-05 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of making unitized three leaflet heart valve
US4574803A (en) 1979-01-19 1986-03-11 Karl Storz Tissue cutter
GB2056023B (en) 1979-08-06 1983-08-10 Ross D N Bodnar E Stent for a cardiac valve
US4343048A (en) 1979-08-06 1982-08-10 Ross Donald N Stent for a cardiac valve
US4373216A (en) 1980-10-27 1983-02-15 Hemex, Inc. Heart valves having edge-guided occluders
US4339831A (en) 1981-03-27 1982-07-20 Medtronic, Inc. Dynamic annulus heart valve and reconstruction ring
US4470157A (en) 1981-04-27 1984-09-11 Love Jack W Tricuspid prosthetic tissue heart valve
US4345340A (en) 1981-05-07 1982-08-24 Vascor, Inc. Stent for mitral/tricuspid heart valve
US4406022A (en) 1981-11-16 1983-09-27 Kathryn Roy Prosthetic valve means for cardiovascular surgery
US4655771A (en) 1982-04-30 1987-04-07 Shepherd Patents S.A. Prosthesis comprising an expansible or contractile tubular body
US4655771B1 (en) 1982-04-30 1996-09-10 Medinvent Ams Sa Prosthesis comprising an expansible or contractile tubular body
EP0103546B1 (en) 1982-08-09 1988-05-04 Domenico Iorio Surgical instrument for implanting prosthetic heart valves or the like
US4605407A (en) 1983-01-11 1986-08-12 The University Of Sheffield Heart valve replacements
US4535483A (en) 1983-01-17 1985-08-20 Hemex, Inc. Suture rings for heart valves
US4612011A (en) 1983-07-22 1986-09-16 Hans Kautzky Central occluder semi-biological heart valve
US6306141B1 (en) 1983-10-14 2001-10-23 Medtronic, Inc. Medical devices incorporating SIM alloy elements
EP0144167B1 (en) 1983-11-09 1989-11-08 Dow Corning Corporation Hard organopolysiloxane release coating
US4787899A (en) 1983-12-09 1988-11-29 Lazarus Harrison M Intraluminal graft device, system and method
US5026366A (en) 1984-03-01 1991-06-25 Cardiovascular Laser Systems, Inc. Angioplasty catheter and method of use thereof
US4592340A (en) 1984-05-02 1986-06-03 Boyles Paul W Artificial catheter means
US4979939A (en) 1984-05-14 1990-12-25 Surgical Systems & Instruments, Inc. Atherectomy system with a guide wire
US4787901A (en) 1984-07-17 1988-11-29 Doguhan Baykut Two-way acting valve and cardiac valve prosthesis
US4643732A (en) 1984-11-17 1987-02-17 Beiersdorf Aktiengesellschaft Heart valve prosthesis
SU1271508A1 (en) 1984-11-29 1986-11-23 Горьковский государственный медицинский институт им.С.М.Кирова Artificial heart valve
US4759758A (en) 1984-12-07 1988-07-26 Shlomo Gabbay Prosthetic heart valve
US4733665B1 (en) 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4922905A (en) 1985-11-30 1990-05-08 Strecker Ernst P Dilatation catheter
US4692164A (en) 1986-03-06 1987-09-08 Moskovskoe Vysshee Tekhnicheskoe Uchilische, Imeni N.E. Baumana Bioprosthetic heart valve, methods and device for preparation thereof
US4878906A (en) 1986-03-25 1989-11-07 Servetus Partnership Endoprosthesis for repairing a damaged vessel
US4777951A (en) 1986-09-19 1988-10-18 Mansfield Scientific, Inc. Procedure and catheter instrument for treating patients for aortic stenosis
US4762128A (en) 1986-12-09 1988-08-09 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US4883458A (en) 1987-02-24 1989-11-28 Surgical Systems & Instruments, Inc. Atherectomy system and method of using the same
US4878495A (en) 1987-05-15 1989-11-07 Joseph Grayzel Valvuloplasty device with satellite expansion means
US4796629A (en) 1987-06-03 1989-01-10 Joseph Grayzel Stiffened dilation balloon catheter device
US4829990A (en) 1987-06-25 1989-05-16 Thueroff Joachim Implantable hydraulic penile erector
US4851001A (en) 1987-09-17 1989-07-25 Taheri Syde A Prosthetic valve for a blood vein and an associated method of implantation of the valve
US5266073A (en) 1987-12-08 1993-11-30 Wall W Henry Angioplasty stent
US5032128A (en) 1988-07-07 1991-07-16 Medtronic, Inc. Heart valve prosthesis
US5080668A (en) 1988-11-29 1992-01-14 Biotronik Mess- und Therapiegerate GmbH & Co. KG Ingenieurburo Berlin Cardiac valve prosthesis
US5007896A (en) 1988-12-19 1991-04-16 Surgical Systems & Instruments, Inc. Rotary-catheter for atherectomy
US4856516A (en) 1989-01-09 1989-08-15 Cordis Corporation Endovascular stent apparatus and method
US4966604A (en) 1989-01-23 1990-10-30 Interventional Technologies Inc. Expandable atherectomy cutter with flexibly bowed blades
US4994077A (en) 1989-04-21 1991-02-19 Dobben Richard L Artificial heart valve for implantation in a blood vessel
US5609626A (en) 1989-05-31 1997-03-11 Baxter International Inc. Stent devices and support/restrictor assemblies for use in conjunction with prosthetic vascular grafts
US5500014A (en) 1989-05-31 1996-03-19 Baxter International Inc. Biological valvular prothesis
US5047041A (en) 1989-08-22 1991-09-10 Samuels Peter B Surgical apparatus for the excision of vein valves in situ
US4986830A (en) 1989-09-22 1991-01-22 Schneider (U.S.A.) Inc. Valvuloplasty catheter with balloon which remains stable during inflation
US5108370A (en) 1989-10-03 1992-04-28 Paul Walinsky Perfusion balloon catheter
US5089015A (en) 1989-11-28 1992-02-18 Promedica International Method for implanting unstented xenografts and allografts
US5591185A (en) 1989-12-14 1997-01-07 Corneal Contouring Development L.L.C. Method and apparatus for reprofiling or smoothing the anterior or stromal cornea by scraping
US5037434A (en) 1990-04-11 1991-08-06 Carbomedics, Inc. Bioprosthetic heart valve with elastic commissures
US5059177A (en) 1990-04-19 1991-10-22 Cordis Corporation Triple lumen balloon catheter
US6168614B1 (en) 1990-05-18 2001-01-02 Heartport, Inc. Valve prosthesis for implantation in the body
US6582462B1 (en) 1990-05-18 2003-06-24 Heartport, Inc. Valve prosthesis for implantation in the body and a catheter for implanting such valve prosthesis
WO1991017720A1 (en) 1990-05-18 1991-11-28 Henning Rud Andersen A valve prosthesis for implantation in the body and a catheter for implantating such valve prosthesis
US5840081A (en) 1990-05-18 1998-11-24 Andersen; Henning Rud System and method for implanting cardiac valves
EP0592410B1 (en) 1990-05-18 1995-10-11 ANDERSEN, Henning Rud A valve prosthesis for implantation in the body and a catheter for implantating such valve prosthesis
US7618446B2 (en) 1990-05-18 2009-11-17 Edwards Lifesciences Ag Valve prosthesis for implantation in the body and a catheter for implanting such valve prosthesis
US5085635A (en) 1990-05-18 1992-02-04 Cragg Andrew H Valved-tip angiographic catheter
US5411552A (en) 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5152771A (en) 1990-12-31 1992-10-06 The Board Of Supervisors Of Louisiana State University Valve cutter for arterial by-pass surgery
US5282847A (en) 1991-02-28 1994-02-01 Medtronic, Inc. Prosthetic vascular grafts with a pleated structure
US5607464A (en) 1991-02-28 1997-03-04 Medtronic, Inc. Prosthetic vascular graft with a pleated structure
US5360444A (en) 1991-03-19 1994-11-01 Kenji Kusuhara Occluder supporter and a method of attachment thereof
US5443446A (en) 1991-04-04 1995-08-22 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification
WO1992017118A1 (en) 1991-04-04 1992-10-15 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification
US5295958A (en) 1991-04-04 1994-03-22 Shturman Cardiology Systems, Inc. Method and apparatus for in vivo heart valve decalcification
US5167628A (en) 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5397351A (en) 1991-05-13 1995-03-14 Pavcnik; Dusan Prosthetic valve for percutaneous insertion
US5370685A (en) 1991-07-16 1994-12-06 Stanford Surgical Technologies, Inc. Endovascular aortic valve replacement
EP0597967B1 (en) 1991-07-16 1999-12-01 Heartport, Inc. Devices for performing intraluminal procedures
WO1993001768A1 (en) 1991-07-16 1993-02-04 Stevens John H Endovascular aortic valve replacement
US5545214A (en) 1991-07-16 1996-08-13 Heartport, Inc. Endovascular aortic valve replacement
US5769812A (en) 1991-07-16 1998-06-23 Heartport, Inc. System for cardiac procedures
US5232446A (en) 1991-10-30 1993-08-03 Scimed Life Systems, Inc. Multi-sinus perfusion balloon dilatation catheter
US5192297A (en) 1991-12-31 1993-03-09 Medtronic, Inc. Apparatus and method for placement and implantation of a stent
US5756476A (en) 1992-01-14 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell proliferation using antisense oligonucleotides
US5163953A (en) 1992-02-10 1992-11-17 Vince Dennis J Toroidal artificial heart valve stent
US5665115A (en) 1992-02-21 1997-09-09 Boston Scientific Technology, Inc. Intraluminal stent
US5332402A (en) 1992-05-12 1994-07-26 Teitelbaum George P Percutaneously-inserted cardiac valve
US5411055A (en) 1992-11-24 1995-05-02 Mannesmann Aktiengesellschaft Flow limiting throttle element
US5549665A (en) 1993-06-18 1996-08-27 London Health Association Bioprostethic valve
US20030158597A1 (en) 1993-08-05 2003-08-21 Quiachon Dinah B. Multicapsule intraluminal grafting system and method
US5411522A (en) 1993-08-25 1995-05-02 Linvatec Corporation Unitary anchor for soft tissue fixation
US5545209A (en) 1993-09-30 1996-08-13 Texas Petrodet, Inc. Controlled deployment of a medical device
US5480424A (en) 1993-11-01 1996-01-02 Cox; James L. Heart valve replacement using flexible tubes
US6245040B1 (en) 1994-01-14 2001-06-12 Cordis Corporation Perfusion balloon brace and method of use
US6302906B1 (en) 1994-02-09 2001-10-16 Boston Scientific Technology, Inc. System for delivering a prosthesis
US5800508A (en) 1994-02-09 1998-09-01 Boston Scientific Technology, Inc. Bifurcated endoluminal prosthesis
US5728068A (en) 1994-06-14 1998-03-17 Cordis Corporation Multi-purpose balloon catheter
US5554185A (en) 1994-07-18 1996-09-10 Block; Peter C. Inflatable prosthetic cardiovascular valve for percutaneous transluminal implantation of same
US5599305A (en) 1994-10-24 1997-02-04 Cardiovascular Concepts, Inc. Large-diameter introducer sheath having hemostasis valve and removable steering mechanism
US5639274A (en) 1995-06-02 1997-06-17 Fischell; Robert E. Integrated catheter system for balloon angioplasty and stent delivery
US5571175A (en) 1995-06-07 1996-11-05 St. Jude Medical, Inc. Suture guard for prosthetic heart valve
US5716417A (en) 1995-06-07 1998-02-10 St. Jude Medical, Inc. Integral supporting structure for bioprosthetic heart valve
DE19532846A1 (en) 1995-09-06 1997-03-13 Georg Dr Berg Valve for use in heart
DE19546692C2 (en) 1995-12-14 2002-11-07 Hans-Reiner Figulla Self-expanding heart valve prosthesis for implantation in the human body via a catheter system
WO1997024080A1 (en) 1995-12-28 1997-07-10 Cogent Kit for surgical treatment of intracorporal lumens
US6042607A (en) 1996-02-23 2000-03-28 Cardiovascular Technologies Llc Means and method of replacing a heart valve in a minimally invasive manner
US6027525A (en) 1996-05-23 2000-02-22 Samsung Electronics., Ltd. Flexible self-expandable stent and method for making the same
US5855601A (en) 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
US6217585B1 (en) 1996-08-16 2001-04-17 Converge Medical, Inc. Mechanical stent and graft delivery system
US20040133263A1 (en) 1996-08-23 2004-07-08 Scimed Life Systems, Inc. Stent delivery system having stent securement apparatus
US5855602A (en) 1996-09-09 1999-01-05 Shelhigh, Inc. Heart valve prosthesis
US5968068A (en) 1996-09-12 1999-10-19 Baxter International Inc. Endovascular delivery system
US6379372B1 (en) 1996-09-12 2002-04-30 Edwards Lifesciences Corp. Endovascular delivery system
US5749890A (en) 1996-12-03 1998-05-12 Shaknovich; Alexander Method and system for stent placement in ostial lesions
US6605112B1 (en) 1996-12-18 2003-08-12 Venpro Corporation Device for regulating the flow of blood through the blood system
US6908481B2 (en) 1996-12-31 2005-06-21 Edwards Lifesciences Pvt, Inc. Value prosthesis for implantation in body channels
EP0850607A1 (en) 1996-12-31 1998-07-01 Cordis Corporation Valve prosthesis for implantation in body channels
US7585321B2 (en) 1996-12-31 2009-09-08 Edwards Lifesciences Pvt, Inc. Methods of implanting a prosthetic heart valve within a native heart valve
WO1998029057A1 (en) 1996-12-31 1998-07-09 Cordis Corporation Valve prosthesis for implantation in body channels
US6171335B1 (en) 1997-01-24 2001-01-09 Aortech Europe Limited Heart valve prosthesis
US5957949A (en) 1997-05-01 1999-09-28 World Medical Manufacturing Corp. Percutaneous placement valve stent
US6132473A (en) 1997-05-02 2000-10-17 St. Jude Medical, Inc. Differential treatment of prosthetic devices
US6245102B1 (en) 1997-05-07 2001-06-12 Iowa-India Investments Company Ltd. Stent, stent graft and stent valve
US5855597A (en) 1997-05-07 1999-01-05 Iowa-India Investments Co. Limited Stent valve and stent graft for percutaneous surgery
US5906619A (en) 1997-07-24 1999-05-25 Medtronic, Inc. Disposable delivery device for endoluminal prostheses
US6221091B1 (en) 1997-09-26 2001-04-24 Incept Llc Coiled sheet valve, filter or occlusive device and methods of use
US5925063A (en) 1997-09-26 1999-07-20 Khosravi; Farhad Coiled sheet valve, filter or occlusive device and methods of use
WO1999033414A1 (en) 1997-12-29 1999-07-08 Ivan Vesely System for minimally invasive insertion of a bioprosthetic heart valve
US6569196B1 (en) 1997-12-29 2003-05-27 The Cleveland Clinic Foundation System for minimally invasive insertion of a bioprosthetic heart valve
WO1999040964A1 (en) 1998-02-16 1999-08-19 Medicorp S.A. Angioplasty and stent delivery catheter
US6174327B1 (en) 1998-02-27 2001-01-16 Scimed Life Systems, Inc. Stent deployment apparatus and method
WO1999047075A1 (en) 1998-03-17 1999-09-23 Medicorp S.A. Reversible-action endoprosthesis delivery device
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8216174B2 (en) 1998-09-10 2012-07-10 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US7736327B2 (en) 1998-09-10 2010-06-15 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
WO2000018333A1 (en) 1998-09-28 2000-04-06 Autogenics Heart valve having tissue retention with anchors and an outer sheath
DE19857887B4 (en) 1998-12-15 2005-05-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anchoring support for a heart valve prosthesis
FR2788217A1 (en) 1999-01-12 2000-07-13 Brice Letac PROSTHETIC VALVE IMPLANTABLE BY CATHETERISM, OR SURGICAL
WO2000041652A1 (en) 1999-01-12 2000-07-20 Brice Letac Prosthetic heart valve implantable by catheter insertion or surgically
US6350277B1 (en) 1999-01-15 2002-02-26 Scimed Life Systems, Inc. Stents with temporary retaining bands
US6425916B1 (en) 1999-02-10 2002-07-30 Michi E. Garrison Methods and devices for implanting cardiac valves
WO2000047139A9 (en) 1999-02-10 2001-09-13 Heartport Inc Methods and devices for implanting cardiac valves
DE19907646A1 (en) 1999-02-23 2000-08-24 Georg Berg Valve for blood vessels uses flap holders and counterpart holders on stent to latch together in place and all channeled for guide wire.
US6210408B1 (en) 1999-02-24 2001-04-03 Scimed Life Systems, Inc. Guide wire system for RF recanalization of vascular blockages
US20100016958A1 (en) 1999-04-09 2010-01-21 Evalve, Inc. Methods and apparatus for cardiac valve repair
US6231602B1 (en) 1999-04-16 2001-05-15 Edwards Lifesciences Corporation Aortic annuloplasty ring
US6790229B1 (en) 1999-05-25 2004-09-14 Eric Berreklouw Fixing device, in particular for fixing to vascular wall tissue
US7524330B2 (en) 1999-05-25 2009-04-28 Eric Berreklouw Fixing device, in particular for fixing to vascular wall tissue
US6287339B1 (en) 1999-05-27 2001-09-11 Sulzer Carbomedics Inc. Sutureless heart valve prosthesis
EP1057460A1 (en) 1999-06-01 2000-12-06 Numed, Inc. Replacement valve assembly and method of implanting same
US6312465B1 (en) 1999-07-23 2001-11-06 Sulzer Carbomedics Inc. Heart valve prosthesis with a resiliently deformable retaining member
US6299637B1 (en) 1999-08-20 2001-10-09 Samuel M. Shaolian Transluminally implantable venous valve
US6527979B2 (en) 1999-08-27 2003-03-04 Corazon Technologies, Inc. Catheter systems and methods for their use in the treatment of calcified vascular occlusions
EP1088529B1 (en) 1999-09-30 2005-06-01 Sorin Biomedica Cardio S.R.L. A device for cardiac valve replacement or repair operations
WO2001028459A1 (en) 1999-10-21 2001-04-26 Scimed Life Systems, Inc. Implantable prosthetic valve
US6440164B1 (en) 1999-10-21 2002-08-27 Scimed Life Systems, Inc. Implantable prosthetic valve
US7892281B2 (en) 1999-11-17 2011-02-22 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
US6830584B1 (en) 1999-11-17 2004-12-14 Jacques Seguin Device for replacing a cardiac valve by percutaneous route
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
WO2001035878A3 (en) 1999-11-18 2002-03-28 Thermamed Gmbh Medical warming device
WO2001049213A3 (en) 1999-12-31 2002-01-24 Advanced Bio Prosthetic Surfac Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US6458153B1 (en) 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US20080125853A1 (en) 1999-12-31 2008-05-29 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US20010021872A1 (en) 1999-12-31 2001-09-13 Bailey Steven R. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
WO2001054624A1 (en) 2000-01-27 2001-08-02 3F Therapeutics, Inc. Prosthetic heart valve
WO2001054625A1 (en) 2000-01-31 2001-08-02 Cook Biotech Incorporated Stent valves and uses of same
DE10010074B4 (en) 2000-02-28 2005-04-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Device for fastening and anchoring heart valve prostheses
WO2001064137A1 (en) 2000-02-28 2001-09-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anchoring system for implantable heart valve prostheses
WO2001062189A1 (en) 2000-02-28 2001-08-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Device for fastening and anchoring cardiac valve prostheses
US7198646B2 (en) 2000-02-28 2007-04-03 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Device for fastening and anchoring cardiac valve prostheses
WO2001076510A8 (en) 2000-04-06 2002-01-03 Edwards Lifesciences Corp Minimally-invasive heart valves and methods of use
US20040186565A1 (en) 2000-04-06 2004-09-23 Stefan Schreck Minimally-invasive heart valves with wireforms
US6454799B1 (en) 2000-04-06 2002-09-24 Edwards Lifesciences Corporation Minimally-invasive heart valves and methods of use
US20020032481A1 (en) 2000-09-12 2002-03-14 Shlomo Gabbay Heart valve prosthesis and sutureless implantation of a heart valve prosthesis
WO2002022054A1 (en) 2000-09-12 2002-03-21 Gabbay S Valvular prosthesis and method of using same
US6461382B1 (en) 2000-09-22 2002-10-08 Edwards Lifesciences Corporation Flexible heart valve having moveable commissures
DE10049812B4 (en) 2000-10-09 2004-06-03 Universitätsklinikum Freiburg Device for filtering out macroscopic particles from the bloodstream during local removal of an aortic valve on the human or animal heart
DE10049813C1 (en) 2000-10-09 2002-04-18 Universitaetsklinikum Freiburg Instrument for the local removal of built-up matter at an aortic valve, in a human or animal heart, is a hollow catheter with a cutting unit at the far end within a closure cap for minimum invasion
DE10049815B4 (en) 2000-10-09 2005-10-13 Universitätsklinikum Freiburg Device for local ablation of an aortic valve on the human or animal heart
DE10049814B4 (en) 2000-10-09 2006-10-19 Universitätsklinikum Freiburg Device for supporting surgical procedures within a vessel, in particular for minimally invasive explantation and implantation of heart valves
WO2002036048A1 (en) 2000-10-31 2002-05-10 Jacques Seguin Tubular support for setting, by percutaneous route, a substitution cusp
FR2815844B1 (en) 2000-10-31 2003-01-17 Jacques Seguin TUBULAR SUPPORT FOR THE PERCUTANEOUS POSITIONING OF A REPLACEMENT HEART VALVE
US6482228B1 (en) 2000-11-14 2002-11-19 Troy R. Norred Percutaneous aortic valve replacement
WO2002041789A3 (en) 2000-11-21 2002-08-22 Rex Medical Lp Percutaneous aortic valve
WO2002043620A9 (en) 2000-12-01 2003-04-17 Prodesco Endovascular valve
WO2002047575A3 (en) 2000-12-15 2002-12-12 Angiomed Ag Stent with valve
WO2002049540A3 (en) 2000-12-21 2003-02-06 Cleveland Clinic Foundation Bioprosthetic cardiovascular valve system
US6468660B2 (en) 2000-12-29 2002-10-22 St. Jude Medical, Inc. Biocompatible adhesives
US6733525B2 (en) 2001-03-23 2004-05-11 Edwards Lifesciences Corporation Rolled minimally-invasive heart valves and methods of use
US7276084B2 (en) 2001-03-23 2007-10-02 Edwards Lifesciences Corporation Rolled minimally invasive heart valves
US7374571B2 (en) 2001-03-23 2008-05-20 Edwards Lifesciences Corporation Rolled minimally-invasive heart valves and methods of manufacture
US6488704B1 (en) 2001-05-07 2002-12-03 Biomed Solutions, Llc Implantable particle measuring apparatus
US20020173842A1 (en) 2001-05-17 2002-11-21 Buchanan Eric S. Prosthetic heart valve with slit stent
US20120283823A1 (en) 2001-08-03 2012-11-08 Jenavalve Technology Inc. Methods of implanting an implantation device
US20090054968A1 (en) 2001-08-03 2009-02-26 Jenavalve Technology Inc. Implant implantation unit and procedure for implanting the unit
US20120209374A1 (en) 2001-08-03 2012-08-16 JevaValve Technology Inc. Methods of treating valves
US20090062908A1 (en) 2001-08-03 2009-03-05 Jenavalve Technology Inc. Implant implantation unit and procedure for implanting the unit
US8206437B2 (en) 2001-08-03 2012-06-26 Philipp Bonhoeffer Implant implantation unit and procedure for implanting the unit
US20030050694A1 (en) 2001-09-13 2003-03-13 Jibin Yang Methods and apparatuses for deploying minimally-invasive heart valves
US6730118B2 (en) 2001-10-11 2004-05-04 Percutaneous Valve Technologies, Inc. Implantable prosthetic valve
US7393360B2 (en) 2001-10-11 2008-07-01 Edwards Lifesciences Pvt, Inc. Implantable prosthetic valve
US20040039436A1 (en) 2001-10-11 2004-02-26 Benjamin Spenser Implantable prosthetic valve
US6893460B2 (en) 2001-10-11 2005-05-17 Percutaneous Valve Technologies Inc. Implantable prosthetic valve
WO2003047468A1 (en) 2001-10-11 2003-06-12 Percutaneous Valve Technologies Implantable prosthetic valve
US7510575B2 (en) 2001-10-11 2009-03-31 Edwards Lifesciences Corporation Implantable prosthetic valve
US20090054974A1 (en) 2001-11-14 2009-02-26 Rex Medical Percutaneous aortic valve
US20030100939A1 (en) 2001-11-23 2003-05-29 Mindguard Ltd. Expandable delivery appliance particularly for delivering intravascular devices
US20030130731A1 (en) 2002-01-09 2003-07-10 Myocor, Inc. Devices and methods for heart valve treatment
US20060142837A1 (en) 2002-02-22 2006-06-29 Haverkost Patrick A Method and apparatus for deployment of an endoluminal device
US20030212454A1 (en) 2002-05-08 2003-11-13 Scott Michael J. Compressed tissue for heart valve leaflets
EP1469797B1 (en) 2002-08-13 2005-11-02 Hans-Reiner Figulla Device for the implantation and fixing of heart valve prostheses
US20040092858A1 (en) 2002-08-28 2004-05-13 Heart Leaflet Technologies, Inc. Leaflet valve
US7318278B2 (en) 2002-09-20 2008-01-15 Edwards Lifesciences Corporation Method of manufacture of a heart valve support frame
US7381210B2 (en) 2003-03-14 2008-06-03 Edwards Lifesciences Corporation Mitral valve repair system and method for use
US20040186563A1 (en) 2003-03-18 2004-09-23 Lobbi Mario M. Minimally-invasive heart valve with cusp positioners
US20040260389A1 (en) 2003-04-24 2004-12-23 Cook Incorporated Artificial valve prosthesis with improved flow dynamics
US6974476B2 (en) 2003-05-05 2005-12-13 Rex Medical, L.P. Percutaneous aortic valve
US20060149350A1 (en) 2003-06-05 2006-07-06 Flowmedica, Inc. Systems and methods for performing bi-lateral interventions or diagnosis in branched body lumens
US7442204B2 (en) 2003-07-08 2008-10-28 Ventor Technologies, Ltd. Fluid flow prosthetic device
US7201772B2 (en) 2003-07-08 2007-04-10 Ventor Technologies, Ltd. Fluid flow prosthetic device
US7429269B2 (en) 2003-07-08 2008-09-30 Ventor Technologies Ltd. Aortic prosthetic devices
EP1653888B1 (en) 2003-07-21 2009-09-09 The Trustees of The University of Pennsylvania Percutaneous heart valve
US7621948B2 (en) 2003-07-21 2009-11-24 The Trustees Of The University Of Pennsylvania Percutaneous heart valve
US8118866B2 (en) 2003-07-21 2012-02-21 The Trustees Of The University Of Pennsylvania Method for heart valve implantation
WO2005034812A1 (en) 2003-10-02 2005-04-21 Edwards Lifesciences Corporation Implantable prosthetic valve with non-laminar flow
US20060259137A1 (en) 2003-10-06 2006-11-16 Jason Artof Minimally invasive valve replacement system
US20060058872A1 (en) 2003-12-23 2006-03-16 Amr Salahieh Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements
US20070010877A1 (en) 2003-12-23 2007-01-11 Amr Salahieh Methods and Apparatus for Endovascularly Replacing a Heart Valve
US20050137688A1 (en) 2003-12-23 2005-06-23 Sadra Medical, A Delaware Corporation Repositionable heart valve and method
US20070203503A1 (en) 2003-12-23 2007-08-30 Amr Salahieh Systems and methods for delivering a medical implant
US20050137698A1 (en) 2003-12-23 2005-06-23 Amr Salahieh Leaflet engagement elements and methods for use thereof
US20050234546A1 (en) 2004-02-05 2005-10-20 Alan Nugent Transcatheter delivery of a replacement heart valve
US20050203617A1 (en) 2004-02-27 2005-09-15 Cardiacmd, Inc. Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same
US20050203614A1 (en) 2004-02-27 2005-09-15 Cardiacmd, Inc. Prosthetic heart valves, scaffolding structures, and systems and methods for implantation of same
EP1570809B1 (en) 2004-03-03 2009-01-14 Sorin Biomedica Cardio S.R.L. Cardiac-valve prosthesis
WO2005087140A8 (en) 2004-03-11 2005-11-24 Percutaneous Cardiovascular So Percutaneous heart valve prosthesis
US20080281411A1 (en) 2004-03-26 2008-11-13 Eric Berreklouw Assembly Comprising A Ring For Attachment In A Passage Surrounded By Body Tissue As Well As An Applicator For Fitting The Ring In The Passage
WO2005102015A3 (en) 2004-04-23 2007-04-19 3F Therapeutics Inc Implantable prosthetic valve
US20060025857A1 (en) 2004-04-23 2006-02-02 Bjarne Bergheim Implantable prosthetic valve
US20090076598A1 (en) 2004-06-16 2009-03-19 Amr Salahieh Everting Heart Valve
US20050288766A1 (en) 2004-06-28 2005-12-29 Xtent, Inc. Devices and methods for controlling expandable prostheses during deployment
US7276078B2 (en) 2004-06-30 2007-10-02 Edwards Lifesciences Pvt Paravalvular leak detection, sealing, and prevention
US7462191B2 (en) 2004-06-30 2008-12-09 Edwards Lifesciences Pvt, Inc. Device and method for assisting in the implantation of a prosthetic valve
WO2006014233A3 (en) 2004-07-02 2006-09-14 Xtent Inc Apparatus and methods for positioning prostheses for deployment from a catheter
US20080161911A1 (en) 2004-09-07 2008-07-03 Revuelta Jose M Replacement prosthetic heart valve, system and method of implant
WO2006034008A2 (en) 2004-09-17 2006-03-30 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US20060161249A1 (en) 2004-11-22 2006-07-20 Fidel Realyvasquez Ring-shaped valve prosthesis attachment device
US20090234443A1 (en) 2005-01-20 2009-09-17 Ottma Ruediger Catheter for the Transvascular Implantation of Prosthetic Heart Valves
WO2011034628A1 (en) 2005-02-07 2011-03-24 Evalve, Inc. Methods, systems and devices for cardiac valve repair
US20060195134A1 (en) 2005-02-28 2006-08-31 Medtronic Vascular, Inc. Device, system, and method for aiding valve annuloplasty
US7579381B2 (en) 2005-03-25 2009-08-25 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US20060229719A1 (en) 2005-04-06 2006-10-12 Salvador Marquez Highly flexible heart valve connecting band
WO2006108090A3 (en) 2005-04-06 2007-03-08 Edwards Lifesciences Corp Connecting band and stress absorbing frame for highly flexible heart valve
US20060259135A1 (en) 2005-04-20 2006-11-16 The Cleveland Clinic Foundation Apparatus and method for replacing a cardiac valve
WO2006111391A1 (en) 2005-04-21 2006-10-26 Edwards Lifesciences Ag A blood flow controlling apparatus
US20060241745A1 (en) 2005-04-21 2006-10-26 Solem Jan O Blood flow controlling apparatus
US20060276874A1 (en) 2005-05-27 2006-12-07 Heart Leaflet Technologies, Inc. Intravascular cuff
WO2006138173A3 (en) 2005-06-13 2007-03-08 Edwards Lifesciences Corp Heart valve delivery system
US20070005131A1 (en) 2005-06-13 2007-01-04 Taylor David M Heart valve delivery system
US20070005231A1 (en) 2005-06-29 2007-01-04 Nissan Motor Co., Ltd. Traffic jam detection system and method
US20090112309A1 (en) 2005-07-21 2009-04-30 The Florida International University Board Of Trustees Collapsible Heart Valve with Polymer Leaflets
US20070027534A1 (en) 2005-07-27 2007-02-01 Bjarne Bergheim Methods and systems for cardiac valve delivery
US7530253B2 (en) 2005-09-09 2009-05-12 Edwards Lifesciences Corporation Prosthetic valve crimping device
US8167932B2 (en) 2005-10-18 2012-05-01 Edwards Lifesciences Corporation Heart valve delivery system with valve catheter
US20070088431A1 (en) 2005-10-18 2007-04-19 Henry Bourang Heart valve delivery system with valve catheter
US8778017B2 (en) * 2005-10-26 2014-07-15 Cardiosolutions, Inc. Safety for mitral valve implant
US8092521B2 (en) 2005-10-28 2012-01-10 Jenavalve Technology, Inc. Device for the implantation and fixation of prosthetic valves
US20120310336A1 (en) 2005-10-28 2012-12-06 Hans-Reiner Figulla Device For The Implantation And Fixation Of Prosthetic Valves
US20070100439A1 (en) 2005-10-31 2007-05-03 Medtronic Vascular, Inc. Chordae tendinae restraining ring
US20090222076A1 (en) 2005-11-04 2009-09-03 Jen. Cardiotec Gmbh Self-Expandable Medical Instrument for Treating of Defects in a Patient's Heart
US20070142906A1 (en) 2005-11-04 2007-06-21 Jen. Cardiotec Gmbh Self-expandable medical instrument for treating defects in a patient's heart
US20070112422A1 (en) 2005-11-16 2007-05-17 Mark Dehdashtian Transapical heart valve delivery system and method
US20090171447A1 (en) 2005-12-22 2009-07-02 Von Segesser Ludwig K Stent-valves for valve replacement and associated methods and systems for surgery
US20120197386A1 (en) 2005-12-22 2012-08-02 Symetis Sa Stent-Valves for Valve Replacement and Associated Methods and Systems for Surgery
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US20090171432A1 (en) 2005-12-22 2009-07-02 Von Segesser Ludwig K Stent-valves for valve replacement and associated methods and systems for surgery
US20090005863A1 (en) 2006-02-16 2009-01-01 Goetz Wolfgang Minimally invasive heart valve replacement
US20070203575A1 (en) 2006-02-27 2007-08-30 Cardiacmd, Inc., A California Corporation Methods and devices for delivery of prosthetic heart valves and other prosthetics
US20070270943A1 (en) 2006-05-18 2007-11-22 Jan Otto Solem Device and method for improving heart valve function
WO2008005405A2 (en) 2006-06-28 2008-01-10 Lemaitre Vascular, Inc. Non-occluding dilation device
US20080065011A1 (en) 2006-09-08 2008-03-13 Philippe Marchand Integrated heart valve delivery system
US20110288634A1 (en) 2006-09-19 2011-11-24 Medtronic Vascular, Inc. Valve Prosthetic Fixation Techniques Using Sandwiching
US20100137979A1 (en) 2006-09-19 2010-06-03 Yosi Tuval Sinus-engaging Valve Fixation Member
US20080071361A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Leaflet-sensitive valve fixation member
US20120185039A1 (en) 2006-09-19 2012-07-19 Medtronic Ventor Technologies Ltd. Methods of treating a native aortic valve insufficiency
US20120046741A1 (en) 2006-09-19 2012-02-23 Medtronic Ventor Technologies Ltd. Valve Prosthesis Fixation Techniques Using Sandwiching
US20100262231A1 (en) 2006-09-19 2010-10-14 Yossi Tuval Sinus-Engaging Valve Fixation Member
US20120046742A1 (en) 2006-09-19 2012-02-23 Medtronic Ventor Technologies Ltd. Valve Prosthesis Fixation Techniques Using Sandwiching
US20120101570A1 (en) 2006-09-19 2012-04-26 Medtronic Ventor Technologies Ltd. Methods for Implanting a Valve Prothesis
WO2008035337A3 (en) 2006-09-19 2009-04-23 Ventor Technologies Ltd Fixation member for valve
US20080071362A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Valve prosthesis implantation techniques
US20080071363A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Valve prosthesis fixation techniques using sandwiching
US20080071369A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Valve fixation member having engagement arms
US20100131054A1 (en) 2006-09-19 2010-05-27 Yosi Tuval Sinus-engaging Valve Fixation Member
US20080071368A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Sinus-engaging valve fixation member
US20080071366A1 (en) 2006-09-19 2008-03-20 Yosi Tuval Axial-force fixation member for valve
US20080082166A1 (en) 2006-09-28 2008-04-03 Mikolaj Styrc Implant which is intended to be placed in a blood vessel
US8029556B2 (en) 2006-10-04 2011-10-04 Edwards Lifesciences Corporation Method and apparatus for reshaping a ventricle
US8007992B2 (en) 2006-10-27 2011-08-30 Edwards Lifesciences Corporation Method of treating glutaraldehyde-fixed pericardial tissue with a non-aqueous mixture of glycerol and a C1-C3 alcohol
DE102006052564B3 (en) 2006-11-06 2007-12-13 Georg Lutter Mitral valve stent for surgical implantation and fixation of heart valve prosthesis to heart, has stent clips arranged distally, where one of stent clips forms section that is externally rolled in unfolded condition of stent
US20080114442A1 (en) 2006-11-14 2008-05-15 Medtronic Vascular, Inc. Delivery System for Stent-Graft With Anchoring Pins
US20080154355A1 (en) 2006-12-22 2008-06-26 Netanel Benichou Implantable prosthetic valve assembly and method of making the same
US20080208328A1 (en) 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
US20080208332A1 (en) 2007-02-23 2008-08-28 Endovalve, Inc. Valve Prosthesis Systems and Methods
US20080221672A1 (en) 2007-02-23 2008-09-11 Endovalve, Inc. Mitral Valve System
US20080255660A1 (en) 2007-04-13 2008-10-16 Volker Guyenot Medical device for treating a heart valve insufficiency
US20080255661A1 (en) 2007-04-13 2008-10-16 Helmut Straubinger Medical device for treating a heart valve insufficiency or stenosis
US20100174362A1 (en) 2007-04-13 2010-07-08 Helmut Straubinger Medical Device for Treating A Heart Valve Insufficiency or Stenosis
US7914575B2 (en) 2007-04-13 2011-03-29 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US20110238159A1 (en) 2007-04-13 2011-09-29 Volker Guyenot Medical device for treating a heart valve insufficiency
US20110015616A1 (en) 2007-04-13 2011-01-20 Helmut Straubinger Handle for manipulating a catheter tip, catheter system and medical insertion system for inserting a self-expandable heart valve stent
US20080288061A1 (en) * 2007-05-14 2008-11-20 Maurer Christopher W Solid Construct Mitral Spacer
WO2008147964A1 (en) 2007-05-25 2008-12-04 Medical Entrepreneurs Ii, Inc. Prosthetic heart valve
WO2008150529A1 (en) 2007-06-04 2008-12-11 St. Jude Medical, Inc. Prosthetic heart valves
US20090216322A1 (en) 2007-08-10 2009-08-27 Le Le Adjustable annuloplasty ring and activation system
WO2009024859A2 (en) 2007-08-21 2009-02-26 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US20100204781A1 (en) 2007-08-24 2010-08-12 Alkhatib Yousef F Prosthetic aortic heart valves
US20090138079A1 (en) 2007-10-10 2009-05-28 Vector Technologies Ltd. Prosthetic heart valve for transfemoral delivery
WO2009053952A2 (en) 2007-10-26 2009-04-30 Mednua Limited A medical device for use in treatment of a valve
US20090157175A1 (en) 2007-12-14 2009-06-18 Edwards Lifesciences Corporation Leaflet attachment frame for a prosthetic valve
US20090164005A1 (en) 2007-12-21 2009-06-25 Edwards Lifesciences Corporation Capping Bioprosthetic Tissue to Reduce Calcification
US20090171456A1 (en) 2007-12-28 2009-07-02 Kveen Graig L Percutaneous heart valve, system, and method
US20090287299A1 (en) 2008-01-24 2009-11-19 Charles Tabor Stents for prosthetic heart valves
US20090216310A1 (en) 2008-02-26 2009-08-27 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20110208290A1 (en) 2008-02-26 2011-08-25 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20130079869A1 (en) 2008-02-26 2013-03-28 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20090216313A1 (en) 2008-02-26 2009-08-27 Helmut Straubinger Stent for the positioning and anchoring of a valvular prosthesis
US8317858B2 (en) 2008-02-26 2012-11-27 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US8398704B2 (en) 2008-02-26 2013-03-19 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US20130073035A1 (en) 2008-03-18 2013-03-21 Medtronic Ventor Technologies, Ltd. Valve Suturing and Implantation Procedures
WO2009116041A2 (en) 2008-03-18 2009-09-24 Ventor Technologies Ltd. Valve suturing and implantation procedures
US20090240320A1 (en) 2008-03-18 2009-09-24 Yosi Tuval Valve suturing and implantation procedures
US8407380B2 (en) 2008-04-10 2013-03-26 Fujitsu Component Limited Remote operation system
US20090276040A1 (en) 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
US20090281619A1 (en) 2008-05-09 2009-11-12 Edwards Lifesciences Corporation Low Profile Delivery System for Transcatheter Heart Valve
US7993394B2 (en) 2008-06-06 2011-08-09 Ilia Hariton Low profile transcatheter heart valve
US20090048668A1 (en) * 2008-06-13 2009-02-19 Cardiosolutions, Inc. System and Method for Implanting a Heart Implant
US20090319037A1 (en) 2008-06-20 2009-12-24 Edwards Lifesciences Corporation Retaining mechanisms for prosthetic valves
US20100049313A1 (en) 2008-08-22 2010-02-25 Edwards Lifesciences Corporation Prosthetic heart valve and delivery apparatus
US20100217382A1 (en) 2009-02-25 2010-08-26 Edwards Lifesciences Mitral valve replacement with atrial anchoring
US8416643B2 (en) 2009-03-24 2013-04-09 Texas Instruments Incorporated Receive beamformer for ultrasound having delay value sorting
US20110015729A1 (en) 2009-07-14 2011-01-20 Edwards Lifesciences Corporation Transapical delivery system for heart valves
US20110137397A1 (en) 2009-12-04 2011-06-09 Edwards Lifesciences Corporation Prosthetic valve for replacing mitral valve
US8449599B2 (en) 2009-12-04 2013-05-28 Edwards Lifesciences Corporation Prosthetic valve for replacing mitral valve
US20110208297A1 (en) 2010-02-24 2011-08-25 Medtronic Ventor Technologies Ltd. Mitral Prosthesis and Methods for Implantation
US20120035722A1 (en) 2010-02-24 2012-02-09 Medtronic Ventor Technologies, Ltd Mitral Prosthesis and Methods for Implantation
US20110208298A1 (en) 2010-02-24 2011-08-25 Medtronic Ventor Technologies Ltd Mitral Prosthesis and Methods for Implantation
US20110319989A1 (en) 2010-05-05 2011-12-29 Neovasc, Inc. Transcatheter mitral valve prosthesis
US20120123529A1 (en) 2010-10-05 2012-05-17 Edwards Lifesciences Corporation Prosthetic heart valve
WO2013059747A1 (en) 2011-10-19 2013-04-25 Foundry Newco Xii, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
Al Zaibag, Muayed, et al., "Percutaneous Balloon Valvotomy in Tricuspid Stenosis," British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53.
Al-Khaja, N., et al., "Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications," European Journal of Cardiothoracic Surgery 3:305-311, Jun. 30, 2009.
Almagor, M.D., Yaron, et al., "Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits," Journal of the American College of Cardiology, vol. 16, No. 6, pp. 1310-1314, Nov. 1, 1990; ISSN 0735-1097.
Andersen, et al., "Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs." European Heart Journal (1992), 13, 704-708.
Andersen, Henning Rud, "History of Percutaneous Aortic Valve Prosthesis," Herz 34 2009 Nr. 5, Urban & Vogel, pp. 343-346, Skejby University Hospital Department of Cardiology, Aarhus, Denmark.
Benchimol, Alberto, et al., "Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man," The American Journal of the Medical Sciences, Jan.-Feb. 1977 vol. 273, No. 1, pp. 55-62.
CN Office Action issued in Application No. 201380057757.8, Issued Dec. 2, 2015.
Dake, Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms, New Engl.J.Med., 1994; 331:1729-34.
Dotter, M.D., Charles T., "Transluminal Treatment of Arteriosclerotic Obstruction," University of Oregon's Minthorn Memorial Laboratory for Cardiovascular Research through Radiology, Circulation, vol. XXX, Nov. 1964, pp. 654-670.
Inoune, M.D., Kanji, et al., "Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter," The Journal of Thoracic and Cardiovascular Surgery 87:394-402, 1984.
Kolata, Gina, "Device That Opens Clogged Arteries Gets a Failing Grade in a New Study," nytimes.com, http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-arteries-gets-a-faili . . . , Jul. 29, 2009, 2 pages.
Lawrence, Jr., M.D., David D., "Percutaneous Endovascular Graft: Experimental Evaluation," Radiology 1897; 163: 357-360.
Pavcnik, M.D., Ph.D., Dusan, et al. "Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement," Cardiovascular Radiology 1992; 183:151-154.
Porstmann, W., et al., "Der Verschlubeta des Ductus Arteriosus Persistens ohne Thorakotomie," Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203.
Porstmann, W., et al., "Der Verschluβ des Ductus Arteriosus Persistens ohne Thorakotomie," Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, im Apr. 1967, pp. 199-203.
Rashkind, M.D., William J., "Creation of an Atrial Septal Defect Withoput Thoracotomy," The Journal of the American Medical Association, vol. 196, No. 11, Jun. 13, 1966, pp. 173-174.
Rashkind, M.D., William J., "Historical Aspects of Interventional Cardiology: Past, Present, Future," Texas Heart Institute Journal, Interventional Cardiology, pp. 363-367.
Rösch, M.D., Josef, "The Birth, Early Years and Future of Interventional Radiology," J Vasc Interv Radiol 2003; 14:841-853.
Ross, F.R.C.S., D.N., "Aortic Valve Surgery," Guy's Hospital, London, pp. 192-197, approximately 1968.
Sabbah, Ph.D., Hani N., et al., "Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview," Journal of Cardiac Surgery, vol. 4, No. 4, pp. 302-309, Dec. 1989; ISSN 0886-0440.
Selby, M.D., J. Bayne, "Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems," Radiology 1990; 176:535-538.
Serruys, P.W., et al., "Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?," European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989.
Sigwart, Ulrich, "An Overview of Intravascular Stents: Old and New," Chapter 48, Textbook of Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815.
Supplementary Search Report for European Application No. 13834484, dated Apr. 29, 2016.
Uchida, Barry T., et al., "Modifications of Gianturco Expandable Wire Stents," AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187.
Urban, M.D., Philip, "Coronary Artery Stenting," Editions Médecine et Hygiéne, Genéve, 1991, pp. 5-47.
Watt, A.H., et al. "Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole," British Journal of Clinical Pharmacology (1986), 21, 227-230.
Wheatley, M.D., David J., "Valve Prostheses," Rob & Smith's Operative Surgery, Fourth Edition, pp, 415-424, Butterworths 1986.

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080656B2 (en) 2012-04-19 2018-09-25 Caisson Interventional Llc Heart valve assembly systems and methods
US10660750B2 (en) 2012-04-19 2020-05-26 Caisson Interventional, LLC Heart valve assembly systems and methods
US11051935B2 (en) 2012-04-19 2021-07-06 Caisson Interventional, LLC Valve replacement systems and methods
US10285810B2 (en) 2012-04-19 2019-05-14 Caisson Interventional, LLC Valve replacement systems and methods
US11833035B2 (en) 2013-10-23 2023-12-05 Caisson Interventional Llc Methods and systems for heart valve therapy
US10117741B2 (en) 2013-10-23 2018-11-06 Caisson Interventional, LLC Methods and systems for heart valve therapy
US10736736B2 (en) 2013-10-23 2020-08-11 Caisson Interventional, LLC Methods and systems for heart valve therapy
US10835375B2 (en) 2014-06-12 2020-11-17 Caisson Interventional, LLC Two stage anchor and mitral valve assembly
US9974647B2 (en) 2014-06-12 2018-05-22 Caisson Interventional, LLC Two stage anchor and mitral valve assembly
US10987220B2 (en) 2014-09-29 2021-04-27 The Provost, Fellows Foundation Scholars, and The Other Members of the Board, of the College of The Holy and Undivided Trinity of Queen Elizabeth Near Dublin (TCD) Heart valve treatment device and method
US10383729B2 (en) 2014-09-29 2019-08-20 The Provost, Fellows Foundation Scholars, and The Other Members of the Board, of the College of The Holy and Undivided Trinity of Queen Elizabeth Near Dublin (TCD) Heart valve treatment device and method
US10682231B2 (en) 2014-09-29 2020-06-16 The Provost, Fellows Foundation Scholars, and The Other Members of the Board, of the College of The Holy and Undivided Trinity of Queen Elizabeth Near Dublin (TCD) Heart valve treatment device and method
US9750606B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US10603167B2 (en) 2014-10-23 2020-03-31 Caisson Interventional, LLC Systems and methods for heart valve therapy
US9750605B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US11439506B2 (en) 2014-10-23 2022-09-13 Caisson Interventional Llc Systems and methods for heart valve therapy
US9750607B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US10524792B2 (en) 2014-12-04 2020-01-07 Edwards Lifesciences Corporation Percutaneous clip for repairing a heart valve
US10517726B2 (en) 2015-05-14 2019-12-31 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11793642B2 (en) 2015-05-14 2023-10-24 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11510782B2 (en) 2015-10-27 2022-11-29 Xetis AG Medical device using bioabsorbable material
US10265166B2 (en) 2015-12-30 2019-04-23 Caisson Interventional, LLC Systems and methods for heart valve therapy
US10939998B2 (en) 2015-12-30 2021-03-09 Caisson Interventional, LLC Systems and methods for heart valve therapy
US11547558B2 (en) * 2016-10-24 2023-01-10 Ningbo Jenscare Biotechnology Co., Ltd. Heart valve prosthesis anchored to interventricular septum and conveying and releasing method thereof
US20210282925A1 (en) * 2016-10-24 2021-09-16 Ningbo Jenscare Biotechnology Co., Ltd Heart valve prosthesis anchored to interventricular septum and conveying and releasing method thereof
US10765518B2 (en) 2016-12-21 2020-09-08 TriFlo Cardiovascular Inc. Heart valve support device and methods for making and using the same
US11833047B2 (en) 2016-12-21 2023-12-05 TriFlo Cardiovascular Inc. Heart valve support device and methods for making and using the same
US10932908B2 (en) 2017-04-18 2021-03-02 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11000373B2 (en) 2017-04-18 2021-05-11 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10888425B2 (en) 2017-04-18 2021-01-12 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10898327B2 (en) 2017-04-18 2021-01-26 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10905553B2 (en) 2017-04-18 2021-02-02 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10905552B2 (en) 2017-04-18 2021-02-02 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10918482B2 (en) 2017-04-18 2021-02-16 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10925732B2 (en) 2017-04-18 2021-02-23 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10925734B2 (en) 2017-04-18 2021-02-23 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10524913B2 (en) 2017-04-18 2020-01-07 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10925733B2 (en) 2017-04-18 2021-02-23 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10869763B2 (en) 2017-04-18 2020-12-22 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10940005B2 (en) 2017-04-18 2021-03-09 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10849754B2 (en) 2017-04-18 2020-12-01 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10945843B2 (en) 2017-04-18 2021-03-16 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10667912B2 (en) 2017-04-18 2020-06-02 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10952853B2 (en) 2017-04-18 2021-03-23 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10874514B2 (en) 2017-04-18 2020-12-29 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10959848B2 (en) 2017-04-18 2021-03-30 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11224511B2 (en) 2017-04-18 2022-01-18 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11179240B2 (en) 2017-04-18 2021-11-23 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11602431B2 (en) 2017-04-18 2023-03-14 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11013601B2 (en) 2017-04-18 2021-05-25 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11020229B2 (en) 2017-04-18 2021-06-01 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10842627B2 (en) 2017-04-18 2020-11-24 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10507108B2 (en) 2017-04-18 2019-12-17 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11096784B2 (en) 2017-04-18 2021-08-24 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11058539B2 (en) 2017-04-18 2021-07-13 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US10959846B2 (en) 2017-05-10 2021-03-30 Edwards Lifesciences Corporation Mitral valve spacer device
WO2019010370A1 (en) 2017-07-06 2019-01-10 Raghuveer Basude Tissue grasping devices and related methods
US11648118B2 (en) 2017-07-06 2023-05-16 Raghuveer Basude Tissue grasping devices and related methods
US11051940B2 (en) 2017-09-07 2021-07-06 Edwards Lifesciences Corporation Prosthetic spacer device for heart valve
US11065117B2 (en) 2017-09-08 2021-07-20 Edwards Lifesciences Corporation Axisymmetric adjustable device for treating mitral regurgitation
US10973639B2 (en) 2018-01-09 2021-04-13 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10925735B2 (en) 2018-01-09 2021-02-23 Edwards Lifesciences Corporation Native valve repair devices and procedures
US10507109B2 (en) 2018-01-09 2019-12-17 Edwards Lifesciences Corporation Native valve repair devices and procedures
US11207182B2 (en) 2018-02-09 2021-12-28 The Provost Fellows, Foundation Scholars and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin (TCD) Heart valve therapeutic device
US10952854B2 (en) 2018-02-09 2021-03-23 The Provost, Fellows, Foundation Scholars And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin (Tcd) Heart valve therapeutic device
US11026791B2 (en) 2018-03-20 2021-06-08 Medtronic Vascular, Inc. Flexible canopy valve repair systems and methods of use
US11701228B2 (en) 2018-03-20 2023-07-18 Medtronic Vascular, Inc. Flexible canopy valve repair systems and methods of use
US11285003B2 (en) 2018-03-20 2022-03-29 Medtronic Vascular, Inc. Prolapse prevention device and methods of use thereof
US11389297B2 (en) 2018-04-12 2022-07-19 Edwards Lifesciences Corporation Mitral valve spacer device
WO2019199421A1 (en) 2018-04-12 2019-10-17 Edwards Lifesciences Corporation Mitral valve spacer device
US11207181B2 (en) 2018-04-18 2021-12-28 Edwards Lifesciences Corporation Heart valve sealing devices and delivery devices therefor
US11903832B2 (en) * 2018-07-29 2024-02-20 Cuspa Ltd. Transcatheter artificial cusp for valve insufficiency
US11717406B2 (en) 2019-05-22 2023-08-08 TriFlo Cardiovascular Inc. Heart valve support device
US10842628B1 (en) 2019-05-22 2020-11-24 TriFlo Cardiovascular Inc. Heart valve support device
WO2020236417A1 (en) 2019-05-22 2020-11-26 Edwards Lifesciences Corporation Expandable anchor for heart valve repair devices
US11219525B2 (en) 2019-08-05 2022-01-11 Croivalve Ltd. Apparatus and methods for treating a defective cardiac valve
US11918469B2 (en) 2021-02-05 2024-03-05 Edwards Lifesciences Corporation Native valve repair devices and procedures

Also Published As

Publication number Publication date
EP2892469A1 (en) 2015-07-15
US20140067052A1 (en) 2014-03-06
EP4042976A1 (en) 2022-08-17
US9510946B2 (en) 2016-12-06
EP3708122A1 (en) 2020-09-16
EP3888598A1 (en) 2021-10-06
US20140067054A1 (en) 2014-03-06
CA2882381C (en) 2022-04-26
CN104768500B (en) 2017-10-03
CA3145958A1 (en) 2014-03-13
CA2882381A1 (en) 2014-03-13
WO2014039392A1 (en) 2014-03-13
US20160317290A1 (en) 2016-11-03
US9907652B2 (en) 2018-03-06
CN104768500A (en) 2015-07-08
EP2892469A4 (en) 2016-06-15
US20140067048A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
US9907652B2 (en) Heart valve sealing devices
US11648118B2 (en) Tissue grasping devices and related methods
US11583396B2 (en) Prosthetic valve for replacing mitral valve

Legal Events

Date Code Title Description
AS Assignment

Owner name: EDWARDS LIFESCIENCES CORPORATION, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHAU, MARK;DELGADO, SERGIO;OBA, TRAVIS;AND OTHERS;SIGNING DATES FROM 20131009 TO 20131025;REEL/FRAME:031733/0219

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8